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ROLE OF THE NEURONAL SPECIFIC TRANSCRIPTION COREGULATOR NPDC-1 IN 
RETINOID AND THYROID RECEPTOR SIGNALING IN HUMAN AND THE AXOLOTL 
AMBYSTOMA MEXICANUM 
 
Section I: This section is an introduction to the field of nuclear receptors.  A 
general overview of nuclear receptor-mediated transcriptional regulation is followed by 
a review of literature on retinoid and thyroid receptor-mediated signaling. 
Section II: An introduction to NPDC-1 (neural proliferation, differentiation, and 
control), its discovery and characterization with regards to developmental expression 
and cellular localization.  In addition NPDC-1 has been found to associate with a 
number of cell cycle regulatory proteins.  NPDC-1 is characterized as a regulator of 
nuclear receptor-mediated transcriptional regulation.  NPDC-1 was also demonstrated 
to be regulated post-transcriptionally through the ubiquitin/proteosome degradation 
pathway. 
 Section III: Axolotl NPDC-1 (aNPDC-1) was cloned from axolotl brain and 
analyzed for homology to NPDC-1 from higher vertebrates.  The tissue distribution and 
developmental expression of axolotl NPDC-1 were also examined. 
 Section IV: The axolotl homolog for RARγ (aRARγ) was isolated from axolotl 
brain.  Axolotl NPDC-1 and aRARγ were then examined in a series of assays for 
interactions.  Axolotl NPDC-1 was found to repress transcription mediated by aRARγ to 
a smaller extent than the repression observed in higher vertebrates.  The DNA binding 
of aRARγ-RXRα was increased in the presence of aNPDC-1 and complex mobility was 
also observed.  The domain of interaction 
between aNPDC-1, aRARγ and hRXRα was localized in the amino terminus of aNPDC-
1.  Axolotl NPDC-1 was also demonstrated to repress proliferation as measured by 
reduced [3H] thymidine incorporation. 
 Section V: The axolotl homologs of TRα and TRβ (aTR) genes were isolated and 
utilized in a series of experiments to demonstrate an interaction between aTRs and 
aNPDC-1.  As observed for βRE, aNPDC-1 increases the binding of aTR-RXR 
heterodimer to xDR4, but no change in the mobility of the complex was observed.  
Interaction between aNPDC-1, aTRα and aTRβ was localized to the amino terminus of 
aNPDC-1.  In contrast to previous observations for other nuclear receptors, aNPDC-1 
was found to stimulate transcription mediated by axolotl TRs, suggesting a role for 
aNPDC-1 in axolotl metamorphosis. 
  Section VI: A summary of data presented in the previous sections as well as a 
presentation of future directions and a proposed model for NPDC-1 actions in retinoid 
and thyroid-receptor mediated signaling in axolotl. 
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SECTION I:  NUCLEAR RECEPTOR SIGNALING 
 
 
Chapter 1:  General Overview of Nuclear receptors 
 
The proper organization and maintenance of the functions of a complex body 
plan by multicellular organisms requires specific intracellular signaling (1).  The 
activities of intracellular kinase cascades and/or signaling pathways are induced by 
growth factors, neurotransmitters and peptide hormones binding to membrane 
receptors (1).  Steroid hormones and other small hydrophobic signaling molecules, 
such as vitamins and metabolic intermediates, either enter the cell or are generated 
within the target cells and bind to cognate members of the nuclear receptor family (1).  
Nuclear receptors are important integrators of intracellular and extracellular signals 
and regulate gene expression in multicellular organisms. 
The nuclear receptor superfamily is the largest group of eukaryotic 
transcription factors (2) and consists of structurally related proteins that are ligand 
inducible and regulate the transcription of target genes by binding to cis-acting DNA 
sequences (3).  NRs regulate transcription by direct physical association with a variety 
of hormonal or other metabolic signals, by integrating diverse signaling pathways (as 
they are themselves targets of post-translational modification) and by signal 
transduction crosstalk (regulating the activities of other signaling cascades) (1).  
Through their ability to control gene expression, NRs regulate complex genetic and 
physiological events that trigger key steps in embryogenesis, development, 
metabolism, control/maintenance of homeostasis, reproduction, cellular proliferation, 
differentiation and death (1, 4, 5).  The NR family can be separated into three 
- 2 - 
subgroups based on the chemical similarity of their ligands and on phylogenetic 
analysis of their DNA binding domain (3).  The first subgroup are the steroid receptors 
and includes the androgen receptor (AR), mineralocorticoid receptor (MR), estrogen 
receptor (ER), glucocorticoid receptor (GR) and progesterone receptor (PR). The second 
subgroup is comprised of non-steroidal, RXR heterodimeric receptors such as the 
thyroid receptor (TR), vitamin D receptor (VDR), peroxisome proliferators activated 
receptor (PPAR), farnesoid X receptor (FXR) and retinoic acid (RAR) receptor, as well as 
the insect ecdysone receptor (EcR).  The third subgroup is composed of the orphan 
receptors for which there is no known physiological ligand.  For some time a 
distinction was made between classical nuclear receptors and orphan receptors.  
Recently, some orphan receptors have been matched with potential physiologic 
ligands, but there might be some orphan receptors that do not require a ligand to 
function (6).  The classification of nuclear receptors into 6-7 phylogenetic families 
containing both orphan and non-orphan receptors further dismisses such 
discrimination (7).  Many nuclear receptors also have been found to have different 
subtypes and isoforms (8-10).  Thyroid receptor for example has two subtypes, TRα 
and TRβ, with two isoforms that are created by alternative RNA splicing (TRα1, TRα2, 
TRβ1, and TRβ2).  With the discovery that different receptor subtypes can respond 
differently to the same ligand (11) as well as the discovery of subtype selective ligands, 
the existence of receptor variants (12-15) increases the potential complexity and 
subtlety of the receptors’ regulatory properties.  The classification of nuclear receptors 
is made by virtue of evolutionarily conserved DNA-binding and ligand-binding regions.  
Comparison of the DNA-binding region reveals that they are derived from a common 
ancestral gene and that evolution of this family was completed before the 
arthropod/vertebrate split (3).  It is speculated that there was a rapid evolution of 
- 3 - 
these genes as they are implicated in cell-cell communication, a crucial need for 
metazoans (the rapid divergence of early nuclear receptor genes coincides with the 
metazoan evolution burst), and when these genes were fixed in their present function 
only minor rearrangements occurred leading to an overall strong gene conservation (3). 
Nuclear receptor proteins are single polypeptide chains with 5-6 major modular 
domains.  The domain structures are variable in length among the receptors.  
Furthermore, some functions, such as activator binding, do not always correspond to 
a simple structural domain.  To date, about 70 nuclear receptors have been identified, 
and with the exception of some unusual NRs which appear to contain only regions 
homologous to the DNA- or ligand-binding domains, all members display an identical 
structural organization.  It is possible that a number of orphan receptors function 
exclusively as constitutive activators or repressors of transcription.  Rev-Erb is such 
an example of a constitutive repressor that recruits corepressors but lacks a 
functional transcription activation function AF-2 (1).  Traditionally the letter names 
A/B, C, D, E and F have been given to the different domains of a nuclear receptor 
(Figure 1).  The amino terminal A/B domain is followed by a DNA-binding domain 
consisting of two zinc fingers (domain C), a hinge region D, and the ligand-binding 
domain (E) (16).  Some nuclear receptors also contain a carboxyl-terminal region F 
that has no known function so far.  The N terminal domain (A/B) is the least 
conserved domain across the superfamily.  The A/B domain varies in length 
considerably between receptors.  In the VDR the domain consists of 23 amino acids 
whereas in mineralocorticoid receptor it is 550 amino acids long.  This domain 
contains one or more autonomous transcriptional activation functions (AF-1) which 
can activate transcription in a constitutive manner.  Comparison of nuclear receptors 
from different subfamilies shows that the A and B domain cannot always be  
- 4 - 
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distinguished from each other.  Efforts to determine the three-dimensional structure of 
this region have proven to be fruitless.  Through alternative splicing and differential 
promoter usage, the presence or absence of different activation functions can be 
regulated (17).  The N-terminus has also been found to be subject to posttranslational 
modifications such as phosphorylation. 
 The DNA binding domain (DBD), or C domain, lies adjacent to the A/B domain.  
This region is highly conserved and confers specificity for recognizing and binding to 
hormone response elements (HREs) on DNA (18).  The DBD contains approximately 68 
amino acids although it varies (e.g. DBD of PPAR consists of 67 amino acids while that 
of TR consists of 70 amino acids) (3).  It is hypothesized that the C domain of the 
ancestral NR gene also contained 68 amino acids (3).  The 68 amino acids in the DBD 
compose two zinc finger motifs, the N-terminal motif Cys-X2-Cys-X13-Cys-X2-Cys (CI) 
and the C-terminal motif Cys-X5-Cys-X9-Cys-X2-Cys (CII).  The four cysteines in each 
motif chelate one Zn2+ ion.  The two zinc finger structures play complimentary roles in 
the DNA binding process (19).  The first zinc finger interacts with DNA in the major 
groove and is responsible for the sequence specificity of binding (20, 21).  This allows 
for the specific recognition of short and imperfect inverted repeats of DNA (for steroid 
receptors) or direct repeats (for RXR heterodimeric receptors).  The second finger and 
the region adjacent to it may be responsible for the definition of optimal spacing and 
alignment of half-sites as well as the direction of subunit interactions (20, 21).  The 
region adjacent to the zinc finger may also be responsible for stabilizing the binding of 
protein monomers to single half-sites for some orphan receptors (20, 21).  Several 
sequence elements within the C domain have been identified that contribute or define 
response element specificity, dimerization interface and contacts with the DNA 
backbone and residues flanking the DNA core recognition sequence.  These sequences 
- 6 - 
have been termed P-, D-, A- and T- boxes.  The P-box contributes to binding motif 
specificity, the D-box provides a dimerization interface, the T-box region forms a helix 
that corresponds to a dimerization surface in RXR homodimers and the A-box is the 
two zinc finger motifs (1). 
The ligand binding domain (LBD) or E region is the hallmark of a nuclear 
receptor.  The E domain is highly structured and encodes a number of distinct 
functions.  The LBD confers specificity for ligand binding and performs a number of 
functions related to ligand binding such as receptor release from the heat shock 
complex, translocation to the nucleus, homodimerization, heterodimerization and 
transcriptional activation (19, 20, 22, 23).  Hormone agonists promote these functions 
whereas antagonists can selectively block them (22).  Evidence has been presented 
that ligand binding is an ability acquired during evolution and that the ancestral NR 
was an orphan (5, 24). 
In addition to the three structural domains, nuclear receptors also have a 
flexible hinge region, D, that is found between the DBD and LBD.  This region may 
allow the DBD and LBD to adopt different conformations without steric hindrance 
problems.  A nuclear localization signal sequence can also be found in region D 
[reviewed in (17)].  The hinge region may also contain recognition sites for certain 
activator and/or repressor molecules (25).   
Nuclear receptor-specific actions are derived from a combination of different 
parameters such as availability of ligand, receptor and non-receptor factors, structure 
of target site, interactions with other proteins such as general transcription factors 
and influences of other signaling pathways.  These interactions result in ligand-
regulated and ligand-independent effects on initiation of transcription of target genes 
(26).  The genetic activities of NRs result from both direct modulation of the activity of 
- 7 - 
cognate gene programs and mutual interference with the activity of other signaling 
pathways (5).  Ligands for nuclear receptors are able to circulate in the body bound to 
plasma proteins.  Dissociation from these proteins allows for cell entry and association 
with their respective receptors.  Steroids and Vitamin D probably enter cells through 
passive diffusion while thyroid hormone and retinoic acid entry require specific 
transport processes (26) (Figure 2).  Non-liganded steroid receptors are bound to heat 
shock proteins (26) and are found in the cytoplasm.  Upon binding of hormone, the 
steroid receptors dissociate from the heat shock proteins and are able to translocate to 
the nucleus, homodimerize and bind to HREs in the promoters of target genes (23).  In 
contrast, TR subfamily members (such as TR, RAR and VDR) are predominantly 
nuclear localized and bound to their response element (usually as heterodimers with 
RXR) free of hsp proteins (26).   
All nuclear receptors recognize derivatives of the same hexameric DNA core 
motif, 5’-PuGGTCA (Pu=A or G) (1).  Mutation, extension, duplication and distinct 
orientations of repeats of this motif give rise to response elements that are selective for 
a given class of receptors.  A spacer rule has been proposed to describe the preference 
of the various direct repeat (DR)-recognizing receptors.  For example TR-RXR 
heterodimers show a preference for DR4, and RAR-RXR heterodimers have a 
preference for DR5 response elements.  This rule is known as the DRn rule where n is 
the number of nucleotides between the two half-site motifs.  These response elements 
can also be promiscuous, with more than one receptor dimer capable of binding to 
them (2).  The half-site motifs also exhibit degeneration with some receptors having a 
preference for individual half-site motifs.  For example, the preference for the half-site 
motif 5’-PuGGTCA over 5’-PuGTTCA follows the order TR>RXR>RAR (1).  In addition to 
nucleotide preference in the half-site motif, certain receptors exhibit a preference for  
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Figure 2: Receptor Interactions in the Nucleus.  Ligand enters the nucleus 
and associates with its respective receptor.  In the case of steroid receptors, this 
causes dissociation from heat-shock factors and translocation to the nucleus 
and dimerization.  In the case of TR subfamily members the receptor is already 
in the nucleus bound to its respective response element.  Binding of ligand 
induces interactions with coregulators and the basal transcriptional machinery 
and transcription occurs. 
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certain nucleotides in the DR spacer (1).  Steroid hormones bind to response elements 
containing two half-sites (AGAACA) oriented as palindromic repeats separated by 3bp 
(IR3 elements) with each half-site binding a receptor monomer.  Some orphan 
receptors recognize response elements composed of single half-sites and are believed 
to bind as monomers to their cognate response elements.  In this case, additional 
residues 3’ of the half-site are also recognized (27).  A summary of NR DNA binding is 
presented in Tables 1 and 2.  In the end the specificity of response element, DNA 
binding is due to both the recognition of a half-site motif and how or whether the 
receptor is dimerized. 
Nuclear receptors can bind their response element as homodimers or 
heterodimers.  Steroid receptors classically bind to their response elements as 
homodimers while RAR, TR, RXR and VDR have the potential to heterodimerize as well 
as homodimerize.  The ability of RXR to promiscuously form heterodimers with RAR, 
TR, VDR and orphan receptors gives this receptor the ability to play an important role 
in various diverse signal transduction pathways.  Heterodimerization is beneficial in 
that it increases DNA binding efficiency relative to the corresponding homodimers, 
leads to novel response element repertoire and allows for two signaling inputs, that of 
ligands of RXR and its partner (1).  The signaling pathway identity for receptors like 
RAR, TR and VDR is maintained by the “RXR subordination” phenomenon, in that in 
heterodimers there is no response to RXR ligand and transcription is “controlled” by 
the RXR partner receptor.  This phenomenon solves a potential problem that could 
arise from the ability of RXR to heterodimerize with a number of receptors and activate 
a number of signaling cascades in response to its ligand.  It is unclear whether some 
RXR complexes will allow for RXR signaling in absence of a ligand for the partner of 
RXR (1). 
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Table 1: Nuclear Receptor Overview.  Table 1 is a general overview of nuclear 
receptor subfamilies and their characteristics. 
Table 2: Nuclear Receptors and their binding characteristics.  This table is an 
overview of the general dimerization, DNA binding and ligand characteristics of 
nuclear receptor family members 
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The LBD of nuclear receptors has been a subject of much research and the first 
crystal structures of certain nuclear receptor LBDs were reported in 1995 (1).  More 
recently the LBDs of heterodimeric receptors also have been solved (1).  All the NR 
LBDs display a similar structure with 12 α-helices (H1-H12) and one β-turn arranged 
as an antiparallel α-helical sandwich in a three-layered structure (1, 5).  Insight into 
the mechanism by which AF-2 becomes transcriptionally active was gained by the 
study of apo (non-liganded) and holo (liganded) LDB structures (Figure 3).  Upon 
ligand binding H11 gets aligned with H10, leading to the swinging of H12 to unleash a 
loop that flips under H6, carrying along the N-terminal part of H3.  In its final position 
H12 seals the ligand-binding cavity and further stabilizes ligand binding by 
contributing additional ligand-protein interactions (1). This is known as the mousetrap 
model.  Coactivators are allowed to bind on the novel surfaces generated by agonist 
binding, and then these are able to recruit additional transcription factors.  
Simultaneously with agonist (but not necessarily antagonist) binding, corepressors 
bound to the apo-LBD dissociate.  Certain antagonists force H12 into a third position 
distinct from the holo position whereby it impairs coactivator binding (1).  The recent 
crystallization of heterodimer LBDs allowed for the comparison to homodimer LBDs.  
Overall, the structure is very similar; however within the heterodimer there is not 
equal contribution to the heterodimerization interface (1).   
Observations of ligand-dependent transcriptional interference led to the 
conclusion that coactivators exist.  The first evidence for the existence of coregulators 
was the observation that ERAP-140 and ERAP-160 (estrogen receptor associated 
proteins) interacted with GST-ER in the presence, but not the absence of, estradiol or 
diethylstilbestrol (28).  An estrogen antagonist and anti-estrogen compounds were 
unable to promote the association of ER with ERAP.  Mutational analysis showed that 
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Figure 3A 
Figure 3B 
Figure 3: Orthographic view of nuclear receptors.  In figure 3A, 
unliganded receptor is shown.  Helix 12 is located below and the volume is 
defined by H12, H11, H5 and H3 provides an opening in the LBD.  Polar 
regions on H5 and H3 near the loop assist in docking the polar regions of the 
ligand.  Figure 3B is an orthographic view of nuclear receptor after ligand 
binding.  The result is a lipophilic ligand surrounded by the hydrophobic 
interior of the receptor.  The resting place of H12 with respect to H11 and H3 
is sequence and ligand dependent. 
 
Figures taken from: http://www-personal.umich.edu/~lpt/domain.htm 
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this ligand-dependent interaction correlates with the ability to activate transcription.  
The first coactivator cloned and characterized, SRC-1, was shown to enhance the 
transcriptional activity of nuclear receptor family members in the presence of ligand 
(28).  There are two intrinsic transferable activation domains in SRC-1 (AD1 and AD2), 
which are needed to achieve maximum steroid receptor activity (28, 29).  SRC-1 
appears to function in both ligand-dependent AF2 and ligand-independent AF-1 
transactivation functions of nuclear receptors, as it is able to interact with both the 
carboxyl and amino terminal domains of nuclear receptors (28, 29).  The carboxyl-
terminus of SRC-1 possesses intrinsic HAT activity and also interacts with other HATs 
such as p300/pCAF (28).  pCAF differs from other coactivators in its ability to bind the 
DBD of nuclear receptors in the absence of ligand.  However, in vivo there appears to 
be a ligand dependency for pCAF, because in the absence of ligand nuclear receptors 
normally are associated with corepressors which inhibit pCAF recruitment.   
Almost all coactivators identified to date have an LXXLL motif (leu-XX-leu-leu; X 
is any amino acid).  This motif is referred to as an NR box and is necessary and 
sufficient to mediate interaction with nuclear receptors in the presence of ligand.  The 
specificity of NR box usage is determined by the carboxyl-terminal sequences to the 
LXXLL motif (28).  The presence of multiple NR boxes in the coactivator protein 
provides the specificity and flexibility for the assembly of nuclear-receptor coactivator 
complexes that serve diverse biological functions.   
Upon ligand binding the receptor undergoes a conformational change and 
functions as a transcriptional activator.  In the unliganded form, the AF-1 domain of 
the NR assumes a conformation that promotes interaction with corepressors.  Several 
models have been postulated for NR transcriptional activation that attempt to 
incorporate the roles of ligand binding with coactivator recruitment (figure 4) (30).   
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This corepressor complex has histone deacetylase activity, which is associated with a 
compact “turned off” chromatin conformation, and transcription is repressed.  Binding 
of ligand induces a conformational change that makes it impossible for the receptor to 
be bound to the corepressor complex, but able to complex now with activator proteins.  
Associated with coactivator complexes are HATs and ATP-dependent chromatin 
remodeling proteins.  These proteins cumulatively relax chromatin structure 
permitting access to this structure by the basal transcriptional machinery. 
 
Copyright © Maria Theodosiou 2006 
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Figure 4: Nuclear Receptors in Action. A | Mode of action of nuclear 
receptors (NRs). After diffusion through the cytoplasmic membrane, the 
ligand can interact with its cognate receptor where it can exert a 'non-
genomic effect' by interacting directly, for example, with kinases (a). The ratio 
between cytoplasmic and nuclear location can vary between different 
receptors and is affected by the nature of a ligand. Ligand binding modulates 
the interaction of the receptor with a plethora of factors. In the absence of 
ligand, several nuclear receptors are believed to be bound to the regulatory 
regions of target genes as a corepressor or histone deacetylase (HDAC) 
complex (b). Histone deacetylation is responsible for the chromatin 
condensation that accounts for the gene-silencing effect of apo receptors. 
Ligand binding releases the HDAC complex (c) and results in the recruitment 
of histone acetyltransferase (HAT) and chromatin-remodelling (CRM) 
complexes (d). The temporal order and requirement of these complexes can 
occur in a receptor-, target-gene- and cell-specific manner. In the last step 
(e), the polymerase II holoenzyme, which comprises the pol II enzyme, TAF 
(TATA-binding protein-associated factor) and mediator complexes, is 
recruited and increases the frequency of transcription initiation.  
 
Figure taken from: Gronemeyer et al Nature reviews 2004 3:950-964  
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Chapter 2: Thyroid Receptors 
 
Thyroid hormone (TH) is produced by the thyroid gland and is a very important 
factor in development, differentiation and metabolism (10).  In the late 19th century it 
was realized that loss of thyroid function led to cretinism and myxederma and this led 
to the discovery of thyroid hormones (10).  Thyroid hormones are the derivatives of the 
amino acid tyrosine covalently bound to iodine (Figure 5).  The two principal thyroid 
hormones are thyroxine (T4 or 3,5,3’,5’-tetraiodo-L-thyronine) and triiodothyronine (T3 
or L-3,5,3’ tri-iodo-L-thyronine).  The basic structure of thyroid hormones is two 
tyrosines linked together with iodine at three (T3) or four (T4) positions on the 
aromatic rings.  The majority of thyroid hormone secreted by the thyroid gland is T4, 
which is deiodinated in peripheral tissues such as liver and kidney to yield T3, a more 
active form of the hormone.  Deiodination of T4 can also yield reverse-T3 which has no 
metabolic activity.  In early development, lack of thyroid hormone leads to cretinism 
(growth disturbances and severe mental retardation) whereas later in life the thyroid 
hormone plays an important role in metabolism.  Thyroid hormones are hydrophobic 
and more than 99% of circulating THs are bound to carrier proteins such as 
thyroxine-binding globulin, a glycoprotein synthesized in the liver.  Carrier proteins 
allow a steady pool of THs from which active, free hormone is released for uptake into 
target cells. 
Insight into the mechanism of action of thyroid hormone came about with the 
cloning of their intracellular receptors.  In 1986, two groups cloned the cellular 
homolog of the oncoprotein c-erbA.  Characterization of the protein product of this 
gene revealed that c-erbA was really a high affinity TR, in that it contained a DBD  
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Figure 5: Structure of Thyroid Hormones.  Thyroid hormones are 
derivatives of the amino acid tyrosine covalently bound to iodine.  The two 
principal thyroid hormones are thyroxine (T4 or 3,5,3’,5’-tetraiodo-L-
thyronine) and triiodothyronine (T3 or L-3,5,3’ triiodo-L-thyronine).  
Thyroxine is the principal hormone secreted by the thyroid gland, which is 
deiodinated to yield T3, the more active form of the hormone. 
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characteristic of nuclear receptors and a unique thyroid hormone binding domain (31, 
32).   
In vertebrates TRs are encoded by two separate genes, TRα and TRβ, which are 
located on different chromosomes.  In humans TRα is located on chromosome 17 
whereas TRβ is located on chromosome 3 (10).  Alternative splicing gives rise to 
multiple TRs; TRα1, TRα2, TRβ1 and TRβ2.  The last exon of TRα overlaps with the 
last exon of the orphan receptor Rev-erbα (1).  Interestingly, this last exon is specific to 
the isoform TRα2, a dominant negative regulator of TRα1 isoform (1).  The TRα gene is 
split into 10 exons spanning 27kb of genomic DNA (1).  The positions of the exons are 
conserved across species (1).  
The expression of TR isoforms is regulated both at the transcriptional and 
posttranscriptional level, and each isoform displays a characteristic pattern of 
regulation (10).  The most highly regulated TR isoform is TRβ2 which is almost 
exclusively expressed in the hypothalamus and anterior pituitary.  All tissues express 
TRα1, TRα2 and TRβ1, but each isoform has a characteristic pattern of distribution.  
The isoform TRα1 is highly expressed in brown fat and skeletal muscle, TRα2 is most 
prominent in the brain and TRβ1 is more homogeneously distributed with high 
concentrations in brain, liver and kidney (10).  The first TR expressed in the fetus is 
TRα1 while TRβ expression in the brain increases dramatically after birth.  Thyroid 
hormones have established effects on fetal and neonatal brain development with 
upregulation of TRβ receptor being critical for the expression of genes that are 
important in brain development.   
Thyroid receptors share the same modular structure as the other nuclear 
receptor family members.  Thyroid receptors contain an amino terminal 
transactivation domain (AF-1) that interacts with other transcription factors to repress 
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or activate transcription, a central DNA binding domain and a carboxyl terminus 
ligand binding/AF2 domain.  The AF-1 domain varies considerably between the TRα 
and TRβ and within the two beta isoforms.  The TRα2 isoform has a unique carboxyl 
terminus and does not bind triiodothyronine (T3) (10, 28).  In this respect it acts 
similarly to a dominant negative mutant of TR, but it is able to be phosphorylated, 
which ultimately affects its DNA binding and dimerization (28, 33). 
Thyroid receptors differ from steroid receptors in that they are bound to DNA in 
the absence of ligand (10).  TRs are able to bind to DNA as either homodimers or 
heterodimers with the major form of DNA-bound TR being the TR-RXR heterodimer.  
TRs recognize and bind to a DR4 element, two half-sites (AGGTCA) separated by 4 
nucleotides, but are able to also recognize other forms of the repeats such as 
palindromic and inverted repeats (34, 35).  The major functional form of the receptor is 
thought to be the TR-RXR heterodimer, as this has the highest DNA binding affinity.  
Apo-TR is also located in the nucleus and even in the absence of T3 it can bind to DNA 
(TREs) and act as a repressor of transcription (10, 28). 
The heterodimerization of TR-RXR increases the ability of TR to bind to specific 
DNA sequences and contributes to the specificity of action of TR.  The area of 
dimerization is, like in other RXR dimers, in the LBD and DBD domains.  The 
interaction between the DBDs allows for specific interactions between monomers and 
the correct binding site recognition.  The heterodimerization interface of RXR is in the 
second zinc finger in the D-box while the heterodimerization domain of TR is in the 
pre-finger region.  The TR A-box is important in preventing binding on other response 
elements.  TRs also interact with other transcription factors such as p53, AP-1 and 
Stat 5.  TRs can also heterodimerize with RAR and chicken ovalbumin upstream 
promoter transcription factor (COUP-TF) although these interactions appear to be 
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weaker than that with RXR (10).  Homodimers form at the expense of heterodimers 
when there is a high enough concentration of TR (10), but it is not clear whether the 
same domains are involved in TR homodimerization versus heterodimerization.  The 
heterodimerized receptors usually adopt a predefined polarity on direct repeats (26).  
In the TR-RXR heterodimer, the 5’ site is occupied by RXR and the 3’ site by TR.  In 
the case of TR-VDR heterodimers, the 3’ site is occupied by VDR in a DR3 and by TR 
in a DR4 response element (26).  TR-VDR heterodimers can activate transcription in 
response to either ligand, but for the receptor at the 5’ site a higher concentration of 
hormone is required for activation (26).   
Transcriptional activation of TRs commence upon ligand binding (Figure 6).  In 
the unliganded form, TR assumes a conformation that promotes interaction with 
corepressors (28).  Corepressor complexes associated with TRs have been shown to 
contain histone deacetylase activity, which is associated with a compact “turned off” 
chromatin conformation and repression of transcription.  Binding of ligand induces a 
conformational change that makes it impossible for the receptor to be bound to the 
corepressor complex but able to complex now with activator proteins.  Typical 
coactivator complexes contain histone acetyltransferase (HAT) activity and ATP 
chromatin remodeling proteins which are associated with “relaxed” chromatin and 
transcription activation (Figure 6).   
Transcriptional activity of TR is under the control of coregulators like all 
nuclear receptor family members.  SRC-1 is a coactivator of transcription in the 
presence of ligand (28).  SRC-1 is important in T3 action as mice without functional 
SRC-1 are T3-resistant (28, 36).  The carboxyl-terminus of SRC-1 possesses intrinsic 
HAT activity and also interacts with other HATs such as p300/pCAF (28).  In addition 
to coactivators with HAT activity, TR uses a different complex called TRAP.  TRAP does  
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Figure 6:  Model for thyroid receptor action.  Model for activation and 
repression by thyroid hormone receptors.  In the absence of T3, TR/RXR 
heterodimer recruits a corepressor complex that has histone deacetylase activity.  
In the presence of T3, TR/T3/RXR releases the corepressor complex and recruits 
a coactivator complex that has histone acetyltransferase activity.  Enzymatic 
modification of nucleosomes by HDAC or HAT activity results in an open or closed 
chromatin structure that leads to transcriptional activation or repression. 
 
Figure modified from Zhang et al, Annu Rev Physiol 2000 62:439-66 
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not possess HAT activity and is transcriptionally active even in the absence of 
chromatin.  TRAP contains multiple polypeptides that are shared with a more general 
regulatory complex called the mediator complex SMCC (28).   
 Physiologically, aberrant coactivator recruitment is a feature of an autosomal 
inherited disease, thyroid hormone resistance (RTH).  Thyroid hormone resistance 
disorder is caused by mutations in the TRβ gene and causes hypothyroidism 
characterized by goiter, elevated serum T3 and T4 and altered TSH levels.  Children 
affected with this disorder have attention deficit disorder.  This trait appears to be 
transmitted as a dominant negative mutation of the TRβ receptor.   
Mice that are null for TRα1 show subnormal body temperature and mild 
abnormalities in cardiac function.  TRα knockout mice (lacking both isoforms) are 
severely hypothyroid, exhibit growth arrest and have a very short lifespan.  TRβ 
knockout mice have elevated TSH levels and are deaf whereas TRβ2 knockout mice 
have normal hearing and elevated TSH, suggesting that TRβ1 is responsible for the 
development of normal hearing and TRβ is responsible for normal serum 
concentrations of TSH.  Finally, lack of TH and absence of TR do not have the same 
phenotype.  Lack of TH has a more severe phenotype than receptor inactivation.  The 
reason for this discrepancy is not fully understood, but it could be that in the case of 
receptor deficiency the receptor responsive genes are left in neutral, rather than being 
suppressed as would happen in the case of TH deficiency.   
 
Copyright © Maria Theodosiou 2006 
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Chapter 3: Retinoid Receptors 
 
 Vitamin A is a fat soluble vitamin essential for the formation and maintenance 
of healthy teeth, skin, bones, mucus membranes, soft tissue and is also responsible 
for the promotion of good vision and immune function [web & (37)].  The active form of 
vitamin A is retinol, and is found naturally in animal liver, eggs and dairy products.  
Retinol can also be manufactured in the body from carotenoids such as β-carotene, 
found in green leafy, orange and yellow vegetables.  Provitamin A compounds such as 
β-carotene have also been demonstrated to have anti-oxidant and anti-proliferative 
properties, and may suppress certain tumors.  Retinol is converted to more active 
compounds called retinoids, such as retinoic acid (RA), by the zinc dependent enzyme 
retinol dehydrogenase (38).  There are six known isomers of retinol; all-trans, 9-cis, 
11-cis, 13-cis, 9,13-di-cis and 11,13-di-cis with the predominant physiological form 
being all-trans.  Figure 7 shows the structure of β-carotene and several natural and 
synthetic retinoids.   
Vitamin A deficiency (VAD) is associated with blindness, infectious diseases, 
diarrhea and malnutrition, the latter being a leading cause of death in children (39, 
40).  Less severe deficiencies in vitamin A retard growth and intensify iron deficiency 
anemia (41).  Therapy with Vitamin A has been demonstrated to be effective in 
reducing the severity of VAD and therefore many immunization programs began 
including vitamin A (42, 43).  Conversely hypervitaminosis A can result in toxicity to 
the liver, CNS, bone and skin (37, 44). 
Vitamin A and retinoids play an important role in vertebrate development, and 
have been identified as potent teratogens.  In 1933, Hale reported the first evidence of  
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Figure 7: Structures of β-carotene and several natural and synthetic 
retinoids. 
 
Figure from: Collins MD, Annu Rev Pharmacol Toxicol 1999 39:399-430 
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teratogenicity due to vitamin A deficiency; a deficient sow gave birth to piglets without 
eyeballs.  In 1950, Wilson and Warkany reported that the offspring of rats fed vitamin 
A-deficient diets prior to and during gestation showed malformations in the eye, 
urogenital tract, heart and lung (37, 45).  In 1954, Cochlan (46) was the first to report 
that excess vitamin A administered during pregnancy can be teratogenic.  The 
malformations reported were exencephaly, hydrocephaly, spina bifida, eye defects, 
cleft palate and shortening of the mandible and maxilla (37).  The teratogenicity of RA 
has been even more firmly established since 1954.  At pharmacological 
concentrations, RA is able to induce malformations in all vertebrate species as well as 
certain invertebrates, with the extent of the malformations depending on the dose and 
developmental stage (37, 47, 48).  Certain retinoids used for treatment of disease, 
such as Accutane® (13-cis RA) and etretinate, are reported human teratogens, and 
therefore prescribed with highly restrictive guidelines especially to women of 
childbearing age.  As a toxicologist one can ask “How does RA fit with the six 
principles of teratology?”  These would include:  
a) Principle I of teratology is that “teratogenic susceptibility is determined by the 
genotype of the conceptus and the interaction of this genotype with environmental 
factors” (37, 49).  Evidence thus far suggest that all species, to varying extents, are 
susceptible to the teratogenic effects of 13-cis RA (37).   
b) Principle II states that “susceptibility to teratogenic agents depends on the 
developmental stage of the embryo or fetus at the time of exposure” (37, 49).  Up until 
the first two weeks of human pregnancy, the embryo is relatively insensitive to 
teratogenesis.   This changes though at the organogenesis stage at weeks 3-8 of 
human gestation when the embryo is highly sensitive to teratogens.  Sensitivity 
gradually decreases after 8 weeks until parturition.  A study of RA-induced 
- 27 - 
teratogenesis in hamsters suggests that small changes in gestational timing of 
exposure will result in major shifts in embryo lethality and malformations, and that 
for each malformation there is a “critical period” where exposure to an agent will cause 
malformation.  Human epidemiological data describe a syndrome associated with 13-
cis RA, called Retinoic Acid Embryopathy (RAE).  Malformations associated with RAE, 
include craniofacial, cardiovascular, CNS and thymic abnormalities (37).  The 
teratogenic effects of RA occur at stages where it is not normally present in the 
embryo.  Most RA teratogenic effects in mice embryos occur at the stage of 
development prior to the onset of RA synthesis by the embryos.  During this time the 
amount of RA required to induce malformations is 50-100 fold less than at other 
stages of development.   
c) Principle III of teratology states that “teratologic agents work by specific 
mechanisms on developing cells and tissues to initiate pathogenesis” (37, 49).  With 
respect to RA, embryonic pathogenesis occurs by an unknown specific mechanism 
early in development.  Most human teratogens have unknown mechanisms of action, 
although there are a number of mechanisms that can be hypothesized with respect to 
RA-induced teratogenesis that are receptor-mediated or receptor independent.   
d) Principle IV states that “perturbations of developmental processes can result 
in death, malformation, growth retardation, and/or functional disorder” (37, 49).  
Generation of transgenic knockout mice is a method often employed to study the 
function of a gene.  Often though, when no gross anatomical phenotype is observed, 
functional redundancy is ‘blamed’, that is, the function of the gene in question can be 
performed by another gene.  It is possible that deletion of a specific gene will produce a 
subtle phenotype that can be detected only through specific assays for postnatal 
functional and anatomic development (37).  Mice null for RARβ, RXRβ and RXRγ were 
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observed to be deficient in forward locomotion compared to wildtype littermates.  
These mice had reduced expression of the dopamine receptors D1 and D2 which 
caused the phenotype.  Expression of these dopamine receptors is induced by retinoid 
receptors [(37) and references therein].  In addition to physical malformations, RA is 
able to induce behavioral teratogenesis as observed in women who had prenatal 
exposure to 13-cis RA and gave birth to children with reduced intelligence [(37) and 
references therein].   
e) Principle V states that “the nature of the influence (or agent) determines the 
extent of the interaction between the environmental agent and conceptus” (37, 49).  
This principle deals with the question of whether the agent acts on the embryo directly 
or indirectly through maternal toxicity.  Transcriptionally active retinoids do not 
normally cross the placenta, but are synthesized within embryonic cells from maternal 
retinol.  At elevated doses the normal biochemical pathways of retinoids change and 
there is placental transport.   
f) Principle VI of teratology states that “there is an increase in the sequelae of 
abnormal development from the no effect level to the totally lethal level” (37, 49).  This 
principle states that there should be a dose-response relationship associated with 
retinoid administration and this has been demonstrated in a number of animal 
experiments (37).  Method of retinoid administration can also play a role; whereas oral 
administration may be teratogenic dermal administration often is not.  Another factor 
of this principle is whether compounds have a threshold for teratogenesis.  Retinoids 
are believed to have a threshold and generally follow a dose-response relationship [(37) 
and references therein].  Finally the teratogenic effects mediated by RA are receptor 
mediated, in that retinoids that are unable to activate RARs are nonteratogenic (50).   
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Retinoic acid plays a role in organogenesis as well as development.  Retinoids 
have been shown to be important to the development of the heart and vasculature and 
in the absence of retinoids these structures do not form or are inoperatively lethal.  In 
1969, Thompson et al (51) showed that in the absence of retinoids the vasculature of 
domestic fowl does not develop and the embryo disintegrates (51).  Furthermore, eggs 
from hens fed with a diet free of retinol, but adequate in RA, do not hatch, probably 
due to failure of RA to be transferred to the egg.  In ovo administration of RA is also 
not as effective as retinol in permitting embryonal development (51, 52).  The results 
first reported by Thompson were subsequently confirmed in the quail embryo (52, 53).   
To study the effect of RAR and RXR in retinoid signaling, a number of studies 
were undertaken in mice.  Transgenic knockout mice for RARα, RARβ and RARγ were 
found to be viable but displayed certain aspects of VAD syndrome and some 
congenital abnormalities in the tissues that normally express these receptors (54).  
The limited phenotype observed in these knockouts leads to the assumption that there 
is some functional redundancy between RARs.  To study this further, double knockout 
mice were constructed and studied.  Mice deficient in RARα/β, RARα/γ and RARβ/γ died 
from severe developmental defects in utero or shortly after birth (54-56).  The severe 
malformations observed in RARα/γ null mice are similar to those of mice deficient in 
retinaldehyde dehydrogenase 2, which functions in RA synthesis, and highlight the 
importance of RA-liganded RARs early in development (57, 58).  Some important early 
development RA functions that have been identified include hindbrain segmentation 
and closure, oocyte formation, axial rotation, development of forelimb buds and 
closure of the primitive gut (57).  In addition to the above, RARs have been shown to 
be important for the ontogenesis of structures derived from mesenchymal cells, the 
development of ocular structures and the formation of the genital tract and ureters 
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[(57) and references therein].  Another function of RARs in development is the 
establishment of the anteroposterior axis of limbs, histogenesis of the retina, the 
regulation of lung branching morphogenesis and alveolar septation, as well as the 
morphogenesis of nasal cavities [(57) and references therein].  Data from RXRα null 
mice suggest that RXRα is the main RXR involved in embryogenesis (57, 59).  RXRβ 
and RXRγ null mice do not have an obvious phenotype, even when one allele of RXRα 
is deleted. 
The role of retinoids in carcinogenesis and disease processes has been 
extensively studied, as has their potential therapeutic value.  As early as 1925, 
Wolbach and collaborators established that vitamin A deficiency causes squamous 
metaplasia and keratinization of epithelia (52).  Because epithelial cancer is 
responsible for the death of many people retinoids became the focus of cancer 
research.  RA is thought to inhibit tumor growth by inhibiting uncontrolled cell 
proliferation, inducing apoptosis of abnormal cells, and promoting normal cell 
proliferation (60).  Pioneering efforts also showed retinoids to be effective in the 
inhibition of tumorigenesis of the skin and in the respiratory, mammary, buccal and 
stomach epithelia of rodents [(52) and references therein].  In preclinical studies, 9-cis 
RA has been shown to be effective in the chemoprevention of mammary and prostate 
cancer.  Targretin (an RXR ligand; Ligand Pharmaceuticals, San Diego, CA) has been 
shown to be effective in the chemoprevention of mammary cancer, suggesting that 
RXR is important in epithelial cancer development.  Retinoids (especially 13-cis RA) 
have been shown to be effective for the prevention of head and neck cancer, but have 
not yet been demonstrated to be effective in the prevention of lung cancer.  Conversely, 
several large scale trials such as the Beta-Carotene and Retinol Efficacy Trial (CARET), 
the Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study and the Lung–
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Study sponsored by the NCI, suggest retinoids may actually raise the risk of lung 
cancer in smokers.  These studies also showed reduced tumor recurrence and 
mortality in nonsmokers and some small evidence of benefit to former smokers, 
suggesting that the response to retinoids differs between smokers and nonsmokers.  A 
study by Kurie et al (61) examined the usefulness of 9-cis RA for the prevention of lung 
cancer in former smokers.  Loss of RARβ expression in the bronchial epithelium is 
considered a biomarker of preneoplasia, and retinoids can restore expression of RARβ 
and presumably halt the progression of carcinogenesis.  With this in mind, in a 
controlled study, 9-cis RA, 13-cis RA + alpha-tocopherol were used to evaluate 
squamous metaplasia, dysplasia and RARβ expression in former smokers.  9-cis RA 
was shown to be more effective than 13-cis RA in restoring RARβ expression.  These 
findings suggested that ligands for both RARs and RXRs may be more effective 
chemopreventors than RAR-selective ligands.  APL (acute promyelocytic leukemia) is 
caused by a translocation fusing the RARα gene to a gene called PML (for 
promyelocytes).  Interestingly, the fusion protein is still RA responsive and RA 
treatment causes partial remissions in APL patients.  RA therapy has been shown to 
improve the survival of children with neuroblastoma by suppressing residual disease 
after chemotherapy, and it now forms an important part of neuroblastoma treatment 
(62, 63).  A study showed that in xeroderma pigmentosum, RA treatment results in a 
reduction of new and recurrent skin tumors (64).  Finally, various skin conditions are 
treated with RA and its derivatives (65, 66).  One of the better established targets of 
retinoids is the skin.  Accutane (13-cis RA) is used for the treatment of cystic acne.  
Retin A is used as topical treatment for acne and etretinate is used for the treatment 
of psoriasis.  Cumulatively these data demonstrate that retinoids and their receptors 
play critical roles in the development and homeostasis of a variety of tissues and that 
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perturbation of either the ligand or receptor function can have both disease and 
therapeutic implications. 
Precursors for RA are derived from multiple food sources and converted to 
active forms of RA in the gut, liver and target tissues [reviewed in (37)].  Retinoids are 
absorbed in the duodenum where retinyl esters from animal products and dairy are 
hydrolyzed to retinol.  Carotenoids, which are derived from plants, are metabolized to 
retinaldehyde in the intestine.  Retinyl esters and retinaldehyde are then bound to 
CRBP II and this complex serves as a substrate for the lecithin-retinol 
acetyltransferase enzyme, which converts retinol to palmitate and other retinyl esters.  
Following their conversion, retinyl esters are packaged into chylomicrons and delivered 
to the liver where hydrolysis to retinol occurs.  Retinol is then bound to lipocalin 
retinol-binding protein (RBP) and the complex is delivered to hepatic stellate cells 
where retinol is converted to retinyl esters, which are stored in lipid droplets in the 
liver.  Prior to reentering the circulatory system retinyl esters must first form the 
retinol-RBP complex to mask its hydrophobicity and then complex with transthyretin 
to prevent kidney elimination.  Once it is delivered to target tissues, retinol undergoes 
multiple enzymatic reactions to be converted to multiple products, including active 
retinoids.  Like retinol, RA is not free but rather is bound to albumin upon entering 
the circulatory system.  Figure 8 shows some of the major enzymatic pathways of 
retinol.  Several cytochrome P450s have been implicated in the creation and 
destruction of RA [(37) and references therein].  There is a second family of retinol 
binding proteins, CRABP types I and II and CRBP I and II.  These are found in specific 
anatomic locations and are highly conserved across species.  These have higher 
affinity for RA than the RARs and are found in greater abundance in cells than their 
respective ligands (all-trans-retinol for CRBP and all-trans-RA for CRABP).  Generation  
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Figure 8: Principal retinoids in the metabolic pathway.  The columns 
represent the various isomerization states, except for the 3,4-didehydro pathway; 
however, the pathway metabolites are only delineated for the all-trans forms.  
Shown here is the 9-cis pathway.  In general the top has relatively reduced 
retinoids, whereas the bottom has relatively oxidized retinoids.  ROG is all-trans-
retinyl-β-glucuronide, RAG is all-trans-β−glucuronide, and RA is retinoic acid.  
The arrow from all-trans-oxo-RA with no product indicates that there are more 
oxidized products that are unknown. 
Figure from: Collins Annu Rev Pharmacol. Toxicol. 1999 39:399-430 
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of transgenic knockout mice for these proteins has shed some light into their function.  
CRABP I null mice displayed no reported phenotype and CRABP II null mice had 
postaxial forelimb polydactyly.  Deletion of both genes resulted in polydactyly, and did 
not display altered sensitivity to teratology following retinoid administration (37).   
Retinoic acid exerts its effects by binding to retinoid receptors.  Retinoid 
receptors can be divided into two subgroups, the retinoic acid receptors (RARs) and 
retinoid “X” receptors (RXRs).  There are three isoforms of RAR, α, β and γ, and they 
bind to all-trans retinoic acid (atRA) and its isomer 9-cis retinoic acid (9cRA).  Retinoid 
X receptors also have three isoforms α, β and γ and are able to bind to 9cRA with very 
high affinity but not to atRA.  Sequence comparisons have shown that there is more 
conservation of a specific receptor isoform between species than is found between the 
three receptor isoforms within a species (8).  This conservation leads to the conclusion 
that each receptor isoform must have a unique and specific function.  RARs are 
phylogenetically more closely related to thyroid receptors but only distantly related to 
RXRs (1). 
The first RAR (RARα) was independently cloned by three different groups in 
1986-87 (67-69).  In 1986, before the cloning of RARα or TRs, Anne Dejean 
characterized an integration site for HBV in a hepatocellular carcinoma, and cloned 
the corresponding cDNA which she named hap for hepatoma (69).  In 1987, Pierre 
Chambon’s group operating on the assumption that RA may, like steroid hormones, 
mediate its transcriptional effects via specific nuclear receptors, used a consensus 
oligonucleotide corresponding to a highly conserved sequence in the DBD of several 
members of the nuclear receptor family to probe two ‘randomly primed’ λgt cDNA 
libraries prepared using total poly(A)+ RNA from the human breast cancer cell lines 
MCF-7 and T47D (68).  The clone isolated was characterized and shown to bind to RA 
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with high selectivity and to retinol with lower affinity.  At the same time, Ron Evans’ 
group, using an oligonucleotide derived from a novel genomic sequence derived from 
hap (69), probed a λgt10 kidney cDNA library and isolated and characterized an RARα 
clone.  Based on the high sequence homology hap had to RARα, it was subsequently 
determined by Anne Dejean’s and Pierre Chambon’s group to be a retinoic acid 
receptor isoform, and was named RARβ (70).  Pierre Chambon’s group was the first to 
identify a third isoform of RAR, RARγ, during their characterization of the murine 
RARα and RARβ (71).   
The DBD of the three RARs is extremely conserved at 97-100% sequence 
identity and the LBD is also well conserved with 85-90% sequence identity (1). Of 
important note is that RARβ has been identified only in mammals and birds and not in 
amphibians and fish.  The reason for this is not known.  RARγ and has orthologs in 
amphibians, fish, mammals and birds (1).   
The identification and characterization of a naturally occurring RARE resulted 
from the analysis of retinoic acid-inducible genes such as RARβ.  The response 
element for retinoic acid receptors consists of two or more degenerate copies of the 
AGGTCA half-site motif organized in direct repeats or palindromes normally separated 
by 5 nucleotides, however there are exceptions to this.  Specific proteins found in 
nuclear extracts were shown to increase the binding efficiency of RARs to these 
response elements (72, 73).  Efficient binding of RAR to DNA occurs when partnered 
with RXR.  When bound to DNA, the 5’ half-site is occupied by RXR and the 3’ half-
site is occupied by RAR [(1) and references therein].  In addition to DR5, RAR-RXR 
heterodimers are able to activate transcription from DR1 and DR2 elements, such as 
those found in the promoters of cellular retinoic acid binding protein (CRABP) and 
cellular retinol binding protein (CRBP) (74, 75).  When bound to DR1 elements the 
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RAR-RXR heterodimer is unresponsive to retinoic acid stimulation, most probably due 
to the inverted polarity of the heterodimer (5’-RAR-RXR-3’) (76).  When the heterodimer 
is in this inverted polarity, RAR ligands cannot induce dissociation of corepressors, 
and therefore transcriptional activation cannot occur.  Dimerization occurs through 
interaction of the second zinc fingers of RAR and RXR.  There are no homodimerization 
domains on RAR, making the RAR-RXR heterodimer solely responsible for the 
response to RA.  Transcriptional activation by RAR is dependent on the pairing of RAR 
with RXR.  Dimerization occurs on two interfaces, the DBD interface which is involved 
in the recognition of response elements on DNA and the LBD interface which is 
independent of the DNA binding activity of the complex. 
RARs are transcription factors, and their target genes have been implicated in a 
large number of biological processes such as embryonic development and liver 
metabolism.  Some of the first target genes reported for RARs include CRABP (74), 
CRBP (75) as well as RARβ itself.  Another group of RAR regulated genes are the Hox 
genes, which play an important role in anteroposterior axis specification in 
development.  Hox genes have also been shown to play an important role in 
transducing the morphogenic signal of RA, in that treatment of a developing embryo 
with exogenous RA leads to axial patterning and this is associated with repatterning of 
Hox gene expression domains (77).  Somites are masked from left-right cues and are 
held in symmetrical register by an RA dependent signal (78).  A symmetry-generating 
mechanism is necessary as proper somite development requires left-right 
refractoriness (78).  To orchestrate differentiation and patterning a number of 
molecular signals such as Wnt, Notch, Hedgehogs and Fibroblast Growth Factors 
(FGFs) are employed in developmental settings often in conjunction with distinct 
cofactors (78).  The anterior-posterior patterning of somites is defined by Notch, Wnt, 
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FGF8 and RA signaling (78, 79) while simultaneously, Notch, FGF8 and RA signaling 
are instrumental in left-right determination (78, 80).  This signaling conflict makes it 
necessary to block the effect of side-specific signaling and to hold somitogenesis in 
synchronized and symmetrical register.  This need is met by an RA-dependent 
signaling mechanism (78, 81-83).  The mechanism by which RA masks left-right 
signals is unclear (78).  FGF8, which is generated at the posterior end of the embryo 
during somitogenesis is antagonized by RA (78) and this is crucial for segmentation to 
proceed (78, 79).  Blocking of endogenous RA production by antisense oligonucleotides 
against raldh2 results in strongly biased LR asymmetric somite development (81).  
Progression of somitogenesis in zebrafish embryos depends on RA signaling and is 
tightly linked to the cascade of LR organ asymmetry information (81). 
RARs have been shown to interact with a number of transcription factors and 
have been used as bait in various assays to identify nuclear receptor coregulators.  
RARs bind to p160 family members SRC-1, TIF2 and p/CIP in a ligand and AF-2 
dependent manner (84).  RARs also bind to p300 and CBP (85).  RAR is able to interact 
with the TRAP220 protein, which belongs to the DRIP/TRAP/SMCC complex (86, 87).  
Apo-RAR is bound to NCoR and SMRT (84, 88); upon ligand binding this interaction 
persists when RAR is bound to a DR1 response element.  This persistence in 
interaction could explain the repressive effect of RAR-RXR heterodimers bound to DR1 
elements (1). 
In summary, retinoid receptors propagate vitamin A induced events in cells.  
Vitamin A deficiency is associated with disease states such as blindness and 
malnutrition.  Too much vitamin A is also detrimental to health leading to toxicity in 
tissues such as liver, CNS and skin.  Vitamin A and its derivatives are also important 
signaling molecules for development where the amount and timing of expression of 
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retinoid receptors is critical.  Mice deficient in more than one retinoid receptor display 
abnormalities and a shortened life span.  Retinoids have also been proposed to act as 
antitumor agents and have been the subject of many clinical and chemopreventive 
trials with mixed results.  For certain retinoid signaling is important for many 
biological systems and processes. 
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SUMMARY 
 
Nuclear receptors are the largest family of transcription factors and are 
responsible for integrating multiple signaling pathways.  They regulate complex 
physiological events and play a role in embryogenesis, development, metabolism and 
apoptosis.  All nuclear receptors identified to date share the same modular structure.  
The DNA binding domain of nuclear receptors is the most conserved domain; the 
ligand binding domain is the least conserved.  These receptors  exert their function 
either as homodimers (steroid subfamily members) or as heterodimers (thyroid 
receptor subfamily members).  Nuclear receptor dimers bind to their respective 
response elements.  Hormone response elements are composed of two half-site motifs 
that are separated by 3, 4, or 5 nucleotides.  The spacing between the two half-sites 
dictates the specificity with which the receptor will bind.  The polarity of the 
heterodimers also dictates the response to ligand stimulation.  Steroid family members 
are bound to heat-shock proteins in the absence of ligand while TR subfamily 
members are bound to their response element regardless of ligand presence.  The 
determination of the crystal structure of these receptors showed that they share a 
common fold and that upon ligand binding, the receptor undergoes a conformational 
change.  This model of conformational change is called the “mousetrap model”. 
An additional “layer” of transcriptional activation by nuclear receptors is the 
discovery of “coregulators”.  A number of transcriptional coregulators have been 
discovered to date.  Corepressors have endogenous HDAC activity which keeps 
chromatin in a compact “turned off” conformation.  Coactivators are associated with 
HAT activity which is associated with “relaxed” chromatin and allows for transcription 
to occur.   A lot of these coregulators were discovered using retinoic acid receptors as 
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bait for the library screens.  Using RXR as bait our lab identified a novel coregulator 
that had a high sequence homology to the published sequence for NPDC-1 (neural 
proliferation differentiation control) gene identified just three years earlier.  The focus 
of this dissertation will be on studies that show NPDC-1 to be a coregulator of retinoid 
and thyroid receptor transcription. 
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SECTION II: NPDC-1 AS A MODULATOR OF TRANSCRIPTION EVENTS BY HUMAN 
RETINOID AND THYROID RECEPTORS 
 
 
Chapter 4: NPDC-1 
 
 The discovery of transcription factors greatly enhanced our understanding of 
the mechanisms of development.  In a search to define the mechanisms involved in 
neural cell commitment and differentiation, Pierre Rouget’s group attempted to identify 
genes that may be involved in the control of neural cell proliferation and differentiation 
(89).  Their criteria for selecting the sequences to be used as probes was both their 
preferential expression in neural precursor cells reaching confluence and their ability 
to encode amino acid sequences yielding helix-loop-helix motifs.  Transcription factors 
in the basic helix-loop-helix family are key regulators in development, particularly cell 
type determination, terminal differentiation and sex determination (90).  From their 
screen a unique gene was identified that was named NPDC-1 for Neural Proliferation, 
Differentiation and Control (89).  Further analysis of the sequence showed some 
regions with homology to jun-fos leucine zippers, but the homology was too short to 
classify NPDC-1 as a member of the helix-loop-helix or leucine-zipper protein families 
(89).  A stretch of potential phosphorylation sites was also identified between amino 
acids 234-244.  This corresponds to the sequence Pro-Thr-Ser-Pro-Ser-Thr-Pro-Arg-
Ile-Ser-Pro which represents three consensus sites recognized by mitogen-activated 
protein kinases (MAPK) (89).  A Northern blot of RNA from proliferating, growth 
arrested or differentiating CLT.T.1.1 cells showed a 1.5kb mRNA that was 
preferentially expressed when the cells were growth arrested. In addition, tissue 
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analyses of NPDC-1 RNA expression suggested that, in mouse, NPDC-1 is almost 
exclusively expressed in brain (89).  Finally, these initial studies also provided the first 
evidence suggesting NPDC-1 might function as a tumor suppressor, in that NPDC-1 
was shown to both suppress proliferation and inhibit growth in soft agar (89). 
The expression pattern of NPDC-1 during the development of the nervous 
system as well as the potential association of NPDC-1 with cell cycle regulatory 
proteins was examined by Dupont et al (91).  Using total RNA from embryonic, 
postnatal and adult mouse brain they showed that NPDC-1 expression increased 
during development with the highest levels in adult brain.  Using in-situ hybridization 
experiments, these investigators next examined the expression of NPDC-1 during 
development.  In mouse brain NPDC-1 was observed to be expressed in different parts 
of the brain at different times of development, with the strongest expression observed 
in the adult hippocampus (Table 3).  The expression of NPDC-1 was also studied in 
P19 and PC12 cells.  P19 are a mouse embryonal carcinoma cell line that can be 
induced with RA to differentiate into neuronal cells or induced with DMSO to 
differentiate into muscle cells (92).  Northern blot analysis of P19 mRNA showed that 
NPDC-1 expression was induced with RA treatment but not with DMSO treatment 
(91).  PC12 cells showed endogenous expression of NPDC-1 mRNA could be 
substantially increased with NGF treatment (91).  These results support the original 
claims of regulated expression of NPDC-1 in neuronal cells.   
The interaction of NPDC-1 with cell cycle regulatory proteins was investigated 
by Dupont and Sansal (91, 93).  Using in vitro pull-down assays these investigators 
were able to demonstrate that cyclin D1, Cdk2 and cyclin A are able to interact with 
NPDC-1 either directly or indirectly.  The interaction between NPDC-1 and cyclin A  
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Table 3: Expression of NPDC-1 mRNA in newborn and adult mouse CNS.  
Highest levels of NPDC-1 are observed in the hippocampus, both in newborn 
and adult mouse.  Expression of NPDC-1 not only varies between tissues but 
also within tissues. 
 
Figure from: Dupont et al, J of Neuroscience research 1998 51:257-267 
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was shown to be indirect, whereas the interaction between cyclin D, Cdk 2 and NPDC-
1 was direct (91).  These data cumulatively demonstrate that NPDC-1 can interact 
with a variety of cell cycle regulatory proteins and suggest that NPDC-1 plays a role in 
neuronal differentiation through its ability to regulate neuronal cell cycle progression. 
NPDC-1 was also shown to complex with the cell cycle regulatory transcription 
factor E2F-1 (91, 93).  Neuronal cell cycle progression and neuronal differentiation 
have been classically linked to the activities of the E2F family of transcription factors.  
The transcriptional activity of E2F-1 is due to its association with the retinoblastoma 
proteins pRb, p107 and p130 (94).  NPDC-1 was shown to complex with E2F-1 
suggesting that these two proteins interact to exert their function.  Sansal et al (93) 
localized the domain of interaction between NPDC-1 and E2F-1 at the amino terminus 
of NPDC-1 although deletion of the carboxyl terminus reduced the interaction.  The 
interaction between NPDC-1 and E2F-1 was also demonstrated in vivo in a two hybrid 
experiment (93).  In gel shift experiments the investigators were able to demonstrate 
that NPDC-1 inhibited the binding of E2F-1 to DNA in a dose dependent manner (93).  
NPDC-1 was also shown to decrease the transcriptional efficiency of E2F-1 (93).   
A widely accepted model is that association of E2F-1 with pRb represses the 
transcription of genes involved in cell cycle regulation and mediates different E2F 
activities depending on the cell type and proliferative or differentiated state of the cells 
(91).  The observation that NPDC-1 can complex with E2F-1 suggests that NPDC-1 
may play a role in the in terminal neural cell proliferation and differentiation through 
an ability to repress E2F-1 mediated transcription.  A hypothetical model for NPDC-1 
repression of E2F-1 mediated transcription is presented in figure 9.  As seen in figure 
9, activation of cyclin D1 leads to the phosphorylation of pRb which then dissociates  
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Figure 9:  E2F-1 and cell cycle regulation.  E2F-1 is normally associated with 
pRb and this leads to inhibition of gene transcription.  Phosphorylation of pRb 
leads to dissociation and E2F-1 is able to stimulate cell cycle entry and 
progression.  NPDC-1 has been shown to complex with E2F-1 and it can be 
hypothesized that these interactions repress E2F mediated transcription and 
therefore cell cycle progression. 
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from E2F-1 and allows E2F-1 to transactivate gene expression and promote cell cycle 
progression.   
The human homolog for NPDC-1 was first published in 2001 when a Chinese 
group isolated a clone that shared a high homology to the mouse NPDC-1 gene by 
screening a human fetal liver cDNA library (90).  Analysis of the composition of 
hNPDC-1 revealed a transmembrane segment at amino acids 182-202, and conserved 
HLH residues in the amino terminus.  Prosite analysis revealed a cAMP and cGMP-
dependent protein kinase phosphorylation site (aa 108-111), four protein kinase C 
phosphorylation sites (aa 9-11, 134-136, 216-218, 223-225), four casein kinase II 
phosphorylation sites (aa 171-174, 236-239, 275-279, 286-289), and eight N-
myristoylation sites (aa 24-29, 33-38, 46-51, 61-66, 141-146, 162-167, 180-185, 294-
299) (90).  Add to these the three consensus sites for MAPK identified by Galiana et al 
(89), these observations would support the hypothesis that phosphorylation is 
important to NPDC-1 function.   
The human genome sequencing project identified NPDC-1 localization at 
chromosome 9q34.  Alignment of hNPDC-1 cDNA with its genomic sequence revealed 
that hNPDC-1 is composed of nine exons and eight introns (90).  According to the 
NCBI website, 
(www.ncbi.nih.gov/IEB/Research/Acembly/av.cgi?db=human&l=NPDC1), NPDC-1 
produces by alternative splicing 14 different transcripts all with introns, putatively 
encoding 14 different protein isoforms.  The gene contains 17 introns and has 3 
probable alternative promoters and four non-overlapping alternative last exons.  The 
transcripts appear to differ by truncation of the 5’ end, truncation of the 3’ end, 
presence or absence of four cassette exons, and common exons with different 
boundaries.  In addition, the gene has 3 shed variants, with exon contact but no 
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shared intron boundary.  The mouse gene is similarly complicated 
(http://gbrowse.informatics.jax.org/cgibin/gbrowse/mouse_build_34?name=chr2:253
35246..25341657). 
Northern blot analysis of human fetal tissues showed at least two transcripts of 
the gene (90).  The smaller 1.55kb transcript appears to correspond to the full-length 
cDNA of NPDC-1, is the most abundant transcript and is most abundantly expressed 
in brain and heart (90).  The bigger 4.6kb transcript is primarily expressed in the 
heart (90) (Figure 10).  A further examination of hNPDC-1 mRNA expression patterns 
using dot blot technologies suggested NPDC-1 is expressed at low levels in a variety of 
tissues and fairly strongly expressed in brain, mammary gland, pituitary and prostate 
(90).  There also appears to be a significant (1.82 fold) upregulation of NPDC-1 mRNA 
expression in adult brain when compared to fetal brain (90).  Although both hNPDC-1 
and mNPDC-1 are expressed highly in the brain, the published expression profiles of 
these two proteins differ substantially.  mNPDC-1 was reported to be exclusively 
expressed in the brain and have only one transcript (89) whereas hNPDC-1 shows 
multiple transcripts and is expressed in other tissues besides brain (90).  This could 
be explained by species differences or by the regions of NPDC-1 that were used as 
probes for the northern and dot blots.  Our data and the available established EST 
sequence data strongly support the multiple transcript and more abundant expression 
of NPDC-1 (95).   
 Subcellular localization studies suggest NPDC-1 can localize to multiple 
locations within cells and this localization may be tissue or cell specific (96).  NPDC-1 
tagged with either FLAG or GFP was transfected into neurons and neuroendocrine 
cells (PC12 and GH3) to study its expression.  In primary differentiated cortical 
neurons, NPDC-1 displayed a punctate staining along and at the distal part of neuritic  
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Figure 10:  Multiple tissue Northern blot analysis of hNPDC-1 
transcription in 12 human fetal tissues.  Lanes 1-12: brain, heart, skeletal 
muscle, colon, thymus, spleen, kidney, liver, small intestine, placenta, 
lung, peripheral blood leukocyte.  The size markers 1.4, 2.4 and 4.4kb are 
indicated in the left. 
 
Figure from: Qu et al Gene 2001 264:37-44 
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processes and accumulated in small varicosities (96).  The fluorescence was primarily 
vesicular and a small fraction appeared diffuse in the cytoplasm.  No NPDC-1 was 
observed in the nucleus of these cells.  Immunocytochemical analysis of FLAG-NPDC-
1 transfected PC12 and GH3 cells, revealed that the protein was inserted in the 
plasma membrane with the N-terminal region outside  the cells (96).  NPDC-1 was also 
detected in the endoplasmic reticulum and in the golgi apparatus (96).  The presence 
of NPDC-1 in transferring positive punctate structures suggests that plasma 
membrane localized NPDC-1 may be internalized by endocytosis (96).  At present it 
cannot be concluded that NPDC-1 is involved in synaptic vesicle trafficking (96), but 
appears to be associated with synaptic vesicles. 
NPDC-1 knockout mice have also been generated and analyzed (97).  No 
observable phenotype was detected in the null mice and histological analysis of adult 
and embryo brains showed no brain anomalies (97).  This is surprising for a protein 
that appears to play a role in development and tissue differentiation.  To complicate 
matters, studies in zebrafish show that NPDC-1 does have an observable phenotype.  
Zebrafish have been an invaluable tool for the study of developmental processes.  In 
situ hybridization of zebrafish embryos at different stages of development show that 
diffuse expression of NPDC-1 mRNA occurs early in zebrafish development and is 
restricted to specific tissues as the embryo develops (98).  NPDC-1 protein is observed 
to be expressed later in zebrafish development suggesting that either NPDC-1 is a 
maternally expressed mRNA and under tight translational control or it is rapidly 
degraded (99).  Overexpression of NPDC-1 in zebrafish embryos led to abnormal 
development phenotypes.  The most consistent phenotypes observed were no tail or 
duplicated head in place of the tail, and a milder phenotype where embryos lack much 
of their muscle layers and blood vessels (98).  Of potential significance to NPDC-1’s 
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mechanism of activity (and something further explored in this dissertation) is the 
observation that the teratogenic effects observed with overexpression of NPDC-1 in 
zebrafish parallel those observed with RA treatment of zebrafish embryos (100).  
Knocking down NPDC-1 in zebrafish embryos using NPDC-1 morpholinos disrupted 
normal organogenesis and resulted in a shortened lifespan.  These data cumulatively 
would suggest that, at least in zebrafish, NPDC-1 plays a critical role in development.  
Possible explanations for these differences might include; the development of some 
compensation system in mice not present in zebrafish, an alternative function for 
NPDC-1 in zebrafish, or alternative expression of a variant of the NPDC-1 gene in 
mice. 
In summary, NPDC-1 has been identified as a novel regulator of cell 
proliferation and differentiation in neuronal cells, but is also expressed in multiple 
tissues.  NPDC-1 was found to associate, either directly or indirectly, with cell cycle 
regulatory proteins such as cyclin D, cdk2, cyclin A and E2F-1.  Expression of NPDC-1 
increases during development and the highest levels are observed in adult tissues.  
Knockout mice for NPDC-1 have no observable phenotype but in zebrafish NPDC-1 
expression appears to be important for development. 
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Chapter 5: NPDC-1 as a regulator of Nuclear Receptor function 
 
 Retinoids have an established and profound effect on cellular differentiation 
and proliferation.  Retinoids exert their effects by stimulating the RAR-RXR receptor 
complex and effect transcription of genes with RARE response elements.  In 
mammalian cells, retinoid mediated transcription is influenced by the cell cycle 
regulator E2F-1.  When E2F-1 is coexpressed with a βRE plasmid, transcription 
induced by atRA is inhibited (95), however the interaction between E2F-1 and RARs or 
βRE is not direct, suggesting an interaction with a common accessory factor or factors 
(95).   
 Using a novel yeast cDNA library screening protocol for identifying positive 
regulators of RXR mediated transcription, Henry et al identified the rat homolog of 
NPDC-1 (95).  The rat NPDC-1 clone was subsequently used to clone a human NPDC-1 
homolog and sequence analysis comparison of rat and human NPDC-1 with mouse 
NPDC-1 (figure 11) showed that the protein is well conserved between these species 
suggesting that the protein has a conserved function.  Conserved motifs found within 
all three proteins include: a) an LXXLL motif (or NR box) which is a mediator of 
interaction between nuclear receptors and coregulators (28), b) a HLH motif, which 
provides the binding site for DNA.  c) a MAPK kinase domain which is involved in 
phosphorylation, a way to regulate protein function, and d) a PEST domain which is 
involved in post-translational modification by targeting proteins for degradation by the 
ubiquitin-proteosome system.  Tissue distribution comparison of rat and human 
NPDC-1, as analyzed by northern blotting, revealed rat brain to express a single mRNA 
species consistent with the published results for mouse, while rat lung, skeletal 
muscle, kidney and heart expressed multiple mRNA species.  In human, multiple  
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Figure 11: Comparative alignment of rat and human NPDC-1 with the 
mouse sequence.  Conserved amino acids are indicated with *.   
 
Figure from: Henry et al Nuclear Receptor 2003 1 
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NPDC-1 mRNA species were detected in brain as well as in other tissues (figure 12).  
These data agree with previously published data by Qu et al (90).   
 To test whether NPDC-1 interacted with RXR, RAR and E2F-1, recombinant 
thioredoxin-tagged hNPDC-1 was used to pull-down protein from PC12 cell lysates 
that had been transfected with haemaglutinin (HA)-tagged E2F-1, human RARβ or 
human RXRα.  Immunoblotting analysis showed that hNPDC-1 is able to bind to 
hRARβ, hRXRα and E2F-1, and binding to the retinoid receptors was observed to be 
ligand independent.  Furthermore, these were the first studies to show a direct in vivo 
interaction between hNPDC-1 and E2F-1.  In addition we were able to localize NPDC-
1’s RXR binding domain to the amino terminus, suggesting that the putative coiled-
coil domain in this region may play a role in the interaction of NPDC-1 with RXRα.  
Finally, it has been shown that interactions between coregulators and NRs often occur 
at LXXLL motifs (1, 28).  In the amino terminus of NPDC-1 is a conserved LXXLL motif 
and to evaluate the importance of this motif to RAR-mediated transcription events, a 
series of mutations were made to this motif and these mutants were analyzed for their 
impact on NPDC-1 repression of RAR-mediated transcription.  The mutants had no 
impact on this event suggesting this motif was not essential for NPDC-1’s RAR 
regulation.   
To assess the functional significance of NPDC-1/NR interactions, the impact of 
NPDC-1 on nuclear receptor mediated transcription was measured in a mammalian 
transcription assay.  Transcription mediated by RAR and RXR was strongly 
suppressed whereas VDR transcription was not affected.  Transcription by PPAR and 
ER were also suppressed, but not as strongly as the retinoid receptors (Figure 13).  
Cumulatively, the above data suggest NPDC-1 functions as a repressor of NR-mediated 
transcription.  This could either be through its ability to repress DNA binding or  
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Figure 12: Northern Analysis of rat and human NPDC-1 distribution.  
Approximately 2µg of poly A+ RNA from the indicated specific tissues was 
used to generate rat and human multiple tissue northern blots.  Each 
blot was probed with a specific DNA derived radiolabelled DNA probes.  
The location of RNA size markers is indicated. 
 
Figure from: Henry et al Nuclear Receptor 2003 1 
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Figure 13: NPDC-1 selectively represses nuclear receptor mediated 
transcription.  A. rNPDC-1 was analyzed for its ability to modulate the 
transcription mediated by endogenous E2F transcription factors.  A pBL-E2FRE-tk-
luc (E2FRE) reporter plasmid and a mammalian expression β-galactosidase 
construct were transfected into HepG2 cells with and without a mammalian 
expression construct for rNPDC-1.  Luciferase data was normalized and data 
reported as a % of the constitutive activation of the E2F reporter plasmid.  B. 
Mammalian expression plasmids for pRS-hRXRα, pRS-hRARβ, pRS-rPPARα, pRS-
hERα and pRS-hVDR were transiently transfected into HEK 293 cells along with 
their respective luciferase reporter constructs and with or without rNPDC-1.  
Transfected cells were incubated with ligand at the indicated doses.  A mammalian 
expression β−gal construct was included in all transfections to normalize for 
transfection efficiency. Data shown here is expressed in normalized values to β-gal. 
Figure from: Henry et al Nuclear Receptor 2003 1 
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through its ability to recruit transcription repressor complexes (e.g. chromatin 
remodeling proteins).  In a preliminary investigation aimed at distinguishing between 
these two possibilities, in these published studies I performed a series of experiments 
characterizing NPDC-1’s impact on retinoid receptor DNA binding (figure 14).  Using 
PC12 nuclear extract and recombinant NPDC-1, I studied the ability of NPDC-1 to 
modulate DNA binding to a DR5 βRARE (figure 14A).  Two major complexes were 
formed in the presence of PC12 nuclear extracts.  Addition of recombinant hNPDC-1 
increased the intensity of the lower shift complex at the expense of the higher 
complex.  NPDC-1 did not however form a measurable unique complex with the 
radiolabeled DNA, nor did it alter the mobility of the complexes, suggesting that 
NPDC-1 facilitates complex formation without remaining in strong association with 
either proteins or the DNA.  In addition to the PC12 nuclear extracts, I also performed 
electromobility shift assays using pure recombinant protein in order to eliminate any 
effects from factors that may be present in the nuclear extract (figure 14B+C).  
Recombinant hRXRα and hNPDC-1 were tested for binding to a DR1 RXRE probe.  
RXRα was bound to DNA in the absence of ligand, forming a homodimer and a 
monomer complex.  Addition of NPDC-1 increased both complexes without a shift in 
the complex mobility.  Supershift experiments with α-RXRα and α-NPDC-1 
demonstrated that NPDC-1 was not a part of the RXR/DR1 complex and that RXRα is 
a major component of both the upper and lower complex  (95).  Similar unpublished 
experiments were performed using nuclear extract from NT2 cells, which is a human 
neuronal cell line (Figure 15).  Addition of NPDC-1 caused the formation of a higher 
complex, but did not diminish the intensity of the lower RAR/RXR complex on βRARE.  
When the NT2 cells were serum starved before making nuclear extract, addition of 
NPDC-1 caused a shift in the complex but with less intensity.  Addition of atRA 
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Figure 14: hNPDC-1 alters hRARβ and hRXRα DNA binding properties.  
Oligonucleotides for RARE (DR5, panel A) and RXRE (DR1, panels B and C) were 32P 
labeled by T4 polynucleotide kinase.  The resultant DNA binding probes were 
incubated with PC12 lysate (A), recombinant RXRα (B&C) and recombinant NPDC-1 
(C) as indicated.  DNA:protein complexes were resolved by non-denaturing PAGE 
and developed by autoradiography.  In C, the presence of NPDC-1 within the RXR 
gel-shift complex was assayed by supershift.  Antibodies specific for either NPDC-1 
or RXR were used to identify proteins present in the complex. 
 
Figure from: Henry et al Nuclear Receptor 2003 1 
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Figure 15: EMSA with NT2 nuclear extracts.  Nuclear extracts from NT2 
cells were assayed for binding to recombinant NPDC-1 and RARE.  The βRE 
oligonucleotide was end-labeled with 32P by T4 polynucleotide kinase 
according to the manufacturer’s instructions.  The resultant DNA binding 
probe was incubated with NT2 nuclear extract and recombinant hNPDC-1 
protein.  The resultant DNA:protein complexes were resolved by non-
denaturing PAGE gels which were subsequently exposed to Kodak Xar-5 film.  
The RARβ antibody (lanes 4, 8, 12) was used to identify proteins in the 
complex and cold βRE oligonucleotide was used to show the specificity of the 
complex (lanes 5, 9, 13).  Complex formation was also assayed in the 
presence of atRA (lanes 10-13).  The RAR/RXR and RAR/RXR/NPDC-1 
complexes are indicated by arrows. 
 
*This is an accurate representation of experiment repeated at least three 
times. 
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resulted in a much stronger shifted complex with NPDC-1, similar to published 
results.  Interestingly, addition of NPDC-1 caused a higher molecular weight complex 
to form without altering the intensity of the lower band, suggesting that in NT2 cells 
there is a direct association between RAR, RXR, NPDC-1 and DNA.  I also tried to 
replicate these results in vitro using recombinant protein to determine the binding 
specificity of each protein to βRARE, and to eliminate any effect intrinsic to the 
nuclear extracts (Figure 16).  NPDC-1, RARβ and RXRα alone did not bind to the 
βRARE and neither did RARβ/NPDC-1 or RXRα/NPDC-1 complexes.  As expected 
RARβ and RXRα formed a complex, and the addition of NPDC-1 increased the intensity 
of the RARβ/RXRα complexes.  As observed with PC12 extracts, no shift in complex 
size is observed with these recombinant proteins.  The addition of RA to these 
reactions appears to slightly increase complex formation but has very little impact on 
NPDC-1’s effects on the complex.  Cumulatively these data suggest NPDC-1 can 
directly facilitate retinoid receptor DNA binding, but the mechanism is unclear and 
how this might be repressive to retinoid-mediated transcription is still a mystery.   
 In keeping with its hypothetical role as a regulator of cellular proliferation, 
NPDC-1 expression was also shown to be tightly regulated at the post-translational 
level (99).  To study NPDC-1 function in vivo, we generated a green fluorescent protein 
(GFP)-tagged hNPDC-1 construct and transfected it into PC12 cells.  Observation 
under a fluorescent microscope 48 hrs post transfection did not yield any green cells, 
although the native GFP expressed from vector alone was easily observed.  Western 
blot analysis showed that NPDC-1 could be detected after prolonged exposure, but 
with a much lower intensity than GFP alone.  This observation suggested that NPDC-1 
is rapidly turned over in PC12 cells.  Although a number of possible explanations 
could explain these results, one of the more prominent is that of targeted degradation 
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Figure 16: NPDC-1 makes the RAR/RXR complex stronger but does 
not complex with RAR or RXR.  Oligonucleotide corresponding to the 
consensus RARβ-RARE was end labeled with 32P by T4 polynucleotide 
kinase according to manufacturer’s instructions.  The resultant DNA 
binding probe was incubated with recombinant hRARβ, hRARα and 
hNPDC-1 proteins as indicated.  The resultant DNA:protein complexes 
were resolved on non-denaturing PAGE gels which were subsequently 
exposed to Kodak Xar-5 film.  Complex formation was also assayed in the 
presence of 10µM atRA (lanes 10-14). 
 
* This is an accurate representation of an experiment repeated at least 
three times. 
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of NPDC-1 protein.  The ubiquitin/proteosome system is an important mechanism for 
protein degradation (101).  Proteins are targeted for destruction by the 
ubiquitin/proteosome system by the addition of multiple ubiquitin molecules.  The 
ubiquitinated protein is targeted to the proteosome where it is cleaved into 
oligopeptides.  There are a number of protease inhibitors that can be used to monitor 
proteosome function.  One such inhibitor is MG-132, which is able to turn off the 
proteosome and allow targeted polyubiquitinated proteins to accumulate in the cell 
(102).  To test whether the ubiquitin/proteosome system was the mechanism through 
which NPDC-1 is eliminated from the cell, we transfected PC12 cells with hNPDC-GFP 
or GFP and 24hrs post transfection treated the cells with 40µM MG-132 (figure 17).  
After an additional 24hrs of incubation cells were fixed and observed under a 
fluorescent microscope.  Once again, GFP transfected cells were easily observable 
under the microscope whereas hNPDC-GFP transfected cells were not detectable.  
However, cells that were treated with MG-132 were detected under the microscope 
suggesting that NPDC-1 is indeed degraded by the ubiquitin/proteosome system (99).  
We went on in these published studies to further demonstrate that NPDC-1 expression 
is regulated post-translationally and NPDC-1 could be ubiquitinated both in vitro and 
in vivo.  Taken together these observations provide conclusive evidence that NPDC-1 is 
targeted and degraded by the ubiquitin/proteosome pathway.   
Ubiquitination complexes have been shown to bind target proteins at 
hydrophobic regions rich in proline, glutamate, serine and threonine (PEST).  
Sequence analysis of NPDC-1 showed a PEST degradation motif in the carboxyl 
terminus of hNPDC-1 (figure 18A+B) (99).  For NPDC-1 this region was observed to be 
totally conserved between species suggesting its significance for NPDC-1 regulation.  
To study the importance of this PEST region further we generated a construct (termed  
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Figure 17: NPDC-1 degradation is mediated by the proteosome.  PC12 
cells were transfected with 1µg NPDC-GFP or GFP control vector.  Cells were 
treated with 40mM MG-132 proteosome inhibitor where indicated.  After 
48hrs the cells were fixed and stained.  In panel A cells were visualized by 
direct fluorescence (red all cells, green transfected cells).  In panel B, cells 
expressing GFP or GFP-NPDC were counted and expressed as a percent of 
total cells. 
 
Figure from: Spencer, M. L. et al. J. Biol. Chem. 2004;279:37069-37078 
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Figure 18: NPDC-1 contains the PEST degradation sequence.  A. use of the 
website www.PESTfind to analyze hNPDC-1 for the presence of a PEST proteosomal 
degradation sequence identified a potential PEST sequence in the carboxyl terminus 
of hNPDC-1.  B. GFP-tagged constructs were generated for NPDC-1 and a mutant 
hNPDC-1 gene truncated at amino acid 286 and missing the putative PEST 
sequence (D1).  C. NPDC-1 and D1 constructs and GFP control protein were 
transfected into PC12 cells.  After 48h the cells were fixed, stained and analyzed for 
fluorescence.  D. Cells expressing GFP, NPDC-GFP and NPDC-D1-GFP were scored 
and expressed as a percent of all cells present. 
 
Figure from: Spencer, M. L. et al. J. Biol. Chem. 2004;279:37069-37078 
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D1) where hNPDC-1 was truncated just before the PEST sequence.  PC12 cells were 
transfected with GFP, hNPDC-GFP or hNPDC-D1-GFP and visualized under a 
fluorescent microscope (Figure 18C+D).  As before, we were not able to detect the full 
length protein fusion, but we were able to detect the truncated construct which 
expressed as well as the GFP control.  Subsequent in vitro ubiquitination experiments 
further demonstrated that hNPDC-D1 is not ubiquitinated, suggesting that the PEST 
sequence is functional and hNPDC-1 degradation can be inhibited by removal of the 
PEST sequence (99).   
To marry our earlier studies looking at NPDC-1 effects on retinoid signaling, 
with these new data on NPDC-1 targeted degradation, we analyzed the impact the 
hNPDC-D1 mutant had on retinoid mediated transcription.  In transcription assays 
using the βRE-tk-luc reporter we observed that hNPDC-D1 functioned as a 
significantly better inhibitor of retinoid transcription than full length hNPDC-1.  This 
result suggests that proteosomal degradation of NPDC-1 could serve as a regulatory 
mechanism for retinoic-acid induced transcription (99).   
In the papers first describing NPDC-1, a number of potential phosphorylation 
sites were reported (89, 90).  Phosphorylation is one of the main mechanisms for 
regulating proteins that function in cellular proliferation and transcriptional 
regulation.  We therefore initiated metabolic studies to evaluate the phosphorylation 
state of hNPDC-1 in vivo (Figure 19).  hNPDC-1 was shown to be a phosphoprotein and 
that it could be phosphorylated by a number of kinases.  These included ERK, 
glycogen synthase 3, casein kinase I and casein kinase II (99).  Although 
phosphorylation of NPDC-1 by ERK and by CKII was previously demonstrated, GSK3 
and CKI had not been reported or predicted.   
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Figure 19: hNPDC-1 is a phosphoprotein.  (A) PC12 cells were transfected with 
hNPDC-FLAG mammalian expression construct.  After 24h, cells were rinsed and 
incubated in serum and phosphate free media.  After 12h cells were labeled with 
0.5mCi of 32P orthophosphate for 4h.  Cells were harvested, and FLAG antisera was 
used to immunoprecipitate hNPDC-FLAG.  The precipitated material was divided 
evenly and subjected to SDS-PAGE.  One gel was dried and developed by 
autoradiography and the other half was immunoblotted with anti-FLAG M2 
antibody.  (B) A series of protein kinases were tested for their ability to 
phosphorylate bacterially expressed hNPDC-1.  1µg of recombinant protein was 
incubated with 500U of kinase in a reaction mixture containing 5mCi of γ-ATP.  
Proteins were separated by SDS-PAGE and developed by autoradiography. 
 
Figure from: Spencer, M. L. et al. J. Biol. Chem. 2004; 279:37069-37078 
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Phosphorylation is a major mechanism for the degradation of many PEST-
containing proteins such as the cyclins (103).  In this paper my major contribution 
was to evaluate the impact ERK phosphorylation of hNPDC-1 had on its ubiquitination 
kinetics in vitro (Figure 20).  Recombinant thioredoxin-tagged NPDC-1 protein was 
phosphorylated for 1hr by ERK and then was subjected to ubiquitination time course 
assays containing rabbit reticulocyte and recombinant ubiquitin protein.  
Phosphorylation of hNPDC-1 by ERK increased the ubiquitination kinetics, suggesting 
the phosphorylation state of NPDC-1 is important for its targeted degradation.  To 
examine this further, HEK293 cells were transfected with a hNPDC-FLAG expression 
construct and assayed for ubiquitination in the presence and absence of PD98059, a 
MAPK inhibitor, and in the presence and absence of the proteosomal inhibitor MG-132 
(Figure 20B).  The amount of ubiquitinated NPDC-1 was observed to decrease with 
increased PD98059 concentration.  In addition to testing ERK for modified 
ubiquitination kinetics, I also tested GSK3 and CKII in a series of unpublished studies 
(Figure 21).  These two kinases, previously shown to be able to phosphorylate NPDC-1, 
modified NPDC-1 ubiquitination kinetics in a similar manner to that observed with 
ERK, in that, in the presence of kinase, ubiquitination occurs earlier leading to an 
increased degradation rate. 
Previously published data introduced NPDC-1 as an inhibitor of cellular 
proliferation (89, 93) and as an inhibitor of growth in soft agar.  NPDC-1 has also been 
shown to associate with cell cycle components such as E2F-1 and various cyclins and 
cdks (91, 93).  NPDC-1 levels also appear elevated in cells that have exited the cell 
cycle (89, 91).  All of these observations taken together suggest that NPDC-1 can 
regulate cell proliferation and perhaps function as a tumor suppressor.  Data from our 
lab (99) further support this hypothesis in that they show that NPDC-1 is regulated  
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Figure 20: Phosphorylation increases the degradation kinetics of NPDC-1. (A) 
Recombinant S-thioredoxin-tagged hNPDC-1 was phosphorylated for 1h with 
500U of ERK kinase in a reaction containing cold ATP.  The reaction was added to 
an equal volume of ubiquitination buffer containing 10% rabbit reticulocyte and 
recombinant ubiquitin.  Reactions were stopped at the indicated time points with 
2X SDS-PAGE buffer, electrophoresed on SDS-PAGE and immunoblotted with 
anti-thioredoxin antibody for NPDC-1.  (B) HEK293 cells were lysed in the 
presence of MG-132 and NEM to preserve ubiquitin chains.  FLAG-NPDC-1 was 
pulled down with a-FLAG M2 beads.  The pellet was divided and one half was 
blotted for ubiquitin and the other half was analyzed for total NPDC-1 with anti-
FLAG-M2 antibody. 
Figure from: Spencer, M. L. et al. J. Biol. Chem. 2004;279:37069-37078 
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Figure 21: CKII and GSK3 increase the degradation kinetics of NPDC-1.  
Recombinant S-thioredoxin-tagged hNPDC-1 was phosphorylated for 1h with 500U 
of either CKII (top) or GSK3 (bottom) in a reaction containing cold ATP.  The 
reaction was added to an equal volume of ubiquitination buffer containing 10% 
rabbit reticulocyte and recombinant ubiquitin.  Reactions were stopped at the 
indicated time points with 2X SDS-PAGE buffer and electrophoresed on SDS-PAGE 
gels, and immunoblotted for NPDC-1 with anti-thioredoxin antibody. 
* This is an accurate representation of an experiment repeated at least three times 
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through phosphorylation and the ubiquitin/proteosome degradation pathway, not 
unlike other cell cycle associated proteins such as cyclins and cdks (103).  Spencer et 
al (99) demonstrated that ERK is able to phosphorylate NPDC-1 and alter its 
ubiquitination kinetics.  In the classic signaling MAPK cascade, MEK phosphorylates 
and activates ERK which then in turn phosphorylates and activates targets involved in 
cellular proliferation (Figure 22).  This is accomplished by translocation of ERK to the 
nucleus.  Furthermore, in unpublished data, I have been able to demonstrate that 
recombinant hNPDC-1 is able to directly bind and interact with GST-tagged MEK, ERK 
and Elk-1 (Figure 23A).  The interaction between NPDC-1 and ERK was also shown in 
vivo (Figure 23B).  Another potential link between the MAPK cascade and NPDC-1 is 
the observation that the MAPK signaling pathway can also be linked to cellular 
differentiation.  An example of this is involvement of MAPK in PC12 neurite outgrowth 
(104).  Treatment of PC12 cells with EGF activates the MAPK cascade transiently and 
results in proliferation while NGF stimulation results in a more sustained MAPK 
cascade and results in differentiation (105).  Cumulatively these data suggest a role for 
NPDC-1 in MAPK-driven cellular proliferation and differentiation. 
 In summary, hNPDC-1 has been shown to act as a coregulator of retinoid 
receptors by suppressing transcription in the presence of retinoic acid.  In addition, 
NPDC-1 is able to exert these effects by directly binding to hRARβ and hRXRα and 
alter the DNA binding of RAR/RXR heterodimers and RXR/RXR homodimers.  The 
carboxyl terminus of NPDC-1 contains a PEST sequence which is conserved between 
species suggesting a function for this region.  The level of NPDC-1 in cells is regulated 
by targeted degradation by the ubiquitin/proteosome system.  Deletion of the PEST 
region leads to accumulation of NPDC-1 in cells and an even stronger repression of 
retinoid receptor mediated transcription. 
- 72 - 
 
Figure 22: MAPK/ERK in growth and differentiation. 
 
Figure from: Cell signaling technology www.cellsignal.com 
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Figure 23: NPDC-1 is capable of interacting with MAPK proteins in vivo and in 
vitro.  In panel A, recombinant GST-tagged MEK, ERK and ELK-1 were bound to 
glutathione beads, and used in pull-down for S-thioredoxin tagged NPDC-1 
recombinant protein and using thioredoxin (Trx) as a control.  Bound proteins were 
eluted from beads, separated by SDS-PAGE, immunoblotted onto nitrocellulose 
membranes and membranes were probed with α-thioredoxin antisera.  The NPDC-1 
specific band is indicated.  In panel B, recombinant NPDC-1 is used in pull-down 
from HEK 293 cell extract.  HEK 293 cell lysate (1mg) was incubated with 
recombinant hNPDC-1 bound to S-protein beads.  The bound proteins were eluted 
from beads, separated by SDS-PAGE, immunoblotted onto nitrocellulose 
membranes and membranes were probed for ERK.  The ERK specific band 
(42,44kDa) is indicated. 
* This is an accurate representation of an experiment repeated at least three times 
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SUMMARY 
  
 Some inroads have been made in deciphering NPDC-1 and its role in cellular 
proliferation and differentiation, but a lot of questions remain.  NPDC-1 has been 
shown to interact with cell cycle regulatory proteins such as E2F-1, cyclins and cdks.  
It has also been shown to impact retinoid signaling, an established player in 
development.  NPDC-1 is also under heavy regulation in the cell and its levels never 
build up in proliferating cells, consistent with its higher expression in differentiated 
tissues and cells. 
 To examine the role of NPDC-1 in development and differentiation we sought a 
model system to carry out some in vivo studies.  Axolotl is a well established, well 
studied model for development and differentiation.  Thyroid hormone is used to induce 
metamorphosis of juvenile salamanders to adult.  Retinoic acid is able to affect 
patterning in developing and regenerating limbs, and therefore impacts cellular 
differentiation.  We therefore established a collaboration with Dr. Randal Voss in the 
Biology department to characterize NPDC-1 in axolotl and to examine its role in axolotl 
retinoic acid and thyroid hormone induced differentiation and development. 
 My hypothesis for the studies presented in this dissertation is that NPDC-1, 
through its ability to regulate the transcription events mediated by the intracellular 
receptors for retinoic acid and thyroid hormone, is able to impact the developmental 
and morphogenic pathways in axolotl.  In studies presented in this dissertation I 
assemble the axolotl signaling components for retinoid and thyroid hormones and I 
investigate the impact that an axolotl NPDC-1 homolog has on gene expression events 
induced by these hormones. 
Copyright © Maria Theodosiou 2006 
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SECTION III: ONGOING COLLABORATIONS FOR THE STUDY OF NPDC-1 IN THE 
AXOLOTL AMBYSTOMA MEXICANUM 
 
 
Chapter 6: Introduction 
 
 In our hands the NPDC-1 protein has proven to be both interesting and 
challenging.  NPDC-1 is a novel gene identified for its involvement in the control of 
neural cell proliferation and differentiation (89), and its high degree of conservation 
suggests it plays some universally critical function in the cells in which it is expressed.  
This is further supported by the accumulating data that demonstrate NPDC-1 
activities are linked to cellular proliferation and differentiation.  Our studies with 
NPDC-1 further link it to retinoid signaling, an event that has been linked to 
embryonic development, cellular differentiation and a variety of cancers.  In spite of 
these data, none of the investigators working in the NPDC-1 field have been able to 
define its biochemical mechanism of activity nor its direct association with disease 
pathogenesis. 
 In an effort to biochemically define the in vivo role of NPDC-1 in development 
and differentiation, we instituted a collaboration with Dr. Randal Voss’ laboratory here 
at the University of Kentucky.  Dr Voss’ lab studies the molecular evolution of the 
axolotl.  The axolotl system, due to their unique regenerative capabilities, has been 
classically used to study differentiation and development.  Dr. Voss’ lab breeds various 
species of axolotl and studies the molecular evolution of gene families in this 
organism.  The availability of the organism, its unique tools for studying differentiation 
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and the Voss’ lab expertise in cloning and characterizing axolotl genes fit well with our 
NPDC-1 needs. 
 The axolotl is an interesting model system for the study of developmental and 
differentiation processes, and these processes in axolotl can be directly linked to and 
mediated by members of the NR family.  The early development of axolotl is three 
times slower than that of Xenopus at the same temperature (106, 107), allowing for the 
study of developmental processes.  Dr Voss has been working with the axolotl, 
Ambystoma mexicanum, a juvenile salamander that does not undergo metamorphosis 
without exogenous thyroid hormone treatment and activation of the thyroid receptor.  
Natural populations of axolotl can be purely neotenic, transforming or polymorphic 
(i.e. some remain as larvae and some undergo metamorphosis (108)).  Phylogenetical 
analyses have shown that metamorphic failure evolved several times during 
Ambystoma evolution (108).  Salamanders, like all urodeles, have the ability to 
regenerate limbs after amputation, and retinoic acid respecifies positional memory, 
this event resulting in the formation of extra limb elements (109-112). 
 The axolotl embryo development has been divided into 44 stages based on 
external morphology and on features visible in dissected embryos (113).  The staging 
series originally published by Bordzilovskaya and Dettlaff (114) is also based on 
external morphology with stage timing beginning with the first appearance of the 
initial cleavage furrow on the animal pole (113).  The early blastula stage is at stage 8, 
approximately 16h after first cleavage and early gastrula forms at stage 10 when the 
first signs of the dorsal blastopore are visible which occurs at 26h (113, 114).  Early 
neurula stage where the boundaries of the neural plate are outlined, occurs at stage 
13 at roughly 55-56.5h (113, 114).  By stage 21 (72h), the neural folds are completely 
fused and at stage 22 (73h) the gill region and the pronephros are more distinct with 
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the tailbud being slightly outlined and five to six pairs of somites present (113, 114).  
The ventral side of the embryo becomes more concave as the downward curvature of 
the head increases (113, 114).  At stage 23, approximately 74h post first cleavage, the 
primordium of the ear is outlined and the boundary between the hyoid arch and the 
first branchial arch is outlined (113, 114).  By stage 27, 86h post first cleavage, the 
second branchial furrow appears and 12 somites are now present (113, 114).  The 
body of the embryo begins to straighten, the tailbud enlarges and sixteen pairs of 
somites are present by stage 29, after 97h (113, 114).  At stage 38, 178h post first 
cleavage, filament sprouts appear as two nodules on each gill and the limb buds are 
slightly outlined (113, 114).  By stage 41, (265h) the gills continue to elongate, the 
number and length of filaments increases and the mouth is outlined (113, 114).  
Hatching begins at stage 41 as well (113, 114).  By stage 43, which occurs 342h post 
first cleavage, the breaking through the mouth occurs or the mouth is already open 
(113, 114).  A figure with pictures from the different stages of axolotl embryos is 
presented in figure 24 with pictures taken from Bordzilovskaya et al (114).  About 4 
weeks post fertilization, a 25mm axolotl has developed forelimbs and the hindlimb 
buds are detectable as bean-shaped structures on either side of the posterior intestine 
(115).  It takes and additional three weeks for the hindlimbs to elongate posteriorly, 
splay laterally, develop digits and differentiate (115). 
 Cumulatively these data suggested the axolotl might be a useful animal model 
system for looking at the in vivo role of NPDC-1 in development and differentiation.  
Unfortunately the molecular genetics of the salamander system are not as developed 
as organisms like zebrafish and mice.  Therefore prerequisite to establishing an axolotl 
model system for studying NPDC-1’s role in NR-mediated development and  
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Figure 24: Developmental staging in axolotl embryos.  Timing begins with 
the first appearance of the initial cleavage furrow on the animal pole.  Stage 
8 is the early blastula stage.  Stage 13 is the early neurula stage I, where the 
blastopore is is narrow vertical slit, the boundaries of the neural plate are 
outlined, but neural folds are not yet raised above the surface of the embryo.  
By stage 21, the neural folds are completely fused and the posterior 
boundary of the gill region is more distinct.  By stage 22, the gill region and 
pronephros are more distinct and the taolbud is very slightly outlined and 5-
6 somites are present.  The ventral side of the embryo becomes more 
concave.  The primordium of the ear is outlined as a shallow depression in 
the region above the future hyoid arch at stage 23.  In the dorsal region of 
the gill swelling, the hyobranchial furrow appears, outlining the boundary 
between the hyoid arch and the first branchial arch.  At stage 27, the second 
branchial furrow appears faintly in the dorsal part of the gill swelling and 12 
pairs of somites are present.  At stage 29 the body of the embryo begins to 
straingthen, the tailbud enlarges and 16 pairs of somites are present.  
Flament sprouts appear as two nodules on each gill at stage 38.  At stage 41, 
the gills continue to elongate, the number of filaments increases and they 
become longer.  The forelimb buds are still small and hatching begins.  At 
stage 43, the breaking through of the mouth occurs or the mouth is already 
open. 
 
Figures from: Bordzilovskaya and Dettlaff, Developmental Biology of the 
axolotl, Oxford University Press, NY 
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differentiation, was the arduous task of both cloning and characterizing the axolotl 
NPDC-1 and nuclear receptor homologs.  Dr Voss’ lab was extremely vital to the initial 
cloning and characterization of these components, and in chapter 7 I present these 
early collaborative studies that were undertaken to identify the axolotl NPDC-1.  In 
section IV of this dissertation I describe the molecular characterization of axolotl RARγ 
while in section V, I describe similar characterization information for axolotl TRα and 
TRβ.  Throughout these sections I also investigate the relationships between axolotl 
NPDC-1 and signaling events mediated through these axolotl nuclear receptors. 
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Chapter 7: Results/Discussion 
 
 NPDC-1 was initially cloned as a mouse gene and characterized as a  protein 
involved in neuronal cell proliferation and differentiation control (89).  Later the 
human (90) and rat (95) homologs were identified and cloned, demonstrating NPDC-1 
is conserved across species.  To determine whether NPDC-1 is conserved in axolotl 
James Monaghan in Dr Randal Voss’ lab identified an axolotl EST cDNA clone.  This 
clone demonstrated high sequence homology to the mouse NPDC-1 gene, and using 5’ 
RACE technology on total RNA isolated from adult axolotl brain, he identified a full 
length coding sequence for axolotl NPDC-1 (aNPDC-1).  The aNPDC-1 amino acid 
sequence demonstrated 39.3% identity and 49.1% similarity with that of the human 
sequence (Figure 25).  When the amino acid sequence for aNPDC-1 was aligned with 
human and rodent sequences, several motifs were observed to be highly conserved 
(Figure 25).  These included the LXXLL motif, the PEST sequence as well as the six 
cysteines of the helix-loop-helix motif.   
 Examination of aNPDC-1 mRNA expression in various adult axolotl tissues was 
done by semi-quantitative RT-PCR using elongation factor 1 alpha (EF-1α) as a 
control.  Axolotl NPDC-1 mRNA was found to be expressed in heart, brain, eye, skin, 
and gill and to a lesser extent in spinal cord, lung, muscle and liver (Figure 26).  
Minimal aNPDC-1 mRNA was detected in the spleen.  Multiple tissue distribution of 
aNPDC-1 mRNA in axolotl agrees with previous published results for rat and human 
NPDC-1 mRNA (90, 95).   
 Previous data showed NPDC-1 expression in mouse to vary with development 
and highest levels to be detected in adulthood (91).  To examine this in axolotl a semi-
quantitative RT-PCR analysis was performed to look at aNPDC-1 expression at  
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human           MATPLPPPSPRHLRLLRLLLSGLVLGAALRGAAAGHPDVAACPGSLDCALKRRARCPPGA 
mouse           MATPVPPPSPRHLRLLRLLLSGLILGAALNGATARRPDATTCPGSLDCALKRRAKCPPGA 
rat             MATPVPPPSPRHLRLLRLLLSGLILGAALNGATARRPDAPTCPGSLDCALKRRAKCPPGA 
axolotl         ---MEPPRATVGARLLLLLCGMLMLSSAAQTGDR-------CPRKLDCTLLKRHYCPPGS 
                     ** :.   *** ** . *:*.:* . .         ** .***:* :*  ****: 
 
human           HACGPCLQPFQEDQQGLCVPRMRRPPGGGRPQPRLEDEIDFLAQELARKE--SGHSTPPL 
mouse           HACGPCLQSFQEDQRGFCVPRKHLSSGEGLPQPRLEEEIDSLAQELALKEKEAGHSRLTA 
rat             HACGPCLQSFQEDQRGVCVPRKHQSSGEGLPQPRLEEEIDSLARELALKEKEAGHPRLTA 
axolotl         DACGPCLPNHVENNDGKCVESATSQKGK-TSDRLPDEDIDFYASLLSPGK---AHQLQAV 
                .******  . *:: * **       *   .:   :::**  *  *:  :   .*   .  
 
human           PKD--RQR--LPEPATLGFSARGQGLELGLPSTPGTPTPTPHTSMGSPVSSDPVHMSPLE 
mouse           QPLLEAAQKLLEPAATLGFSQWGQRLEPGLPSTHGTSSPIPHTSLSSRASSGPVQMSPLE 
rat             QPLPEASQKLLEPAATLGFSQWGQQLEPGLPSTHGTSSPTPHTSLSARASSGPVQMSPLE 
axolotl         MEST---------AAPE---------ESSEKNRAGNVTPKPLPPTKGGVKSSPVPK---E 
                             .*.          * .  .  *. :* * ..  . ..*.**     * 
 
human           PRGGQGDGLALVLILAFCVAGAAALSVASLCWCRLHREIRLTQKADY-ATAKAPGSPAAP 
mouse           PQGRHGNGLTLVLILAFCLASSAALAVAALCWCRLQREIRLTQKADYAATAKGPTSPSTP 
rat             PQGRG-NGLALVLILAFCLASTAALAVAALCWCRLQREIRLTQKADYTATAKGPTSPTTP 
axolotl         ---KMSDALLLGLVVTCTAAGLTALIVATVCWCRLQKEMKLAEKADY-SSNKGASPPPYD 
                      :.* * *:::   *. :** **::*****::*::*::**** :: *.. .*.   
 
human           RISPGDQRLAQSAEMYHYQHQRQQMLCLERHKEPPKELDTASSDEENEDGDFTVYECPGL 
mouse           RISPGDQRLAHSAEMYHYQHQRQQMLCLERHKEPPKELESASSDEENEDGDFTVYECPGL 
rat             RISPGDERLAHSAEMYHYQHQRQQMLCLERHKDPPKELESASSDEENEDGDFTVYECPGL 
axolotl         RSSPVDKKLAQSAQMYHYQHQKQQMLSMENKDEPKLPDSNTTSDEENEDGDFTVYECPGL 
                * ** *::**:**:*******:****.:*.:.:*    ..::****************** 
 
human           APTGEMEVRNPLFDHAALSAPLPAPSSPPALP 
mouse           APTGEMEVRNPLFDHSTLSAPVPGPHSLPPLQ 
rat             APTGEMEVRNPLFDHSTLSAPVPGPHSSPPLQ 
axolotl         APTGEMEVKNPLFDDSSLHHPNSKPQ------ 
                ********:*****.::*  * . *        
 
Figure 25: NPDC-1 protein alignment.  Shown here is a sequence 
alignment between human, mouse, rat and axolotl NPDC-1.  Conserved 
amino acids are denoted by *.  Conserved across species are the LXXLL motif 
shown in pink, the HLH motif (the conserved cysteines comprising the HLH 
motif are shown in red), the PEST region which is shown in blue and the 
MAPK domain is shown in green. 
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Figure 26: aNPDC-1 tissue distribution in axolotl.  A. Semi-quantitative 
RT-PCR to examine tissue distribution of aNPDC-1 in non-metamorphosed 
axolotl tissues.  mRNA from the listed tissues was isolated, reverse 
transcribed into cDNA and analysed by PCR using aNPDC-1 specific primers 
(NPDC-1).  As a control, RT-PCR analysis of axolotl elongation factor 1α (EF-
1α) was assayed using the same cDNAs.  PCR products were run on 1.2% 
agarose gels and analysed on a Kodak Gel logic gel imaging system.  B. Using 
Gel Logic software (Kodak), the relative intensity of the aNPDC-1 specific PCR 
bands from A were normalized to the EF-1α bands for the various tissues. 
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different stages of axolotl development.  As shown in Figure 27 expression of aNPDC-1 
mRNA peaks at hatching and remains at constant levels post-hatching. 
In summary, NPDC-1 appears to be a conserved protein across species 
suggesting its function is also conserved and important for physiological processes.  
The expression of aNPDC-1 was observed to occur in multiple tissues and to fluctuate 
during axolotl embryogenesis and early larval development.  The cloning of the axolotl 
homolog of NPDC-1 was an essential component for the subsequent chapters 
presented in this dissertation and I wish to thank the Voss lab for helping me with 
these preliminary data and for tissues and other assistance provided in the 
dissertation work presented in Sections IV and V. 
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Figure 27: Developmental Expression of aNPDC-1. A.  Semi-quantitative 
RT-PCR to examine the expression of aNPDC-1 during embryogenesis in 
axolotl.  mRNA from the listed embryo stages was isolated, reverse 
transcribed into cDNA and analyzed by PCR using aNPDC-1 specific primers 
(NPDC-1).  As a control, RT-PCR analysis of axolotl elongation factor 1α (EF-
1α) was assayed using the same cDNAs.  PCR products were run on 1.2% 
agarose gels and analyzed on a Kodak Gel logic gel imaging system. B.  Using 
Gel Logic software (Kodak), the relative intensity of the aNPDC-1 specific PCR 
bands from A were normalized to the EF-1α bands for the various embryo 
stages. 
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SECTION IV: CONVERGENCE OF RETINOIC ACID AND NPDC-1 SIGNALING 
PATHWAYS IN AXOLOTL 
 
 
Chapter 8: Introduction 
 
 Retinoids are important signaling molecules for a variety of biological 
phenomena such as differentiation, proliferation and cell communication (106).  The 
effects of RA are mediated through the retinoid receptors (RARs and RXRs).  Retinoic 
acid is important for the morphogenesis of the nervous system and appears to re-
specify positional values within the neural plate (106).  RA is a morphogen for the 
CNS, heart, respiratory system, limbs, eyes, urogenital system and skin (106).   
 Retinoic-acid induced embryonic patterning has been studied in many 
organisms including Xenopus, axolotl and chicken.  Treatment of Xenopus laevis 
embryos with retinoic acid at gastrula and early neurula stages results in the 
transformation of anterior neural tissue to a more posterior fate (106, 116).  In the 
regenerating amphibian limb, retinoids induce proximodistal duplications giving rise 
to additional skeletal elements that are already present in the stump (117, 118).  
Maden (110) described the effects of retinoids on  limb regeneration in the axolotl 
Ambystoma Mexicanum.  In this study, it was shown that retinoids cause specific 
alterations in the proximo-distal pattern of regenerating axolotl limbs and suggested 
that retinoids are responsible for changing the positional information of limb cells.  
Finally, in chickens, retinoids induced the formation of two sets of digits in the 
developing chick wing bud (117, 119, 120). 
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In Xenopus, the intracellular receptors for retinoids, RARα and RARγ, are 
expressed during embryogenesis (106, 121).  RARα1 is expressed in the oocyte and in 
the embryo until gastrulation, whereas RARα2 is expressed at the end of gastrulation 
in the neuroectoderm (106).  RARγ2 expression, on the other hand, begins in the 
oocyte and peaks at the developmental period during which the anteroposterior axis of 
the embryo is determined, which is between early gastrulation and mid-neurulation 
(106).   
RAR expression in axolotl embryogenesis has been limitedly studied.  Using an 
axolotl neurula cDNA library, Wirtanen et al (106) isolated the axolotl RARγ2 and 
identified a splicing variant RARγ3.  Examination of aRARγ2 expression in axolotl 
embryos using semi-quantitative RT-PCR showed that the expression of aRARγ2 was 
monophasic.  The levels of aRARγ2 were low during segmentation before the mid-
blastula transition (MBT) (106), increased rapidly during gastrulation and reached a 
maximum during neurulation (stage 16.5).  The levels at neurulation were 20-fold 
higher than at segmentation.  The expression diminished between stages 16.5 and 28, 
then again between stages 36 and 38 and RNA levels remained low until stage 42 
(hatched larvae) (106).  It appears that in amphibians (X. laevis and axolotl) the main 
RAR isoform expressed during early development is RARγ2.  
Retinoids are able to impact patterning in both developing and regenerating 
limbs (122-125).  Retinoid administration has the ability to modify positional 
information along the three cardinal axes: the proximodistal (PD), anteroposterior (AP) 
and the dorsoventral (DV) (125).  Positional memory of blastema cells along these axes 
is modified in one direction, positional memory is proximalized in the PD axis (111, 
124, 125), posteriorized in the AP axis (119, 120, 125) and ventralized in the DV axis 
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(125-127).  Metabolic inhibitors that block RA synthesis such as disulfuram and citral, 
interfere with limb regeneration (125, 128). 
During chick limb development RA may act by modifying pattern directly 
and/or inducing an additional zone of polarizing activity (ZPA), which in turn may 
provide the pattern modification stimulus (117).  The ZPA is a region at the distal-
posterior margin of the developing limb bud capable of inducing mirror-image digit 
duplications when grafted to the anterior margin of a host limb (129).  Regenerating 
amphibian limbs lack a ZPA or anything corresponding to it, therefore a ZPA is not 
necessary for the formation of an RA gradient in regenerating or developing limbs 
(117).  In axolotls, an RA gradient is observed in regenerating limbs but not in 
Xenopus (117).  While Xenopus is capable of limb regeneration it is not able to pattern 
the regenerate appropriately (117).  The establishment of an RA gradient seems to be 
essential for pattern formation in regenerating and developing limbs (117). 
The expression of sonic hedgehog (shh), a gene first associated with 
segmentation patterning in Drosophila melanogaster (130), also is expressed within 
the ZPA.  Shh is a mediator of anterior-posterior (AP) patterning within the developing 
limb (129, 130).  In chick limbs shh expression correlates with the mapped domain of 
maximal ZPA activity at most developmental stages (129-131) and shh peptides alone 
can induce the same mirror-image duplications observed after ZPA grafting (129).  
Retinoic acid is capable of inducing digit duplications (120, 129, 132) and upregulates 
expression of shh on the developing chick wing and zebrafish fin (129, 130, 133).  
Expression of shh is responsible for the activity of the ZPA and for establishing the 
anterior-posterior axis of the developing vertebrate limbs (129, 134). 
Urodele limbs are homologous to those of other vertebrates and share 
conserved mechanisms of development (129), but have certain unique features that set 
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them apart from other tetrapods.  These unique features include a reversed sequence 
of digit formation (anterior to posterior rather than the reverse as in other tetrapods), 
absence of a region equivalent to ZPA, ability to regenerate limbs as adults and their 
multiple responses to treatment with RA causing patterning changes in all three limb 
axes (129).  Torok et al (129) studied shh expression in development and regeneration 
in axolotl.  Shh expression occurs later, and is downstream of, Hox-d11 expression 
both in development and regeneration.  Shh expression is detectable by stage 37 in 
axolotl embryos in mesenchymal cells on the posterior side of the limb bud and its 
expression is downregulated by the three digit stage (129).  In regenerating limbs, shh 
is not expressed until a medium bud blastema has formed (129).  In regeneration, as 
in limb development, shh is not necessary for the initial establishment of the AP axis 
(129).  Initially, the shh-expressing domain is detected at the stump-blastema junction 
and later more distally in association with the base of the forming autopod (129).  
Expression of shh domain in regenerating limbs is small compared to developing 
limbs, and is very transient (129).  Expression of shh is downregulated when RA levels 
in the blastema are high and is re-expressed as the levels decline (129).  A unifying 
hypothesis is that RA acts to establish a ZPA (129, 135, 136) through its ability to 
downregulate expression of shh. 
In summary, retinoids are important for embryonic patterning, limb 
development and limb regeneration.  Administration of exogenous retinoids leads to 
skeletal deformities in regenerating limbs of tetrapods.  The urodele axolotl 
Ambystoma mexicanum is an ideal model system for the study of developmental 
patterns.  Studies in axolotl have shown the establishment of an RA gradient in 
regenerating limbs that are directly linked to this regeneration process.  In this section 
of the dissertation, I investigate a potential molecular mechanism for regulation of 
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axolotl retinoic acid signaling.  These studies include cloning of the axolotl RARγ gene 
and the analysis of axolotl NPDC-1 expression on aRARγ DNA binding and aRARγ-
mediated gene expression events. 
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Chapter 9: Experimental Procedures 
 
Chemicals, Enzymes and Antibodies 
Standard chemicals used throughout these studies, unless otherwise stated, were 
purchased from Sigma chemical or Fisher Scientific.  Restriction enzymes, 
polymerases, ligases and kinases used, unless otherwise stated, were purchased from 
New England Biolabs.  Benzonase nuclease was purchased from Novagen.  Anti-
thioredoxin antibody was purchased from Santa Cruz. 
 
NPDC-1 antibody 
The peptide sequence NH2-EENEDGDFTVYECPGLAPT-COOH that is found in the 
PEST regions of NPDC-1 and observed to be conserved from axolotl to humans, was 
used as an immunogen to generate a rabbit polyclonal antibody directed against 
NPDC-1.  The synthesis of the peptide, development of the antibody and affinity 
purification of the antibody was performed by Washington Biotechnology (Baltimore, 
MD). 
 
Plasmids and Constructs 
aRARγ: Using axolotl lung RNA as template, an RT-PCR was performed using primers 
Forward: 5’-AAG CGG CCG CGT ACG ACT GCA TGG AGG CC-3’ and Reverse: 5’-AAG 
GAT CCC TAG AGC TCT TTG GAA CT-3’ to amplify the aRARγ2 cDNA.  To generate a 
FLAG-tagged mammalian expression construct, the amplified fragment was then 
subcloned into the NotI/BamHI sites of p3XFLAG-CMV-10 vector (Sigma).  This 
construct was used in subsequent PCR reactions to obtain aRARγ2 with the 
appropriate overhangs for further subcloning.  Using the primers Forward: 5’-AAG 
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GAT CCA TGT ACG ACT GCA TGG AGG CC-3’ and Reverse: 5’-AAC TCG AGC TAG 
AGC TCT TTG GAA CT-3’, aRARγ was subloned into the BamHI/XhoI sites of the 
mammalian expression vectors pcDNA3.1/Zeo/3HA (a gift from Dr. Andres at the 
University of Kentucky) and pcDNA3.1/Zeo (Invitrogen).  Amplification with Forward: 
5’-AAG GAT CCT ACG ACT GCA TGG AGG CC-3’ and Reverse: 5’-AAC TCG AGC TAG 
AGC TCT TTG GAA CT-3’ allowed the subcloning of aRARγ into the BamHI/XhoI sites 
of the bacterial protein expression vector pGEX-KG (Amersham), which contains a 
Glutathione tag.  Amplification with Forward: 5’-AAG GAT CCA TGT ACG ACT GCA 
TGG AGG CC-3’ and Reverse: 5’-AAC TCG AGC ACT AGA GCT CTT TGG AAC T-3’ was 
performed for cloning into the BamHI/XhoI sites of the bacterial protein expression 
vector pET32a (Novagen) which expresses a His-thioredoxin tag fusion protein.   
aNPDC-1:  To create a bacterial aNPDC-1 expression construct, full length aNPDC-1 
(pGEM aNPDC-1 a gift from R. Voss lab) was digested with AvrII, filled in with Klenow 
and then digested with NotI.  This fragment was then subcloned into the EcoRV/Not I 
sites of the bacterial protein expression vector pET32c (Novagen) (pET32c-aNPDC-
CDS).  A bacterial expression helix-loop-helix deletion construct (pET32-aNPDC-∆HLH) 
was constructed by digesting the full length pET-aNPDC with Sma/NotI and inserting 
the fragment into the bacterial protein expression vector pET32a digested with 
EcoRV/NotI.  This deletes amino acids 1-97 and eliminates the transmembrane and 
helix loop helix domain of aNPDC-1 on the amino terminus.  To generate the PEST 
deletion construct (deletion of amino acids 209-288), PCR amplification was used.  
Using primers Forward: 5’-AAA GGA TCC GAG CCT CCC AGG GCG ACC-3’ and 
Reverse: 5’-AAG GAC TCG AGT TAT TAT TAT TGT GCC AAC TTC TTG TC-3’ the ∆PEST 
fragment was amplified, isolated and cloned into the BamHI/XhoI sites of the bacterial 
protein expression vector pET32a.  To generate pcDNA3.1-aNPDC-CDS, full length 
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aNPDC-1 was digested with SacII restriction enzyme, filled in with Klenow and 
digested with NotI and inserted into the EcoRV/NotI sites of the mammalian expression 
vector pcDNA3.1/Zeo.  To generate pcDNA-aNPDC∆PEST, pET32a-aNPDC-CDS was 
digested with BglII/EcoRI and inserted in to the BamHI/EcoRI sites of pcDNA3.1/Zeo. 
Other plasmids and constructs 
In these experiments the following plasmids were used that were generated previously.  
The βRE-tk-luc plasmid was generated previously (in our lab) by subcloning a single 
copy of annealed synthetic oligonucleotides for βRE 5’-AGC TTA AGG GTT CAC CGA 
AAG TTC ACT CGC AT-3’ and 5’-AGC TAT TGC GAG TGA ACT TTC GGT GAA CCC 
TTA-3’ into the HindIII/BamHI sites of pBL-tk-luc vector (137).  This plasmid contains 
an imperfect DR5 and was used for both the mammalian transcription assays and for 
generating a DR5 response element for electromobility gel shift assays.  The β-
galactosidase plasmid used in the mammalian transcription assay contains the β-
galactosidase gene driven by a CMV promoter was purchased from Clontech. 
 
RT-PCR 
Axolotl tissue cDNA derived from multiple mRNA populations (a gift from Dr. Voss’ 
lab), was subjected to PCR using the following aRARγ primers: forward: 5’ CCC AGA 
CAA ATA TAC AGA AAC TGC-3’ and reverse: 5’ CCA TGC ACC ACA GGC CAT TTG 
AGA-3’ as published by Wirtanen et al (106).  cDNA template corresponding to 400ng 
total RNA was used per PCR reaction.  PCRs were performed on a T-Gradient 
thermocycler PCR machine as described by the manufacturer (Biometra) using the 
following cycling conditions 940Cx3min, 940Cx45s, 500Cx45s, 720Cx45s for 32 cycles, 
720Cx 5min.  PCR products were resolved on a 1.2% agarose gel and detected using 
the Gel logic gel imaging system (Kodak). 
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Recombinant Protein Expression 
Glutathione:  To develop GST and GST-aRARγ fusion proteins, BL21-RP Escherichia 
coli cells were transformed with bacterial expression constructs in the pGEX-KG 
plasmid system.  Transformants were plated on double selection media containing 
carbanecillin (50µg/ml) and chloramphenicol (34µg/µl) overnight at 370C.  Isolated 
colonies were picked and used to grow a 2.0mL starter culture which was then used to 
inoculate 500mL of 2X-YT (16mg/ml Tryptone, 10mg/ml NaCl, 10mg/mL Yeast 
extract, pH 7.2-7.4) supplemented with carbanecillin and chloramphenicol.  Cultures 
were grown to log phase at room temperature (OD600 of 0.6).  Protein expression was 
induced for 6h by the addition of IPTG (isopropyl-β-D-thiogalactopyranoside) (Gold 
BioTechnology, Inc) to a final concentration of 1mM.  Bacterial cells were pelleted by 
centrifugation for 15 minutes at 6000rpm and resuspended in 5mL of 10mM Tris-HCl 
pH 7.5 containing 100mg of lysozyme (Sigma), followed by the addition of 20mL of 
Triple Detergent Lysis buffer [50mM Tris-HCl pH 8.0, 150mM NaCl, 0.02% sodium 
azide (v/v), 1% NP-40 (v/v), 0.5% sodium deoxycholate (v/v), 1µM PMSF and 1X 
protease inhibitor cocktail (Roche Applied Science) and Benzonase Nuclease (1µl/ml)] 
and incubated at room temperature with agitation (150rpm) for 30 minutes on an 
orbital floor shaker.  The soluble fraction was clarified by ultracentrifugation for 1h at 
50000rpm in a Ti70 rotor.  GST fusion proteins were purified by Fast Performance 
Liquid Chromatography (FPLC) on a GSTrap Fast Flow column (GE Life Sciences).  
Eluates were desalted by FPLC on a G-50 desalting column into TBS-P (10mM Tris-
HCl pH 8.0, 150mM NaCl, 10% glycerol (v/v), 1mM DTT) and the resulting proteins 
were aliquoted and stored at -700C until use.  The protein concentration was 
determined using Bradford reagent (Advance, Cytoskeleton Inc). 
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Thioredoxin:  To generate Thioredoxin and thioredoxin-tagged aNPDC-1, 
aNPDC∆PEST, aNPDC∆HLH and aRARγ, bacterial expression constructs in the pET32 
(Novagen) system were transformed into BL21-RP E. coli cells.  Transformants were 
plated on double selection media containing carbanecillin (50µg/ml) and 
chloramphenicol (34µg/µl) and incubated overnight at 370C.  Isolated colonies were 
picked and used to grow a 2.0mL starter culture which was then used to inoculate 
500mL of 2X-YT supplemented with carbanecillin and chloramphenicol.  Cultures 
were grown at room temperature, to an OD600 of 0.6.  Protein expression was induced 
for 6h by the addition of IPTG (isopropyl-β-D-thiogalactopyranoside) to a final 
concentration of 1mM.  The transformed bacterial cells were pelleted by centrifugation 
at 6000rpm for 15 minutes and resuspended in 5mL of 10mM Tris-HCl pH 7.5 
containing 100mg of lysozyme (Sigma) followed by the addition of 20ml of Triple 
Detergent Lysis buffer and incubated at room temperature with agitation (150rpm) for 
30 minutes on an orbital floor shaker.  The soluble fraction was clarified by 
ultracentrifugation for 1h at 50000rpm in a Ti70 rotor.  The clarified lysate was 
purified by FPLC on a HiTrap chelating HP column (Amersham Biosciences) preloaded 
with Nickel.  Bound protein was washed with 10 column volumes of His wash (50mM 
NaH2PO4, 300mM NaCl, 20mM Imidazole pH 8.0) and eluted in His elution buffer 
(50mM NaH2PO4, 300mM NaCl, 500mM Imidazole pH8.0).  Eluates were desalted by 
FPLC on a G-50 desalting column into TBS-P (10mM Tris-HCl pH 8.0, 150mM NaCl, 
10% glycerol (v/v), 1mM DTT), and the resulting proteins were aliquoted and stored at 
-700C until use.  The protein concentration was determined using Bradford reagent 
(Advance, Cytoskeleton Inc). 
 
Pulldown Assays 
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Recombinant GST-aRARγ and GST-hRXRα (10µg/reaction) were prebound to 
glutathione sepharose beads (50% slurry in APB buffer) [APB: 50mM Tris-HCl ph 7.5, 
150mM NaCl, 10% glycerol (v/v), 1% NP-40 (v/v)] by rotating for 1h at 40C.  To the 
GST prebound proteins, equimolar amounts of thioredoxin or thioredoxin-tagged 
aNPDC-1 proteins were added as described in results and figure legends.  The proteins 
were allowed to interact by rotating for at least 1h at 40C.  The beads were recovered 
by centrifugation in a microcentrifuge and washed 5 times with 1ml APB.  The bound 
proteins were analyzed by western blot analyses probing with antisera for thio-probe 
(Santa Cruz). 
 
Western Blot analysis 
Western blot analyses were performed as previously described (99).  Briefly, proteins 
were separated by SDS-PAGE electrophoresis and electroblotted onto nitrocellulose 
membranes (Stratagene Inc).  Blocking was performed in PC buffer (1% casein in 1X 
PBS) [PBS: 0.30g/L NaH2PO4 anhydrous, 1.15g/L Na2HPO4 anhydrous, 9g/L NaCl, pH 
7.2-7.4] overnight.  Primary antibody was diluted in PCT buffer (1% casein in 1X PBS, 
0.01% Tween-20) and incubated for 1h.  Blots were subsequently washed with TBST 
buffer (20mM Tris pH7.5, 137mM NaCl, 0.1% Tween-20), then incubated with an 
appropriate secondary antibody coupled to horseradish peroxidase, reacted with ECL 
reagents (Pierce) as described by the manufacturer and detected on X-ray film by 
autoradiography.  
 
Electromobility Shift Assays 
EMSAs were performed as described previously (95).  Briefly, βRE-tk-luc construct, 
generated previously as described in plasmids and constructs section, was digested 
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with HindIII/BamHI to obtain a double stranded RARE response element (βRE) 
containing 5’ overhangs.  The overhangs were radioactively labeled with [α-32P]-dCTP 
using a standard Klenow fill-in reaction (138).  The radioactive response element was 
purified by centrifugation through a microspin G-25 column (Amersham).  The 
radiolabeled response element was incubated in binding buffer [for 1X binding buffer: 
5% glycerol, 1mM MgCl2, 0.5mM EDTA, 0.5mM DTT, 50mM NaCl, 10mM Tris pH 7.5, 
0.25mg/mL poly (dIdC)-poly (dIdC)] with recombinant aRARγ, hRXRα, aNPDC-1, 
aNPDC∆PEST or aNPDC∆HLH in the presence of 1µM atRA as indicated.  The response 
element/protein complexes were separated by electrophoresis on 5% non-denaturing 
polyacrylamide gels.  The gels were dried and the results visualized by 
autoradiography on X-ray film. 
 
Mammalian Transcription Assays 
Cos7 cells were transfected using SuperFect reagent (Quiagen) using a modification of 
the manufacturer’s protocol.  Briefly, 5µg total DNA (1.25µg βRE-tk-luc, 0.25µg 
pcDNA, 0.5µg pcDNA-aNPDC-1, 0.25µg 3HA-pcDNA-aRARγ, 0.5 µg cmv-βgal and 2.5µg 
pUC) were combined with 150µl OptiMEM (Gibco) and vortexed briefly.  To the 
OptiMEM-DNA mixture 20µL of SuperFect reagent was added and incubated at room 
temperature for 20 minutes.  During this time, Cos7 cells were washed with 1XPBS 
once, and then 3ml of OptiMEM was added.  To the OptiMEM-DNA mixture, 2mL of 
OptiMEM was added and after mixing by pipetting up and down, the mixture was 
added to the 10cm plates dropwise.  After 4h incubation at 37 degrees, the media was 
removed and the cells were washed with 1XPBS 3 times.  After trypsinizing, the cells 
were resuspended in 10mL DMEM containing 10% CAFBS (charcoal absorbed fetal 
calf serum) and 20µl cells/well were plated into a 96 well plate with and without 1µM 
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atRA.  Cells were assayed in 6 wells per treatment.  The cells were incubated for 24h 
in the presence of retinoic acid, and then luciferase and normalizing β-gal activities 
were determined as previously described (139).  The highest and lowest values for each 
treatment were dropped.  Activity was expressed as the average of luciferase response 
normalized to the average β-gal response/minute.  
 
Proliferation Assay 
HEK293 cells were transfected using a standard calcium phosphate precipitation 
protocol as previously described (140).  Briefly, HEK293 cells at 70% confluence were 
transfected with 3HApcDNA-aRARγ, pcDNA-aNPDC-CDS or pcDNA-aNPDC∆PEST and 
βRE-tk-luc luciferase reporter plasmid.  The total amount of plasmid per 10cm2 plate 
transient transfection was brought up to 20µg by the addition of the appropriate 
amount of pUC-19 plasmid.  The calcium phosphate/DNA mix was allowed to 
incubate with the cells for 6h at 370C and then cells were washed three times with 1X 
PBS, and fresh media (DMEM with 10% FBS) was added.  Transfections were 
incubated overnight and the next morning (~12h later) the cells were trypsinized and 
counted.  50,000 cells were plated per well in a 24 well plate; six wells per transfection 
with three wells being treated with 1uM atRA and three wells serving as controls.  
Each well received 2µl of [3H] thymidine as well at 120Ci/mmol.  At 6h, 24h and 48h 
following treatment the cells were harvested and lysed.  DNA was precipitated using 
10% TCA and radioactivity was trapped by filtration through a vacuum filter 
apparatus (Hoefer Scientific Instruments) on glass fiber filter circles (Fisherbrand).  
Total radioactivity was measured using a scintillation counter.  
 
Bradford Assay 
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Proteins were diluted 1:200 in 1X Bradford reagent (Advance, Cytoskeleton Inc) and 
the OD595 was measured using a BioRad microplate reader.  The OD reading of each 
protein was adjusted to a blank and the concentration of each protein was calculated 
based on the dilution factor and the manufacturers’ instructions. 
 
Copyright © Maria Theodosiou 2006 
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Chapter 10: Results 
 
Cloning of axolotl RARγ 
 Further studies into the biochemical mechanism of the putative retinoid 
receptor coregulatory protein NPDC-1 necessitated the identification of an animal 
model system in which the discrimination between differentiation and developmental 
effects was possible.  The axolotl system appears to fit these needs and the availability 
of both breeding colonies and the laboratory of one of the leaders in molecular 
evolution of axolotls, made this system accessible.  The axolotl is an interesting model 
system for the study of development and regeneration in view of the fact that urodeles 
are capable of regenerating perfect limbs following amputation (141-145).  
Furthermore, its early development is three times slower than that of Xenopus (106, 
107) at the same temperature, thus favoring the identification and analysis of 
intermediate rather than terminal differentiation products (106).  Finally, retinoids 
have been implicated in both axolotl embryogenesis and limb regeneration (141-145).  
The axolotl was therefore chosen as an animal model for studying NPDC-1 modulation 
of retinoid receptor signaling.   
Having identified and cloned an axolotl NPDC-1 homolog, it next became vital 
that we generate clones for the axolotl RAR homolog.  We were fortunate in this regard 
in that the axolotl RARγ gene had been previously identified and partially 
characterized by Wirtanen et al in 2000 (106).  Using the published sequence, 
oligonucleotide primers were designed and used in an RT-PCR approach to isolate an 
aRARγ cDNA from axolotl lung mRNA.  This cDNA was subcloned into the pcDNA and 
3HApcDNA vectors for mammalian expression of the protein, and into pGEX-KG and 
pET32 for bacterial expression of the protein.  Sequence analysis showed this aRARγ 
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to be identical to the previously published axolotl sequence, and comparison of the 
aRARγ cDNA with other RARγ sequences shows it to be well conserved between 
humans and rodents, with differences mostly confined in the amino terminus (Figure 
28).  As expected the DBD is the most conserved (98.5% conservation), but with the 
LBD also being fairly well conserved (89% conservation) (Figure 28).  Now with the 
availability of an axolotl homolog of RAR it was possible to initiate molecular 
investigations into the mechanisms governing RA action in urodeles. 
 
Tissue expression of aRARγ 
 While the embryogenic expression pattern of aRARγ has been published (106) 
the localization of RARγ in various tissues in axolotl has not been determined.  To 
determine the pattern of expression of RARγ in axolotl, RT-PCR was used.  Using 
previously published aRARγ-specific primers, PCR was performed on cDNA from 
various axolotl tissues (Figure 29).  RARγ was observed to be expressed very highly in 
axolotl heart, highly in skin and eye and at low levels in lung, spinal cord, gill and 
liver.  Very little if any expression was observed in muscle, spleen and brain. 
 
Expression of aRARγ during late embryogenesis and early larva stage 
 Axolotl aRARγ has been previously shown to express early in development (106), 
to peak at neurulation (stage 16.5) and to diminish by stage 28.  In my studies, the 
first embryonic stage examined for aRARγ expression was stage 27, but as opposed to 
these earlier studies that were terminated at hatching, my analyses continued through 
2 months post-hatching.  As shown in Figure 30, aRARγ mRNA levels decreased 
between stage 43 and hatching.  The aRARγ mRNA levels are observed to increase 2 
months post-hatching back to levels similar to pre-hatching. 
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human           MATNKERLFAAGALGPGSGYPGAGFPFAFPGALRGSPPFEMLSPSFRGLGQPDLPKEMAS 
mouse           MATNKERLFAPGALGPGSGYPGAGFPFAFPGALRGSPPFEMLSPSFRGLGQPDLPKEMAS 
xenopus         ----MYDCMEAFPLMPRPLYDMSPQGPCMLRKAG----------CFGGLDPFGWMQSHSM 
axolotl         ----MYDCMEAFMLAPHPLYDVTNPGACMLRKARLSP-------CFGGLDPFGWPQPASL 
                        : .  * * . *  :    .:               .* **.  .  :  :  
 
human           LSVETQSTSSEEMVPSSPSPPPPPRVYKPCFVCNDKSSGYHYGVSSCEGCKGFFRRSIQK 
mouse           LSVETQSTSSEEMVPSSPSPPPPPRVYKPCFVCNDKSSGYHYGVSSCEGCKGFFRRSIQK 
xenopus         QSVETQSTSSEEMVPSSPSPPPPPRVYKPCFVCNDKSSGYHYGVSSCEGCKGFFRRSIQK 
axolotl         QSVETQSTSSEEMVPSSPSPPPPPRVYKPCFVCNDKSSGYHYGVSSCEGCKGFFRRSIQK 
                 *********************************************************** 
 
human           NMVYTCHRDKNCIINKVTRNRCQYCRLQKCFEVGMSKEAVRNDRNKKKKEVKEEGSP-DS 
mouse           NMVYTCHRDKNCIINKVTRNRCQYCRLQKCFEVGMSKEAVRNDRNKKKKEVKEEGSP-DS 
xenopus         NMVYTCHRDKNCQINKVTRNRCQFCRLQKCFQVGMSKEAVRNDRNKKKKEIKEEVVLPDS 
axolotl         NMVYTCHRDKNCQINKVTRNRCQYCRLQKCFEVGMSKEAVRNDRNKKKKEIKEEVVT-DS 
                ************ **********:*******:******************:***    ** 
 
human           YELSPQLEELITKVSKAHQETFPSLCQLGKYTTNSSADHRVQLDLGLWDKFSELATKCII 
mouse           YELSPQLEELITKVSKAHQETFPSLCQLGKYTTNSSADHRVQLDLGLWDKFSELATKCII 
xenopus         YEMPPEMEELIQKVSKAHQETFPSLCQLGKYTTNSSADQRVQLDLGLWDKFSELSTKCII 
axolotl         YEMPPEMEALIAKVSKAHQETFPSLCQLGKYTTNSSADHRVQLDLGLWDKFSELATKCII 
                **:.*::* ** **************************:***************:***** 
 
human           KIVEFAKRLPGFTGLSIADQITLLKAACLDILMLRICTRYTPEQDTMTFSDGLTLNRTQM 
mouse           KIVEFAKRLPGFTGLSIADQITLLKAACLDILMLRICTRYTPEQDTMTFSDGLTLNRTQM 
xenopus         KIVEFAKRLPGFTTLTIADQITLLKSACLDILMLRICTRYTPEQDTMTFSDGLTLNRTQM 
axolotl         KIVEFAKRLPGFATLTIADQITLLKAACLDILMLRICTRYTPEQDTMTFSDGLTLNRTQM 
                ************: *:*********:********************************** 
human           HNAGFGPLTDLVFAFAGQLLPLEMDDTETGLLSAICLICGDRMDLEEPEKVDKLQEPLLE 
mouse           HNAGFGPLTDLVFAFAGQLLPLEMDDTETGLLSAICLICGDRMDLEEPEKVDKLQEPLLE 
xenopus         HNAGFGPLTDLVFSFADQLLPLEMDDTETGLLSAICLICGDRMDLEEPEKVEKLQEPLLE 
axolotl         HNAGFGPLTDLVFAFAEQLLPLEMDDTETGLLSAICLICGDRMDLEEPEKVDKLQEPLLE 
                *************:** **********************************:******** 
 
human           ALRLYARRRRPSQPYMFPRMLMKITDLRGISTKGAERAITLKMEIPGPMPPLIREMLENP 
mouse           ALRLYARRRDPAKPYMFPRMLMKITDLRGISTKGAERAITLKMEIPGPMPPLIREMLENP 
xenopus         GLKFYARRRRPDKPYMFPRMLMKITDLRGISTKGAERAITLKLEIPGPMPPLIREMLENP 
axolotl         ALKIYARRRRPNKPYMFPRMLMKITDLRGISTKGAERAITLKMEIPGPMPPLIREMLENP 
                .*::***** * :*****************************:***************** 
 
human           EMFEDDSSQPGPHPNASSEDEVPGGQGKGGLKSPA---- 
mouse           EMFEDDSSKPGPHPKASSEDEAPGGQGKRGQSPQPDQGP 
xenopus         EAFEDGAATPKPSERSSSESSNGSPTGEDSSGSKTP--- 
axolotl         EAFEDDALSSPKAEEKPIKVEEIPAEKPSSKEL------ 
                * ***.:  .    . . : .        .          
 
 
Figure 28: Sequence alignment of RARγ.  
RARγ appears to be largely conserved 
between higher and lower vertebrates.  
Conserved amino acids are deonoted by *. 
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Figure 29: aRARγ tissue distribution in axolotl.  A. Semi-quantitative RT-
PCR to examine tissue distribution of aRARγ in non-metamorphosed axolotl 
tissues.  mRNA from the listed tissues was isolated, reverse transcribed into 
cDNA and analysed by PCR using aRARγ specific primers (aRARγ).  As a 
control, RT-PCR analysis of axolotl elongation factor 1α (EF-1α) was assayed 
using the same cDNAs.  PCR products were run on 1.2% agarose gels and 
analysed on a Kodak Gel logic gel imaging system.  B. Using Gel Logic 
software (Kodak), the relative intensity of the aRARγ specific PCR bands from 
A were normalized to the EF-1α bands for the various tissues. 
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Figure 30: Developmental Expression of aRARγ. A.  Semi-quantitative 
RT-PCR to examine the expression of aRARγ during embryogenesis in 
axolotl.  mRNA from the listed embryo stages was isolated, reverse 
transcribed into cDNA and analyzed by PCR using aRARγ specific primers 
(aRARγ).  As a control, RT-PCR analysis of axolotl elongation factor 1α (EF-
1α) was assayed using the same cDNAs.  PCR products were run on 1.2% 
agarose gels and analyzed on a Kodak Gel logic gel imaging system. B.  
Using Gel Logic software (Kodak), the relative intensity of the aRARγ 
specific PCR bands from A were normalized to the EF-1α bands for the 
various embryo stages. 
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Localization of domain of interaction between aNPDC-1 and aRARγ 
 Previous studies had shown that hNPDC-1 complexes with hRARβ and hRXRα 
(95).  The first question addressed in my studies was whether this interaction between 
NPDC-1 and RAR also occurs in the axolotl, and if so, if the region of interaction could 
be identified.  To investigate this interaction 10µg of GST-aRARγ and/or GST-hRXRα 
was bound to glutathione sepharose beads and allowed to interact with equimolar 
amounts of thioredoxin or thioredoxin-tagged aNPDC-1 proteins.  Bead bound proteins 
were resolved by SDS-PAGE and immunoblotted using a Thio-probe polyclonal 
antibody (Santa Cruz).  As shown in Figure 31B, full length aNPDC-1 (aNPDC-CDS) 
and aNPDC-1 with its PEST domain deleted (aNPDC∆PEST) were able to complex with 
aRARγ, but not the aNPDC-1 protein with its helix-loop-helix domain deleted 
(aNPDC∆HLH).  These data suggest that the domain of interaction between aRARγ and 
aNPDC-1 is at the amino terminus within amino acids 1-97.  The domain of 
interaction between aNPDC and hRXRα also lies within the amino terminus (Figure 
31C).  These findings are consistent with what was observed with hNPDC-1 and 
hRXRα (95).  As shown in Figure 31D, the differences in binding observed between the 
different aNPDC-1 constructs, and aRARγ, and hRXRα are not due to unequal loading, 
but rather are due to the region deleted being critical for interaction between the 
retinoid receptor and aNPDC-1.  These data would suggest that the amino terminus of 
aNPDC-1 is important for interaction with nuclear receptors.  Within this region are 
found the LXXLL motif, the signal peptide, the HLH motif and a coiled-coil domain 
(95).  Further studies are necessary to more definitely establish which of these 
domains might be responsible for NR binding. 
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Figure 31:  Direct in vitro interaction between aRARγ and aNPDC-1.  In 
panel A, recombinant aRARγ protein is shown.  Protein tagged with either 
Glutathione (GST) or Thioredoxin (Trx) was generated as described in 
materials and methods.  10µg of purified recombinant protein was resolved 
on a 10% SDS-PAGE gel and stained with Coomassie Blue.  In panels B and 
C, 10µg of GST-aRARγ (B) or 10µg of hRXRα (C) were bound to glutathione 
beads and allowed to react with equimolar amounts of thioredoxin (Trx), 
aNPDC-1, aNPDC∆PEST and aNPDC∆HLH.  Bead bound proteins were 
resolved on a 10% SDS-PAGE gel, and immunoblottled on nitrocellulose 
membranes.  The membranes were then blotted with antisera for Thio probe.  
In panel D, equimolar amounts of thioredoxin and thioredoxin-tagged 
proteins were bound to S-protein beads and resolved on a 10% SDS-PAGE 
gel and immunoblotted for thioredoxin using anti-thioredoxin antisera. 
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Analysis of the impact aNPDC-1 has on aRARγ DNA binding 
 Initial observations demonstrated that hNPDC-1 impacted RAR/RXR 
heterodimer DNA binding, but did not shift the retinoid receptor complex (95).  In the 
studies presented here, I investigated whether a similar result is observed with the 
axolotl RARγ and NPDC-1.  A βRE oligonucleotide was obtained through the digestion 
of the βRE-tk-luc plasmid with HindIII/BamHI enzymes.  The oligonucleotide was 
radioactively labeled with 32P using a Klenow fill-in reaction.  The radiolabeled βRE 
was then allowed to complex with recombinant proteins and the DNA/protein 
complexes were resolved on a non-denaturing polyacrylamide gel.  Shown in Figure 32 
is a representative EMSA of the observations made.  Neither aRARγ, aNPDC-1 nor any 
of the aNPDC-1 deletions able to independently complex with the βRE DNA response 
element (lanes 2-5).  The combination of hRXRα and aRARγ recombinant proteins was 
observed to form a shift complex (lane 6).  Specificity of the complex was shown by 
competing it away with cold oligonucleotide (lane 7).  Addition of aNPDC-1 made the 
aRARγ/hRXRα complex stronger in intensity and generated a second higher band 
(lane 8) which most likely represents an aNPDC-1 shifted complex.  This is supported 
by the observation that anti-NPDC-1 antibody (raised against the conserved PEST 
region) eliminates the upper complex (lane 9) and diminishes the lower complex.  It is 
worth noting that the commercial anti-thio probe antibody used in these studies is 
fairly dilute and not advertised as useful in supershift assays.  Therefore the mild 
response observed here (lane 10) could be a reflection of this caveat. Although the 
above data support the hypothesis that axolotl NPDC-1, like rodent and human NPDC-
1, can modulate retinoid receptor DNA binding, this generation of an additional 
aNPDC-1-specific higher mobility shift complex appears to be unique to axolotls. 
s.  mRNA from the listed tissues waation that anti-NPDC-1 antibody also reduces the  
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Figure 32: Electromobility Shift Assay with axolotl NPDC-1 and RARγ.  
An oligonucleotide corresponding to βRE was radiolabelled with 32P-dCTP 
with Klenow enzyme.  The resultant DNA binding probe was incubated with 
recombinant hRXRα, aRARγ, aNPDC-1, aNPDC∆PEST and aNPDC∆HLH.  
Unlebelled (cold) oligo was used to show specificity of binding and antisera 
specific for NPDC-1 and thioredoxin were used to assay supershifts. In all 
reactions 1µM atRA was included.  DNA:protein complexes were resolved 
on non-denaturing PAGE gels which were subsequently exposed to Kodak 
Xar-5 film. 
 
*This is an accurate representation of an experiment performed at least 
three times. 
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intensity of the lower band in these complexes warrants further study and suggests 
that aNPDC-1 can both facilitate aRARγ/hRXRα DNA binding as well as form novel 
aRARγ/hRXRα/aNPDC-1 complexes. 
 
Analysis of the impact aNPDC-1 has on transcription events mediated by aRARγ 
 The ability of rat and human NPDC-1 to impact retinoid receptor mediated 
transcription has been previously reported (95).  To investigate whether aNPDC-1 can 
likewise impact aRARγ mediated transcription, in vitro transcription analyses were 
performed.  Using a lipid based transfection method, Cos7 cells were transfected with 
mammalian expression constructs for aRARγ and aNPDC-1, a βRE luciferase reporter 
plasmid and a β-galactosidase expression plasmid (for normalizing transfection 
efficiency).  Transfected cells were stimulated with 1µM atRA for 24h.  After 24h the 
cells were lysed and assayed for luciferase and β-galactosidase activity.  In Figure 33, 
the average luciferase values normalized to their respective β-gal activities are shown 
for the various transfection scenarios.  As seen here, and as previously observed with 
hNPDC-1, aNPDC-1 repressed aRARγ-mediated transcription.  Transcription 
repression was observed to be approximately 30%.  This value is somewhat lower than 
that reported for rat and human receptors (90%), but it must also be noted that these 
comparisons are difficult to make due to the use of the different host cell systems and 
the different transfection technologies employed (95). 
 
Proliferation Assay 
 A hallmark of rodent NPDC-1 was its observed ability to inhibit cell proliferation 
(89).  To evaluate this with respect to aNPDC-1, I investigated the effects over-
expression of aNPDC-1 and aNPDC-1∆PEST had on cell proliferation (Figure 34). Using  
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Figure 33: Impact of aNPDC-1 on aRARγ-mediated transcription.  
Cos7 cells were transiently transfected with mammalian expression 
plasmids for aNPDC-1, aRARγ, βRE-tk-luc, β-galactodisase and treated 
with 1µM atRA.  Luciferase data was normalized to β-galactosidase and 
data was reported as a % of the response of aRARγ and aRARγ+aNPDC-1 
in the presence of βRE. 
 
* This result presents the average from experiments repeated at least four 
times. 
       aRARγ                  aRARγ                                      aRARγ           aRARγ 
                               +atRA                                +aNPDC-1      +aNPDC-1  
                                     +atRA 
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pcDNA      pcDNA aNPDC-1  aNPDC-1     ∆PEST         ∆PEST 
       +atRA         +atRA                 +atRA 
Figure 34: aNPDC-1 negatively impacts proliferation of HEK293 cells.  HEK 
293 cells were transfected with mammalian expression plasmids for aNPDC-1 
and aNPDC∆PEST using calcium phosphate technologies.  Cells were allowed to 
recover overnight before being plated at a density of 50,000 cells/well in a 24-
well plate.  Cells were incubated with 2µCi [3H]-thymidine/well and either 
treated with 1µM atRA or untreated for 6h, 24h, 48h.  Cells were lysed and DNA 
was precipitated with 10% TCA and radiation was trapped by filtration through 
a vacuum filter apparatus.  The incorporation of [3H]-thymidine was measured 
by TCA precipitation. 
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calcium phosphate precipitation technologies, HEK 293 cells were transfected with 
mammalian expression plasmids for aNPDC-1 or aNPDC∆PEST and a βRE-tk-luc 
reporter plasmid.  Transfections were allowed to recover overnight and the next 
morning the cells were trypsinized, counted and plated at a density of 50,000 
cells/well in a 24 well plate.  Cells were either treated with 1µM atRA or untreated, 
and incubated in the presence of 2µCi [3H]-thymidine/well for 6h, 24h and 48h.  The 
incorporation of [3H] thymidine was measured by TCA precipitation and the average 
incorporation for 3 wells was plotted.  The over-expression of full-length aNPDC-1 was 
observed to significantly reduce proliferation at all three timepoints.  Although the 
aNPDC-1 with the PEST deletion also significantly reduced proliferation, its impact 
was not statistically different from that observed for full-length aNPDC-1.  In addition, 
the presence of retinoic acid appears to significantly inhibit the 24h aNPDC-1 
proliferation results whereas it had no effect on the aNPDC∆PEST transfections.  
Cumulatively, these data support a role for NPDC-1 in suppression of cellular 
proliferation. 
 
Copyright © Maria Theodosiou 2006 
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Chapter 11: Discussion 
 
The NPDC-1 protein has been shown to associate with cell cycle regulators and 
regulate cellular proliferation events, and we have previously shown that NPDC-1 can 
regulate retinoic acid signaling events, a classical pathway for defining early 
embryonic differentiation events in both higher and lower eukaryotes.  In spite of these 
advances in NPDC-1 cellular biochemistry, the precise biochemical mechanism by 
which NPDC-1 functions has not been defined by any of the investigators working with 
it, nor has NPDC-1 been directly associated with any disease pathogenesis.  In an 
effort to define the biochemical role of NPDC-1 in vivo, we established a collaboration 
with Dr Randal Voss at the University of Kentucky.  Dr. Voss is a leader in the field of 
axolotl development and evolution, and his laboratory houses one of the few 
established facilities for breeding and studying axolotl development.  Axolotl 
represents a unique and well-defined system for the study of proliferation and 
differentiation, both functions impacted by NPDC-1 and retinoic acid (RA) signaling. 
Metabolic inhibitors of RA, such as citral, inhibit limb regeneration (125, 128) in 
axolotls, suggesting retinoic acid impacts patterning in the developing axolotl limb 
(122-125) and is able to modify positional information in the regenerating limb (111, 
119, 120, 124-127).  Given the phenotype of RA signaling in axolotl and its similarity 
to NPDC-1 signaling, we investigated the impact of NPDC-1 on the intracellular 
mediator of axolotl retinoic acid signaling, the axolotl retinoic acid receptor (aRAR).  
To initiate our studies, it was necessary to first isolate and clone the axolotl 
homolog for NPDC-1 (aNPDC-1).  As described in Chapter 6, aNPDC-1 was isolated 
from axolotl brain using 5’ RACE.  Sequence comparison of the axolotl homolog with 
the sequence of NPDC-1 from higher vertebrates showed conservation of certain key 
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regions of the protein such as the LXXLL motif, MAPK domain, PEST sequence and the 
helix-loop-helix motif.  Overall the protein is conserved between higher vertebrates and 
axolotl with a consensus of 97.3% and identity of 36.3%, compared to 97.9% 
consensus and 73.3% identity between human, rat and mouse sequences.  The biggest 
deviation in sequence conservation is observed between human and axolotl with only 
49.1% consensus conservation and 39.3% identity conservation. 
The tissue distribution of NPDC-1 is as varied in axolotl tissues as it is in 
human and mouse.  Although NPDC-1 was isolated initially as a neuronal protein it 
has been demonstrated by a number of groups (90, 95) to have a more diverse 
distribution in higher vertebrates.  In studies presented here it is demonstrated that in 
lower vertebrates such as the axolotl, the pattern of expression of NPDC-1 is just as 
widespread.  In axolotl, NPDC-1 is highly expressed in heart, brain, skin, gill and eye.  
High expression of NPDC-1 was also observed to occur in human heart and brain 
tissues (95).  The high level of NPDC-1 expression in juvenile axolotl gill would also 
appear to agree with previously reported data showing high level of expression of 
NPDC-1 in both human and rat lung (95).  In metamorphosized axolotls, it is 
reasonable to hypothesize that NPDC-1 expression in lung would be higher than in 
juvenile animals.  Cumulatively these tissue distribution data would circumstantially 
suggest that NPDC-1 serves a similar role in axolotl as it does in higher vertebrates. 
Axolotl NPDC-1 also appears to functionally share with higher vertebrate NPDC-
1 its ability to suppress cellular proliferation.  In the original studies characterizing 
NPDC-1, cells transfected with NPDC-1 were observed to have lower proliferation 
rates.  The doubling times of cells stably transfected with NPDC-1 were higher 
compared to controls, and the addition of NPDC-1 antisense oligonucleotides restored 
the generation times to control levels, demonstrating that NPDC-1 was responsible for 
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the observed slower proliferation rates (89).  In studies presented here it was observed 
that transfection of aNPDC-1 into HEK293 cells resulted in decreased [3H] thymidine 
incorporation signifying a lower proliferation rate, in agreement with these previously 
reported results for mouse NPDC-1 (89).  In the studies presented here it was also 
observed that treatment of aNPDC-1 transfected HEK cells with 1µM atRA resulted in 
a lower proliferation rate compared to untreated cells.  The potential mechanism for 
NPDC-1’s actions in inhibiting cellular proliferation is not fully understood, but NPDC-
1 has been reported to associate either directly or indirectly with cell cycle regulatory 
proteins such as E2F-1, cyclin A, cyclin D1 and cdk2 (91, 93).  Further examination is 
necessary to determine whether these associations are responsible for NPDC-1’s 
properties as an anti-proliferative protein. 
Similar to NPDC-1, my studies in axolotl also mandated that I clone an axolotl 
homolog for retinoic acid receptor.  This was accomplished by utilizing RT-PCR to 
clone the RARγ from axolotl lung.  Sequence comparison between human and axolotl 
RARγ showed a 98.5% conservation of the DBD and 89% conservation of the LBD.  
Although three distinct isoforms of RARs have been identified in human (68), mouse 
(146), and chicken (147), the amphibians Notophtalmus viridescens (148-150), 
Xenopus laevis (151, 152), and zebrafish (153) have been reported to express only two 
isoforms, RARα and RARγ.  In the study by Wirtanen et al (106) looking at RAR 
expression in axolotl, cDNAs coding for a full-length aRARγ and partial sequence for 
aRARα were isolated by screening an axolotl neurula cDNA library.  In the same study, 
these investigators isolated three splice variants of aRARγ; aRARγ1, aRARγ2 and 
aRARγ3.  The axolotl homologs for RXR have not been cloned so far, but all RXR 
homologs have been identified in other amphibians such as Xenopus (151, 154, 155) 
and in zebrafish (153).  Although the studies presented here are restricted to aRARγ2, 
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the overlap in tissue distribution with aNPDC-1 would suggest these data are 
biologically relevant. 
Amphibian RARγ tissue distribution appeared to also mirror that observed for 
higher vertebrate RARγ.  In humans RARγ mRNA is the predominant RAR subtype 
expressed in both fetal and adult skin (1, 156).  A low level of RARγ mRNA expression 
can also be found in lung (1).  The size of murine RARγ mRNA transcript is the same 
size as in human and is found in the skin and at lower levels in lung and spleen (1, 
71).  In studies presented here I demonstrate axolotl RARγ localizes to the heart, eye, 
skin, and to a lesser extent gill, spinal cord, liver and lung.  These findings are in line 
with previously published data on axolotl and other amphibians where it was shown 
that RARγ is expressed, at both the mRNA and protein levels, in mesenchymal and 
epidermis tissues of normal and regenerating limbs of the newt (1, 150, 157).  In 
Xenopus, RARγ is expressed during early development in the anterior and posterior 
ends of the neurula, and later in the head mesenchyme and tail bud (1).  This 
localization of RARγ is consistent with the spatial and temporal pattern of retinoic acid 
sensitivity of Xenopus (1, 152).  
Axolotl RARγ also appeared to function as a transcription factor in a similar 
manner to that observed for the higher vertebrate form of the receptor.  RARs have 
been shown to heterodimerize with members of the RXR family of receptors and bind 
DNA response elements for retinoid receptors (RAREs) composed of two half-site motifs 
separated by 5 bases (DR5).  In the studies presented here I demonstrate that aRARγ 
can bind to, and initiate transcription from, a DR5 RARE.  This is consistent with 
published studies for higher vertebrates (95).  As with higher vertebrate RARs, aRARγ 
utilizes RXR as a heterodimer partner.  Although human RXRα was used for the 
studies presented here, as mentioned above, previously published data support the 
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existence of RXR isoforms in axolotls (158), but axolotl RXRs have yet to be cloned and 
sequenced.  Cumulatively these data would suggest that aRARγ signaling functions 
through a similar mechanism to that of higher vertebrate RARs and most probably 
regulates the expression of similar sets of genes. 
Expression of aNPDC-1 and aRARγ were observed to overlap during axolotl 
development, but peak at different times.  NPDC-1 was initially isolated in terminally 
differentiated neuronal cells and shown to be inhibitory to cellular proliferation (89).  
In addition, NPDC-1 expression in mouse brain was found to increase during 
development with peak levels occurring at adulthood (91).  A similar developmental 
pattern of NPDC-1 expression was observed in our studies in axolotl, where aNPDC-1 
expression was strongly detected beginning at stage 38 and peaked at hatching.  
Although the pattern of RARγ expression during axolotl development appeared to 
partially overlap with that seen for NPDC-1, aRARγ expression was observed to occur 
earlier in development and peak prior to that seen for aNPDC-1 expression.  In axolotl 
development, Wirtanen et al observed RARγ2 levels begin to rise by stage 11, peak by 
stage 16 and decline as the embryo approaches hatching (106).  In studies presented 
here we have also detected aRARγ levels to decrease at hatching but extending our 
analyses we observed aRARγ to begin to increase 2 months post-hatching.  In essence, 
RARγ expression in axolotl increases during the gastrula and neurula stages, through 
the fusion of the neural fold, gill region and ear pit development and extension of the 
body to 20 somites, whereas NPDC-1 expression peaks substantially later during the 
development and differentiation of gills, gill filaments and mouth (113).  From a purely 
developmental perspective, it appears that NPDC-1 and RARγ expression are 
antagonistic in that aRARγ expression is reduced to background levels as aNPDC-1 is 
beginning to increase its expression. 
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Previous studies with higher vertebrate NPDC-1 demonstrated it could impact 
RAR signaling through direct binding of RXR and RAR-RXR heterodimers (95). In the 
research presented here I demonstrate that axolotl NPDC-1 can also bind aRARγ, and 
that this binding event can be localized to the amino terminus within amino acids 1-
97. Two highly conserved domains occur within this amino terminus region.  The first 
is an LXXLL motif.  This motif has been previously reported to be an important 
nuclear receptor binding site for a variety of transcription coregulatory proteins (1), 
although Henry et al (95) demonstrated that, at least with respect to human NPDC-1 
and RAR signaling, this motif appears not to be critical for transcriptional regulatory 
events modulated by NPDC-1.  The second motif is a helix-loop-helix (HLH) domain 
that occurs downstream of the LXXLL motif.  This domain has been shown to function 
as a binding site for DNA, and proteins belonging to the HLH family have been shown 
to be key regulators of development, particularly cell type determination, terminal 
differentiation and sex determination (90).  Further studies will be required to 
establish what, if any, role the HLH domain might be playing in aNPDC-1-aRARγ 
binding events. 
Most coregulatory proteins mediate their regulation of transcription through 
modulation of the protein complexes that associate with specific DNA regulatory 
sequences in the promoters of the genes they regulate (18).  In the studies presented 
here I demonstrate that the mechanism for aNPDC-1 regulation of aRARγ-mediated 
transcription appears complex and may involve both direct associations with aRARγ as 
well as facilitating complex formation on RAR response elements.  It was observed that 
the presence of aNPDC-1 increased the amount of response element DNA bound of the 
RAR-RXR heterodimer complex, suggesting that aNPDC-1 is capable of altering the 
DNA binding capacity or affinity of the RAR-RXR heterodimers.  These results parallel 
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what we have published for higher vertebrates, in that it was shown that in PC12 
extracts, NPDC-1 increases the intensity of the complex formed on a DR5 response 
element without altering the mobility of the complexes formed (95).  In the same 
published study, human NPDC-1 was similarly shown to enhance the binding of 
recombinant human RXRα complexes to a DR1 response element (95).  These data 
cumulatively suggest that NPDC-1 is able to alter the DNA binding capacity of the 
RAR-RXR complex without altering the mobility of the complex.  The mechanism for 
this observation is unclear but one possibility is that NPDC-1 facilitates complex 
formation on the response element, but its loose associations are lost in the 
subsequent electrophoretic procedures.  There have been previous reports in literature 
where addition of nuclear extracts increased the binding efficiency of RAR to DNA (72, 
73), but these reports focused on the DNA binding activity of RARα and not the RAR-
RXR heterodimer.  Yang et al and Glass et al (72, 73), demonstrated that addition of 
nuclear extracts from various cell lines increased the DNA binding affinity of RARα, 
and this was dependent on the origin of the nuclear extract.  It is possible that merely 
the presence of RXR from the nuclear extract would change the complex mobility and 
intensity, although the study by Glass et al (73) also suggests that specific 
combination of retinoic acid receptors and cell-type specific coregulator proteins may 
function to integrate the effects of retinoic acid on patterns of gene expression within 
specific cell types during development.  Based on the size of the various proteins 
observed to cross-link with RARα in the study by Glass et al (73), NPDC-1 appears not 
to be one of them.  
Interestingly, in contrast with what we have published for high vertebrate 
NPDC-1-RAR DNA binding events, using recombinant axolotl NPDC-1 and RARγ 
proteins, a unique shift in the RAR-RXR complex was also observed with the addition 
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of aNPDC-1.  This more logical increase in complex size due to binding of aNPDC-1 is 
supported by the observation that NPDC-1 antibody effectively eliminated the complex.  
It should be noted that NPDC-1 antibody also eliminated the enhanced complex 
described above, suggesting that these multiple effects axolotl NPDC-1 is having on 
aRARγ-RXR DNA binding complexes are both NPDC-1-specific.  These data would also 
support the hypothesis presented above that aNPDC-1 can transiently or loosely 
associate with aRARγ-RXR complexes and facilitate their DNA binding.  Cumulatively, 
these data demonstrate that aNPDC-1 shares many of the features higher vertebrate 
NPDC-1 proteins possess with respect to their impact on RAR-RXR DNA binding, but 
also suggests aNPDC-1 may complex with aRAR-RXR heterodimers in a somewhat 
different capacity.  
The potential functional consequences of aNPDC-1 binding of aRARγ and its 
impact on aRARγ DNA binding, appears to be a repression of aRARγ-mediated 
transcription events.  In studies presented here I demonstrate that DR5-driven 
reporter gene transcription can be moderately repressed by over-expression of aNPDC-
1 in in vitro transcription analyses.  This is similar to what has been reported for 
human NPDC-1 (95), although the repression observed for aNPDC-1 is not as great as 
the repression observed for hNPDC-1 (95).  This could be due to a number of factors, 
not the least of which is the expression of axolotl proteins in mammalian cells.  It is 
difficult to predict if the axolotl proteins are expressed and processed correctly in the 
mammalian cells.  Ideally, these studies should be performed in an axolotl cell line, 
but due to the lack of any established axolotl cell line and the culturing and 
transfection limitations of axolotl primary cells, I was relegated to using the Cos7 
mammalian cell line for the studies presented here.  The Cos7 cell line was chosen 
primarily because of its low endogenous level of RAR and its transfectability.   
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Cumulatively these studies present a potential paradox in that, although NPDC-
1 can enhance RAR-RXR DNA binding to a DR-5 response element, the end result is 
repression of gene expression events from this response element.  Several possible 
explanations for these observations exist and might include aNPDC-1 enhancing 
RAR/RXR heterodimer binding but blocking ligand binding and subsequent 
recruitment of transcription co-activator complexes, aNPDC-1 enhancing RAR/RXR 
heterodimer binding that results in the recruitment of transcription co-repressor 
complexes, or even the possibility that aNPDC-1 facilitates the formation of a 
homodimer complex (RAR or RXR) that can compete for binding to the DR5 element 
and in that capacity repress RAR/RXR heterodimer-mediated transcription.  Further 
studies will be required to establish the biochemical mechanism for repression of RAR-
mediated transcription events by NPDC-1. 
 In summary, this study presents the first evidence for interaction between 
NPDC-1 and RARγ in axolotl.  The axolotl is an established animal model system for 
studying development and differentiation, functions that are impacted by both RAR 
and NPDC-1.  In studies presented here, it is demonstrated that aRARγ is able to bind 
to and activate transcription from a DR5 element, and that aNPDC-1 is able to repress 
this transcription.  The axolotl NPDC-1 was also shown to decrease cell proliferation, 
confirming previously published results for mouse NPDC-1 (89).  Finally, it was shown 
that aNPDC-1 could alter aRARγ-RXR DNA binding complexes, suggesting that 
aNPDC-1 can directly modulate gene expression events mediated through retinoic acid 
signaling. Future directions for these studies include the utilization of the axolotl as a 
model organism to study the interactions between aNPDC-1 and aRAR in vivo and 
their impact on differentiation.  Overall, these studies are the first step towards 
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dissecting the impact of NPDC-1 on RAR mediated signaling in development and 
differentiation. 
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SECTION V: CONVERGENCE OF THYROID AND NPDC-1 SIGNALING PATHWAYS 
IN AXOLOTL 
 
 
Chapter 12: Introduction 
 
 Amphibian metamorphosis is a postembryonic developmental process governed 
by thyroid hormone (TH) during which larval tissues are being replaced by adult 
tissues.  The dramatic changes that occur during metamorphosis, which are easily 
observed due to the accessibility of the animals compared to amniotes, include 
organogenesis and tissue remodeling (159).  At the biochemical level, metamorphosis 
involves a coordinated process of cell proliferation, differentiation and death (159).  
During premetamorphosis, the circulating levels of TH are minimal (160), increasing 
slowly (161) and peaking at metamorphosis (108).  This peak is caused by an 
increased secretion of circulating TSH and is accompanied by dramatic and rapid 
morphological and biochemical changes (161).  The circulating levels of the TH 
isoforms, T3 and T4, return to premetamorphic levels several days after 
metamorphosis is completed (161).  TH is responsible for metamorphosis, although 
other hormones such as prolactin, glucocortocoids and estrogen are thought also to 
play a role in this process (160-165).  Furthermore, it has been clearly demonstrated 
that the T4 isoform is responsible for induction of metamorphosis (159, 166, 167).  
During metamorphosis, enzymatic processes convert T4 to the more biologically active 
and potent T3 isoform, and T3 levels rise and reach a peak at climax (159, 165, 168).  
In addition to T3, corticosteroid levels also rise and have been demonstrated to 
synergize with T3 to promote metamorphosis (159, 165, 168).  Administration of TH to 
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anuran tadpoles, even before the period of metamorphosis, triggers the process (108), 
and blockage of endogenous TH production by goitrogens blocks metamorphic 
induction and produces giant tadpoles (108). 
 Thyroid gland secretions are under strict hormonal control.  Thyrotropin (TRH) 
secreted by the pituitary gland controls T3 production and adrenocorticotropin (ACTH) 
controls the production of corticosteroids (159, 165, 167).  The biosynthesis and 
secretion of both TRH and ACTH are under the control of neurohormones produced by 
the hypothalamus, thus placing the neuroendocrine system at the center of the 
metamorphological processes (159).  The primary regulator of TSH secretion is 
thyrotropin-releasing hormone (TRH).  However, TRH does not appear to control 
thyroid secretions during metamorphosis (159, 167, 169), but corticotrophin-releasing 
hormone (CRH) may function in this capacity instead, controlling the release of both 
TSH and ACTH during metamorphosis (159, 165, 167, 170-174). 
 In nature, the importance and extent of metamorphosis across amphibian 
species varies (108).  Alternative mechanisms such as neoteny (sexual maturity in the 
larval form) and direct development can be found in both urodeles and anurans [(108) 
and references therein].  In Ambystoma, neoteny is facultative, whereas in Necterus, 
Proteus or Siren species it is obligatory (108).  Populations of Ambystoma found in 
nature can be purely neotenic, transforming or polymorphic (108).  In the laboratory, 
most Ambystoma species undergo metamorphosis when treated with TH, whereas the 
concentration of TH necessary to trigger metamorphosis varies (108).  In salamander 
the term metamorphosis is used to describe changes that occur naturally or can be 
induced by TH in sexually mature adults, and therefore are not necessary to complete 
the life cycle (115, 175).  Spontaneous metamorphosis has been described for some 
salamander species where they resorb their gills and tail fins, change their head shape 
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and undergo skin thickening (115).  Phylogenetic analyses have shown that 
metamorphic failure evolved independently several times during Ambystoma evolution, 
suggesting that there is an increased ability to select this life history trait in all species 
of this genus (108).   
The reasons some Ambystoma do not undergo metamorphosis are unclear and 
seem dependent on environmental conditions (161).  The cause of this metamorphic 
failure has been a subject of study at the molecular level.  Axolotl tissues respond to 
TH changes and this suggests that failure resides with TH production in these animals 
and abnormally low TSH secretion (108, 161, 176).  With the cloning of the axolotl 
thyroid hormone receptors in 2004 it was observed that both TRα and TRβ are 
expressed in larval and adult axolotl, and that their target genes could be regulated by 
TH (108, 177). Furthermore, these receptors were also observed to be upregulated in 
axolotl tissues following TH administration (108).   
Structurally, axolotl TR homologs show a strong sequence identity to known 
TRα and TRβ sequences, with the strongest conservation in the DBD and LBD.  Within 
the DBD the helix responsible for contact with the HRE is fully conserved.  Within the 
LBD there is strong conservation in the 12 α-helices that form the core of the 3-D 
structure (178), suggesting that axolotl TRs have the capability to bind TH and 
transactivate target genes in response to hormone (108).  Further experiments 
presented by Safi et al (108), show that axolotl TRs are functional, able to bind DNA 
and T3, and able to activate transcription off a xDR4 luciferase reporter in a T3 
dependent manner (108). 
During metamorphosis of axolotls the levels of TRs are modified.  At 
premetamorphosis the levels of TRα mRNA are higher compared to TRβ mRNA.  At the 
beginning of metamorphosis, TH binds to TRα, which then induces early genes such 
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as TRβ, which upregulates its own transcription and mediates the response to TH by 
inducing different cascades of gene activation (108).  The levels of TRβ never exceed 
those of TRα (161), and after the climax of metamorphosis the levels of both isoforms 
return to normal (179-181).  
The role of thyroid hormone in axolotls is not confined to metamorphosis, but 
rather extends to the developmental changes that take place in the nervous system 
prior to metamorphosis, such as the remodeling of CNS regions necessary for the 
transition from larval to adult life.  The importance of TH for the maturation of 
neurosecretory centers was demonstrated by Norris and Gern (182) who showed that 
neotenic tiger salamanders could be induced to metamorphose when injected 
intrahypothalamically with T4 but not intraperitoneally (170).  During this time of 
premetamorphosis CNS remodeling, certain larval structures are eliminated and adult-
specific neural structures develop.  
 The axolotl is an excellent model for the study of postembryonic development, 
in that their life cycle has distinct boundaries and these changes from juvenile to adult 
can be regulated in vitro by TH (108).  This process of metamorphosis is highly 
regulated and is mediated through the modulation of gene expression events via TH 
interaction with its nuclear receptor family members.  Because of its importance and 
level of commitment, it stands to reason that the process of thyroid receptor-mediated 
gene transcription is itself under close regulation during metamorphosis.  In the 
previous chapters I defined a role for the axolotl nuclear receptor coregulatory protein 
aNPDC-1 in regulation of axolotl retinoid signaling, an event closely aligned with 
axolotl embryonic development.  In this section of the dissertation I investigate the 
possibility that this same coregulatory protein might be involved also in the regulation 
of thyroid hormone signaling.  Here I demonstrate that axolotl NPDC-1 can alter 
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transcription mediated by thyroid receptors, can complex with both aTRα and aTRβ, 
and can modify TR/RXR DNA binding.  These preliminary studies into the regulation 
of thyroid hormone signaling provide the foundation for dissecting the molecular 
mechanisms regulating amphibian morphogenesis, which, due to the conservation 
seen in these protein structures, could prove applicable to our understanding of 
thyroid signaling in high vertebrates. 
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Chapter 13: Experimental Procedures 
 
Chemicals, Enzymes and Antibodies 
Standard chemicals used throughout these studies, unless otherwise stated, were 
purchased from Sigma chemical or Fisher Scientific.  Restriction enzymes, 
polymerases, ligases and kinases used in these studies, unless otherwise stated, were 
purchased from New England Biolabs.  Benzonase nuclease was purchased from 
Novagen.  The antibodies used for these studies were purchased from Santa Cruz 
unless otherwise stated. 
 
Plasmids and Constructs 
aTRα: To clone axolotl TRα into the bacterial expression  vector pGEX-KG, a PCR 
reaction was performed on pGEM-aTRα (a gift from Dr. Voss’ lab) using the following 
primers: Forward 5’-GGA AGA ATT CTA GAC CAG AAC CCC AGC GAT-3’ and Reverse: 
5’-GCA AAA GCT TTC AAA CTT CCT GGT CTT CGA A-3’.  The amplified receptor was 
then subcloned into the EcoRI/HindIII sites of the bacterial expression vector pGEX-
KG.  To clone aTRα into the mammalian expression vector pcDNA3.1/Zeo, full length 
aTRα was digested with SacII, filled-in with Klenow and subsequently digested with 
Not I and inserted into the EcoRV/NotI sites of pcDNA 3.1/Zeo.  The primers forward: 
5’-TTG AAT TCA TGG ACC AGA ACC CCA G-3’ and reverse: 5’-TAT AAG CTT TCA AAC 
TTC CTG GTC TTC-3’ were used to amplify aTRα and clone it into the EcoRI/HindIII 
sites of the bacterial expression vector pET32. 
aTRβ: To clone axolotl TRβ into the bacterial expression vector pGEX-KG, a PCR 
reaction was performed on pGEM-aTRβ (a gift from Dr. Voss’ lab) using the following 
primers: forward: 5’-GGC CGA ATT CTA CCC ATC AGT ATG TCA GGG-3’ and reverse: 
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5’-GGC CAA GCT TTT AGT AGT TGG AGA CGA TCA G-3’.  The amplified receptor was 
then subcloned into the EcoRI/HindIII sites of the bacterial expression vector pGEX-
KG.  The reverse primer was modified using the redundancy of the genetic code to 
increase the Tm of the primer.  To clone aTRβ into the mammalian expression vector 
pcDNA3.1/Zeo, full length aTRβ was digested with SacII, filled-in with Klenow and 
subsequently digested with Not I and inserted into the EcoRV/NotI sites of pcDNA 
3.1/Zeo.  The primers forward: 5’-TTG AAT TCA TGC CCA TCA GTA TG-3’ and reverse: 
5’-TAT AAG CTT CTA ATC CTC AAA GAC C-3’ were used to amplify aTRβ and clone it 
into the EcoRI/HindIII sites of the bacterial expression vector pET32.  To clone aTRβ 
into the EcoRI/HindIII sites of pTriex (Novagen) (can be used for both mammalian and 
bacterial expression), the primers used were: forward: 5’-TTG AAT TCT ATG CCC ATC 
AGT ATG-3’ and reverse: 5’-TAT AAA GCT TCT ACT GTG GCT TAG AG-3’. 
aNPDC-1: The generation of aNPDC-1 clones was described in section IV materials and 
methods. 
RPA probe plasmids: RT-PCR was performed on axolotl lung RNA to obtain aTRα, 
aTRβ, aNPDC-1 and RPL13A (a control gene) for use as RPA probes.  The primers used 
for aTRα were: forward 5’-GCT TGA ATT CGC ATC GCT GTG GGC ATG GC-3’ and 
reverse: 5’-CAC GAA GCT TGG CCG GTG CTG CAT GGA CT-3’.  For aTRβ the primers 
used for the RT reaction were forward: 5’-GTC TGA ATT CGC ACC TAC GTT GGC ATG 
GC-3’ and reverse: 5’-CAC GAA GCT TCG TTG GTG GCC ATG TGT GC-3’.  For aNPDC-
1, the primers used were forward: 5’-GTC TGA ATT CGA CAG ATC CTC GCC AGT AG-
3’ and reverse: 5’-CAC GAA GCT TCG TGA AAT CGC CAT CCT C-3’ whereas for 
RPL13A the following primers were used: forward: 5’-GTC TGA ATT CGG CAG GCT 
GCC CTG GAA AG-3’ and reverse: 5’-CAC GAA GCT TCA ACC GCA CAA TCT TGA GC-
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3’.  The amplified fragments were then subcloned into the EcoRI/HindIII sites of 
pGEM4. 
Other plasmids and constructs: For these experiments, in addition to the plasmids 
described above, the previously described TRE-tk-luc plasmid (183) and RSV-βgal 
plasmid (137) were utilized. 
 
RT-PCR Assays 
Axolotl tissue cDNA (a gift from Dr. Voss’ lab), was subjected to PCR using the 
following primers: For aTRα forward: 5’-CTG GAT AAA GAT GAA CCG TGC GTT-3’ and 
reverse: 5’-ACT TCA GCA TTT CCT CTT TGC GCC-3’ and for aTRβ forward: 5’-ATG 
GAT TTC TAA CTC AGA CGA CAC CG-3’ and reverse: 5’-CCA AAA TGT TTC TTT TTT 
TAC ACT CGA CT-3’.  cDNA template corresponding to 400ng total RNA was used per 
PCR reaction. PCR were performed on a T-Gradient thermocyler as described by the 
manufacturer (Biometra) using the following cycling conditions: 940Cx3min, 940Cx45s, 
550Cx45s, 720Cx45s for 32 cycles, 720Cx 5min.  PCR products were resolved on a 
1.2% agarose gel and detected using the Gel logic gel imaging system (Kodak). 
 
Recombinant Protein expression 
Glutathione:  To develop GST and GST-aTRα and GST-aTRβ fusion proteins, BL21-RP 
Escherichia coli cells were transformed with bacterial expression constructs in the 
pGEX-KG plasmid system.  Transformants were plated on double selection media 
containing carbanecillin (50µg/ml) and chloramphenicol (34µg/µl) overnight at 370C.  
Isolated colonies were picked and used to grow a 2.0mL starter culture which was 
then used to inoculate 500mL of 2X-YT (16mg/ml Tryptone, 10mg/ml NaCl, 10mg/mL 
Yeast extract, pH 7.2-7.4) supplemented with carbanecillin and chloramphenicol.  
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Cultures were grown to log phase at room temperature (OD600 of 0.6).  Protein 
expression was induced for 6h by the addition of IPTG (isopropyl-β-D-
thiogalactopyranoside) (Gold BioTechnology, Inc) to a final concentration of 1mM.  
Bacterial cells were pelleted by centrifugation for 15 minutes at 6000rpm and 
resuspended in 5mL of 10mM Tris-HCl pH 7.5 containing 100mg of lysozyme (Sigma), 
followed by the addition of 20mL of Triple Detergent Lysis buffer [50mM Tris-HCl pH 
8.0, 150mM NaCl, 0.02% sodium azide (v/v), 1% NP-40 (v/v), 0.5% sodium 
deoxycholate (v/v), 1µM PMSF and 1X protease inhibitor cocktail (Roche Applied 
Science) and Benzonase Nuclease (1µl/ml)] and incubated at room temperature with 
agitation (150rpm) for 30 minutes on an orbital floor shaker.  The soluble fraction was 
clarified by ultracentrifugation for 1h at 50,000rpm in a Ti70 rotor.  GST fusion 
proteins were purified by Fast Performance Liquid Chromatography (FPLC) on a 
GSTrap Fast Flow column (GE Life Sciences).  Eluates were desalted by FPLC on a G-
50 desalting column into TBS-P (10mM Tris-HCl pH 8.0, 150mM NaCl, 10% glycerol 
(v/v), 1mM DTT) and the resulting proteins were aliquoted and stored at -700C until 
use.  The protein concentration was determined using Bradford reagent (Advance, 
Cytoskeleton Inc). 
Thioredoxin:  To generate Thioredoxin and thioredoxin-tagged aNPDC, aNPDC∆PEST, 
aNPDC∆HLH, aTRα and aTRβ, bacterial expression constructs in the pET32 (Novagen) 
vector system were transformed into BL21-RP E. coli cells.  Transformants were plated 
on double selection media containing carbanecillin (50µg/ml) and chloramphenicol 
(34µg/µl) and incubated overnight at 370C.  Isolated colonies were picked and used to 
grow a 2.0mL starter culture which was then used to inoculate 500mL of 2X-YT 
supplemented with carbanecillin and chloramphenicol.  Cultures were grown at room 
temperature, to an OD600 of 0.6.  Protein expression was induced for 6h by the 
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addition of IPTG (isopropyl-β-D-thiogalactopyranoside) (Gold Biotechnology Inc) to a 
final concentration of 1mM.  The transformed bacterial cells were pelleted by 
centrifugation at 6000rpm for 15 minutes and resuspended in 5mL of 10mM Tris-HCl 
pH 7.5 containing 100mg of lysozyme (Sigma), followed by the addition of 20ml of 
Triple Detergent Lysis buffer, and incubated at room temperature with agitation 
(150rpm) for 30 minutes on an orbital floor shaker.  The soluble fraction was clarified 
by ultracentrifugation for 1h at 50,000rpm in a Ti70 rotor.  The clarified lysate was 
purified by FPLC on a HiTrap chelating HP column (Amersham Biosciences) preloaded 
with Nickel.  Bound protein was washed with 10 column volumes of His wash (50mM 
NaH2PO4, 300mM NaCl, 20mM Imidazole pH 8.0) and eluted in His elution buffer 
(50mM NaH2PO4, 300mM NaCl, 500mM Imidazole pH8.0).  Eluates were desalted by 
FPLC on a G-50 desalting column into TBS-P (10mM Tris-HCl pH 8.0, 150mM NaCl, 
10% glycerol (v/v), 1mM DTT), and the resulting proteins were aliquoted and stored at 
-700C until use.  The protein concentration was determined using Bradford reagent 
(Advance, Cytoskeleton Inc). 
 
Pulldown Assays 
Recombinant GST-aTRα and GST-aTRβ (10µg/reaction) were prebound to glutathione 
sepharose beads (50% slurry in APB buffer) [APB: 50mM Tris-HCl ph 7.5, 150mM 
NaCl, 10% glycerol (v/v), 1% NP-40 (v/v)] by rotating for 1h at 40C.  To the GST 
prebound proteins, equimolar amounts of thioredoxin or thioredoxin-tagged aNPDC-1 
proteins were added as described in results and figure legends.  The proteins were 
allowed to interact by rotating for at least 1h at 40C.  The beads were recovered by 
centrifugation in a microcentrifuge and washed 5 times with 1ml APB.  The bound 
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proteins were analyzed by western blot analyses probing with antisera for thio-probe 
(Santa Cruz). 
For pulldown studies investigating aNPDC-1 and aTR interaction in HEK cells, HEK 
cells transfected with tagged constructs for aNPDC-1 and aTRs were lysed and purified 
as described below and processed as described above. 
 
TR Cell Extract Preparation 
HEK cells were transiently transfected with either the expression vector pTriex or 
pTriex-aTRβ using the calcium phosphate transfection method as previously described 
(140).  Following 48h incubation at 370C, the cells were washed with 1X PBS [PBS: 
0.30g/L NaH2PO4 anhydrous, 1.15g/L Na2HPO4 anhydrous, 9g/L NaCl, pH 7.2-7.4] 
and lysed in 1ml APB [APB: 50mM Tris-HCl ph 7.5, 150mM NaCl, 10% glycerol (v/v), 
1% NP-40 (v/v)].  The cell lysate was then spun briefly to precipitate cellular debris.  
The supernatant was collected, the concentration was determined using the Bradford 
method, and was stored at -800C until needed.   
 
Cross-linking aNPDC-1 to Cyanogen bromide sepharose 
Recombinant axolotl NPDC-1 protein was cross-linked to Cyanogen Bromide-activated 
Sepharose 4 Fast Flow agarose (Amersham) according to manufacturers’ instructions.  
Briefly, the matrix was washed in low pH (pH 2-3) to remove additives added by the 
manufacturer.  The washed medium was then mixed with coupling solution [0.1M 
NaHCO3 pH 8.3 containing 0.5M NaCl] and ligand (aNPDC-1) and coupling was 
allowed to occur at 40C overnight.  The excess ligand was then washed with 5 volumes 
coupling buffer and non-reacted groups on the medium were blocked by incubation in 
0.1M Tris-HCl pH 8.0 for 2 hours.  The coupled medium was then washed using 
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alternate low and high pH solutions.  For low pH washes 0.1M acetate buffer pH 3-4 
containing 0.5M NaCl was used and for high pH washes 0.1M Tris-HCl buffer pH 8-9 
containing 0.5M NaCl was used.  The washes were repeated a total of 5 times.  The 
coupled medium was stored at 40C in 20% ethanol to prevent microbial growth. 
 
Western Blot Analysis 
Western blot analyses were performed as previously described (99).  Briefly, proteins 
were separated by SDS-PAGE electrophoresis and electroblotted onto nitrocellulose 
membranes (Stratagene Inc).  Blocking was performed in PC buffer (1% casein in 1X 
PBS) [PBS: 0.30g/L NaH2PO4 anhydrous, 1.15g/L Na2HPO4 anhydrous, 9g/L NaCl, pH 
7.2-7.4] overnight.  Primary antibody was diluted in PCT buffer (1% casein in 1X PBS, 
0.01% Tween-20) and incubated for 1h.  Blots were subsequently washed with TBST 
buffer (20mM Tris pH7.5, 137mM NaCl, 0.1% Tween-20), then incubated with an 
appropriate secondary antibody coupled to horseradish peroxidase, reacted with ECL 
reagents (Pierce) as described by the manufacturer and detected on X-ray film by 
autoradiography.  
 
Electromobility Shift Assays 
To generate nuclear extracts for EMSAs, cells were washed with non-sterile PBS twice 
and scraped into 1mL PBS and transferred to microcentrifuge tubes on ice.  The cells 
were then spun for 2 minutes at 2500 rpm.  The resulting pellet was resuspended into 
buffer A [10mM Hepes pH 7.9, 1.5mM MgCl2, 10mM KCl, 0.5mM DTT, 0.2mM PMSF] 
and incubated on ice for 10 minutes.  After vortexing, the lysate was spun at top speed 
for 3 minutes.  The pellet was then resuspended into 100µl buffer C [20mM Hepes pH 
7.9, 25% glycerol, 420mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 0.5mM DTT, and 
- 137 - 
0.2mM PMSF].  Following vortexing, the resuspended pellet was incubated on ice for 
1hr.  After a 3 minute spin at top speed, the supernatant was aliquoted into 10uL 
aliquots and stored at -800C until needed.  
EMSAs were performed as described previously (95).  Briefly, to generate the DR4 
response element the following oligos were annealed, Forward: 5’-GGG TCG ACC TAG 
GCA GGT CAT TTC AGG ACA GCC CAG CG-3’ and Reverse: 5’-GGG TCG ACG CTG 
GGC TGT CCT GAA ATG ACC TGC CTA GG-3’.  The sequence for Xenopus DR4 used 
here was first reported by Safi et al to be responsive in axolotl (108) and in the 
sequence shown here the SalI site was added.  The annealed oligos have 5’ overhangs.  
The overhangs were radioactively labeled with [α-32P]-dCTP using a standard Klenow 
fill-in reaction (138).  The radioactive response element was purified by centrifugation 
through a microspin G-25 column (Amersham).  The radiolabeled response element 
was incubated in binding buffer [for 1X binding buffer: 5% glycerol, 1mM MgCl2, 
0.5mM EDTA, 0.5mM DTT, 50mM NaCl, 10mM Tris pH 7.5, 0.25mg/mL poly (dIdC)-
poly (dIdC)] with recombinant aTRα, aTRβ, hRXRα, aNPDC, aNPDC∆PEST or 
aNPDC∆HLH in the presence of 1µM T3 as indicated.  The response element/protein 
complexes were separated by electrophoresis on 5% non-denaturing polyacrylamide 
gels.  The gels were dried and the results visualized by autoradiography on X-ray film. 
 
Mammalian Transcription Assays 
Cos7 cells were transiently transfected by the method of Calcium Phosphate as 
previously described (140).  Briefly, 20µg total DNA (5µg TRE-tk-luc, 1µg pcDNA, 2µg 
pcDNA-aNPDC, 1µg pcDNA-aTRα or 1µg pcDNA-aTRβ, 5 µg rsv-βgal and 7µg pUC) were 
dissolved in 420ul of water and combined with 60µl 2M CaCl2 and vortexed briefly.  
The DNA-CaCl2 mixture was added dropwise, with light vortexing, to 500µl 2X HBS 
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[10g/L Hepes, 16g/L NaCl pH 6.95] that was mixed with 10ul 100X Phosphate [70mM 
Na2HPO4, 70mM NaH2PO4] and incubated at room temperature for 30 minutes.  After 
the 30 minute incubation the DNA precipitate was mixed by pipetting up and down 
and then the mixture was added to the 10cm plates dropwise.  After 6h incubation at 
37 degrees, the media was removed and the cells were washed with 1XPBS 3 times.  
After trypsinizing, the cells were resuspended in 10mL DMEM containing 10% CAFBS 
(charcoal absorbed fetal calf serum) and 20ul cells/well were plated into a 96 well 
plate with and without 1µM T3.  Cells were assayed in 6 wells per treatment.  The cells 
were incubated for 24h in the presence of thyroid hormone (T3), and then luciferase 
and normalizing β-gal activities were determined as previously described (139).  The 
highest and lowest values for each treatment were dropped.  Activity was expressed as 
the average of luciferase response normalized to the average β-gal response/minute.  
The data presented here is an average of at least four independent experiments. 
 
Nucleic Acid isolation 
Axolotl tissues were a generous gift from Dr. Voss’ lab.  Tissues were snap frozen in 
liquid nitrogen and kept at -800C until needed.  Frozen tissue was ground to a powder 
in liquid nitrogen using mortar and pestle.  The powderized tissue was then 
transferred to a Dounce homogenizer containing 1mL TRIzol reagent (Sigma).  RNA 
was obtained following the manufacturers protocol.  In short, tissue was homogenized 
and allowed to stand for 5 minutes at RT.  Then 0.2mL chloroform was added per 1mL 
of TRIzol reagent and after shaking the sample was allowed to stand at RT for 5 
minutes and then centrifuged at 12,000g for 15 minutes at 40C.  The aqueous phase 
was then transferred to a new tube and the RNA was precipitated with 0.5mL 
isopropanol per 1mL TRIzol reagent.  The RNA pellet was rinsed with 75% ethanol, air-
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dried and resuspended in autoclaved distilled water.  The O.D260 was measured using 
a spectrophotometer and the concentration determined using the formula: 
O.D260*dilution factor*40=mg/mL. 
 
RNAse Protection Assays 
RNAse protection assays were performed as previously described (184).  The RPA 
probe plasmids, generated as described above, were linearized with EcoRI and purified 
from agarose gels using DEAE paper purification.  Briefly, the band to be purified was 
run onto DEAE-cellulose paper which was previously soaked in 2.5M NaCl, washed 
with DI water and stored at 40C in 1mM EDTA.  The DEAE paper with DNA was then 
placed in a 1.5mL tube and washed with water to eliminate possible agarose and other 
contaminants.  After all water was removed, the paper is saturated with elution buffer 
[0.01M Tris pH 7.5, 1.5M NaCl, 0.001M EDTA].  The elution buffer was separated from 
the DEAE paper following vigorous vortexing (2-5minutes) and a centrifugation for 2-5 
minutes.  The solution was transferred to a 1.0 mL syringe and passed through a 
column (Promega) to eliminate contamination from the paper.  To the eluate, an equal 
volume of isopropanol was added and the DNA was precipitated at -200C for at least 
30 minutes.   
The linearized plasmids were used with the Promega riboprobe kit to synthesize a 
labeled cDNA probe using T7 RNA polymerase and [32P] UTP.  Following measurement 
of the cpm, the probe was adjusted to 500cpm x #UTP in probe sequence, and 
incubated overnight with RNA sample (10µg/reaction) and allowed to form complexes.  
The next day, the RNA/probe complexes were subjected to RNase digestion, 
precipitated and separated on a 5% sequencing gel.  Gels were analyzed by 
autoradiography. 
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Bradford Assay 
Proteins were diluted 1:200 in 1X Bradford reagent (Advance) and the OD595 was 
measured using a BioRad microplate reader.  The OD reading of each protein was 
adjusted to a blank and the concentration of each protein was calculated based on the 
dilution factor and the manufacturers’ instructions. 
Copyright © Maria Theodosiou 2006 
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Chapter 14: Results 
 
Developing axolotl thyroid receptor plasmid tools for analyzing receptor-mediated gene 
expression events 
Amphibian metamorphosis results in extensive organogenesis and tissue 
remodeling, each involving coordinated processes of cell proliferation, differentiation 
and death (159).  TH, as a controller of metamorphosis, initiates the many gene 
expression events required for morphogenesis through its ability to bind and activate a 
pair of nuclear receptor transcription factors.  It has been observed in higher 
vertebrates that the expression and activation of these thyroid hormone receptors are 
also under complex biochemical regulatory mechanisms including; the physical 
expression of the receptors, the DNA binding of the receptors, the ligand binding of the 
receptors and the ability of the receptors to interact with a variety of coregulatory 
proteins.  Our preliminary studies with the nuclear receptor coregulatory protein 
NPDC-1 suggest it may play a central role in coordinating nuclear receptor-mediated 
gene expression during embryogenesis in axolotls.  We therefore hypothesized that 
NPDC-1 might also be serving a similar function with respect to thyroid receptor-
mediated events during morphogenesis.  To preliminarily investigate this hypothesis 
we developed a set of axolotl thyroid receptor (aTRα and aTRβ) recombinant DNA tools. 
For the identification of the axolotl TR homologs, it was fortunate that they had been 
previously identified and partially characterized by Safi et al in 2004 (108).  Using the 
published sequence, the axolotl homologs were cloned by PCR into the pGEM-Easy T 
vector using axolotl brain cDNA as template.  Integrity of the constructs was confirmed 
by sequencing using vector specific primers.  PCR primers were designed also to clone 
aTRα and aTRβ into the mammalian expression vector pcDNA 3.1/Zeo and the 
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bacterial expression vector pGEX-KG.  Sequence comparison of the cloned aTRα and 
aTRβ revealed them to be identical to the previously published sequence (108), and, as 
defined by these investigators, to have strong sequence identities with the human and 
rat TR sequences.  With the availability of the axolotl homologs for TRα, TRβ and 
NPDC-1, it was possible to investigate aNPDC-1’s ability to regulate gene expression 
events mediated by thyroid receptors in axolotl. 
 
Tissue distribution of aTRα and aTRβ in axolotl 
 To characterize the tissue distribution of the aTRα, aTRβ and aNPDC-1, an 
RNAse protection assay was performed as previously described (184).  Axolotl tissues 
(a generous gift from Dr. Voss’ lab) were harvested and snap frozen in liquid nitrogen 
and kept at -800C.  Frozen tissue was ground and total RNA was isolated using TRIzol 
reagent (Sigma).  Total RNA was allowed to hybridize with 32-P-labeled complementary 
RNAs (cRNAs) of unique fragments for aTRα, aTRβ, aNPDC-1 and axolotl ribosomal 
protein L13A (aRPL13A).  Single-stranded RNA was digested away with RNAse, 
hybridized fragments were separated on denaturing urea-polyacrylamide sequencing 
gels, and gels were analyzed by autoradiography. As observed in Figure 35, all three 
axolotl proteins (aTRα, aTRβ, and aNPDC-1) are highly expressed in brain and gill, 
whereas lung is the only tissue tested that expressed all three proteins lowly.  The 
axolotl homolog of NPDC-1 was not detected in the spleen, and the liver had an 
intermediate level of expression.  On the other hand, aTRβ was poorly expressed in 
both liver and spleen in addition to lung, and aTRα was lowly expressed in liver and 
intermediately expressed in spleen.  A possible explanation for the low levels of protein 
expression in the lung is that the animals used to obtain the tissues were juvenile and  
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Figure 35: Tissue distribution of aTRα, aTRβ and aNPDC-1 in axolotl 
tissues.  Tissues from adult axolotl were harvested and snap frozen.  
Frozen tissue was ground to powder under liquid Nitrogen.  RNA was 
extracted using TRIzol reagent and the RNA was allowed to hybridise with 
32P-labelled complimentary RNAs (cRNAs) of unique fragments of aTRα, 
aTRβ, aNPDC-1 and aRPL13A (ribosomal protein L13A).  Single straned 
RNA was digested away with RNAse and hybridized fragments were 
separated on denaturing urea-polyacrylamide sequencing gels.  Gels were 
analysed by autoradiography. 
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therefore the lung was not fully developed.  A different pattern of expression may be 
expected in metamorphosed axolotl. 
A complimentary experiment to examine the tissue distribution of TRα and TRβ 
in axolotl tissue was performed by RT-PCR.  Axolotl tissue cDNA was used in a PCR 
assay to examine tissue distribution.  As shown in Figure 36, aTRα was observed to be 
expressed at high levels in the heart, and at lower levels in all other tissues examined, 
namely, brain, eye, spleen, skin, gill, spinal cord, lung, liver and muscle.  The tissue 
distribution of aTRβ was examined and is shown in Figure 37.  As shown in Figure 37, 
aTRβ was expressed highly in heart, eye, skin, gill, brain and spinal cord and at lower 
levels in spleen, lung, liver and muscle.   
 
Developmental expression of aTRα and aTRβ 
 A wealth of information exists on the pattern of TRα and TRβ expression during 
amphibian metamorphosis.  However, the embryonic developmental pattern of TRs in 
axolotl has not been previously reported.  Using cDNA from different stages of axolotl 
embryonic development, PCR analysis was performed to determine the pattern of 
expression of aTRα and aTRβ.  As shown in figure 38, aTRα is expressed in late 
embryogenesis at stage 27, and its levels drop in later stages and remain fairly 
constant at hatching and larva stage.  In figure 39, the expression pattern of aTRβ in 
embryogenesis is shown.  The levels of aTRβ appear to peak at stage 36 and drop 
gradually until hatching and remain constant at the larval stage 2 months post-
hatching.  At all stages though, aTRβ levels of expression are lower than aTRα levels, 
consistent with previously published results for other amphibians before 
metamorphosis. 
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Figure 36: aTRα tissue Expression in axolotl.  A. Semi-quantitative RT-
PCR to examine tissue distribution of aTRα in axolotl tissues.  mRNA from 
the listed tissues was isolated, reverse transcribed into cDNA and analysed 
by PCR using aTRα specific primers (aTRα).  As a control, RT-PCR analysis of 
axolotl elongation factor 1α (EF-1α) was assayed using the same cDNAs.  
PCR products were run on 1.2% agarose gels and analysed on a Kodak Gel 
logic gel imaging system.  B. Using Gel Logic software (Kodak), the relative 
intensity of the aTRα specific PCR bands from A were normalized to the EF-
1α bands for the various tissues. 
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Figure 37: aTRβ tissue Expression in axolotl.  A. Semi-quantitative RT-
PCR to examine tissue distribution of aTRβ in axolotl tissues.  mRNA from 
the listed tissues was isolated, reverse transcribed into cDNA and analysed 
by PCR using aTRβ specific primers (aTRβ).  As a control, RT-PCR analysis 
of axolotl elongation factor 1α (EF-1α) was assayed using the same cDNAs.  
PCR products were run on 1.2% agarose gels and analysed on a Kodak Gel 
logic gel imaging system.  B. Using Gel Logic software (Kodak), the relative 
intensity of the aTRα specific PCR bands from A were normalized to the EF-
1α bands for the various tissues. 
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Figure 38: Developmental Expression of aTRα. A.  Semi-quantitative RT-
PCR to examine the expression of aTRα during embryogenesis in axolotl.  
mRNA from the listed embryo stages was isolated, reverse transcribed into 
cDNA and analyzed by PCR using aTRα specific primers (aTRα).  As a 
control, RT-PCR analysis of axolotl elongation factor 1α (EF-1α) was 
assayed using the same cDNAs.  PCR products were run on 1.2% agarose 
gels and analyzed on a Kodak Gel logic gel imaging system. B.  Using Gel 
Logic software (Kodak), the relative intensity of the aTRα specific PCR 
bands from A were normalized to the EF-1α bands for the various embryo 
stages. 
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 Figure 39: Developmental Expression of aTRβ. A.  Semi-quantitative 
RT-PCR to examine the expression of aTRβ during embryogenesis in 
axolotl.  mRNA from the listed embryo stages was isolated, reverse 
transcribed into cDNA and analyzed by PCR using aTRβ specific primers 
(aTRβ).  As a control, RT-PCR analysis of axolotl elongation factor 1α 
(EF-1α) was assayed using the same cDNAs.  PCR products were run on 
1.2% agarose gels and analyzed on a Kodak Gel logic gel imaging 
system. B.  Using Gel Logic software (Kodak), the relative intensity of 
the aTRα specific PCR bands from A were normalized to the EF-1α 
bands for the various embryo stages. 
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Expression of aTRα, aTRβ and aNPDC-1 during metamorphosis 
 To compare the pattern of expression of the axolotl TRs with that of aNPDC-1 
during metamorphosis, tissues (a generous gift from Dr. Voss’ lab) were obtained from 
juvenile axolotls treated with 150nM T4 for up to 28 days. Total RNA was isolated from 
the tissues and analyzed by RNAse protection assay for expression of aNPDC-1, aTRα, 
and aTRβ (Figure 40).  Single-stranded RNA was digested away with RNAse, hybridized 
fragments were separated on denaturing urea-polyacrylamide sequencing gels and gels 
were analyzed by autoradiography. Overall, the levels of aNPDC-1 mRNA appear to 
decrease with T4 treatment in gill, skin and liver and increase with T4 treatment in 
lung.  The levels of aTRβ mRNA were observed to decrease with T4 treatment in skin 
and increase with T4 treatment in gill.  In lung and brain, the levels of aTRβ mRNA 
appear to peak at day 8 following T4 treatment and decrease at days 14 and 28.  The 
levels of aTRα mRNA, generally expressed at lower levels than aTRβ and aNPDC-1 
mRNA, were observed to decrease with T4 treatment in skin, appear unchanged in 
liver and gill, increase with T4 treatment in lung, and in brain appear to peak at day 8 
and decrease after that.  No clear pattern in expression emerges from this, although it 
must be noted that RNA levels do not always translate to protein levels.  The changes 
observed here may not accurately correlate with changes in the protein levels for these 
mRNAs, because it is fairly well established that during metamorphosis TRβ levels 
increase (161), and that NPDC-1 can be post-translationally regulated through 
targeted protein degradation (99).  In spite of these shortcomings, these data clearly 
demonstrate that TH can modulate the mRNA levels for these putative regulators of 
axolotl metamorphosis. 
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Figure 40: Expression of aTRα, aTRβ and aNPDC-1 during 
metamorphosis.  Tissues from axolotl treated with 150nM T4 for up to 28 
days were harvested at day 0, 8, 14 and 28 and snap frozen.  Frozen tissue 
was ground to powder under liquid Nitrogen.  RNA was extracted using 
TRIzol reagent and the RNA was allowed to hybridise with 32P-labelled 
complimentary RNAs (cRNAs) of unique fragments of aTRα, aTRβ, aNPDC-1 
and aRPL13A (ribosomal protein L13A).  Single stranded RNA was digested 
away with RNAse and hybridized fragments were separated on denaturing 
urea-polyacrylamide sequencing gels.  Gels were analysed by 
autoradiography. 
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Localization of the domain of interaction between aNPDC-1 and aTRs  
Higher vertebrate NPDC-1 has been previously shown to directly bind retinoic 
acid nuclear receptors and this binding appears to directly impact gene expression 
events mediated by these receptors (95).  In previous chapters of this dissertation I 
demonstrate that this is also the case with the axolotl RARγ. To investigate this same 
possibility for the thyroid receptor family members, recombinant protein pulldown 
experiments were performed.  The first question investigated was whether axolotl 
NPDC-1 and axolotl TRs could interact.  To address this question, we generated 
recombinant axolotl TR proteins that were tagged with GST at their amino terminus 
(Figure 41A).  For each pull-down reaction, 10µg GST-aTRα or GST-aTRβ were bound 
to glutathione sepharose beads and allowed to interact with equimolar amounts of 
thioredoxin or thioredoxin-tagged aNPDC-1 proteins (figure 41C).  Bead bound 
proteins were resolved by SDS-PAGE and immunoblotted.  Blots were probed with an 
anti-Thio-probe polyclonal antibody (Santa Cruz).  As shown in figure 41B, both full 
length aNPDC-1 and aNPDC-1 with its PEST domain deleted were able to complex with 
aTRα and aTRβ, but the aNPDC-1 protein with its helix-loop-helix domain deleted was 
not.  These data suggest that the domain of interaction between aTRs and aNPDC-1 is 
at the amino terminus within amino acids 1-97, and are consistent with what was 
observed for binding of aNPDC-1 and aRARγ.   
 
aNPDC-1 binding  of  aTRβ in cellular lysates 
To further validate the above in vitro findings for aTR recombinant proteins, 
aNPDC-1 was examined for its ability to selectively bind aTRβ from cellular lysates. 
HEK293 cells were transfected with the expression vector pTriex or pTriex-aTRβ.  The 
transfected cells were harvested 48h later, lysed in APB buffer in the presence of  
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Figure 41:  Direct in vitro interaction between aTRα, aTRβ and aNPDC-
1.  In panel A, recombinant glutathione-tagged axolotl TR protein is shown.  
10µg of purified recombinant protein was resolved on a 10% SDS-PAGE gel 
and stained with Coomassie Blue.  In panel B, 10µg of GST-TRα or 10µg of 
aTRβ were bound to glutathione beads and allowed to react with equimolar 
amounts of thioredoxin (Trx), aNPDC-1, aNPDC∆PEST and aNPDC∆HLH.  
Bead bound proteins were resolved on a 10% SDS-PAGE gel, and 
immunoblottled on nitrocellulose membranes.  The membranes were then 
blotted with antisera for Thio probe.  In panel C, equimolar amounts of 
thioredoxin and thioredoxin-tagged proteins were bound to S-protein beads 
and resolved on a 10% SDS-PAGE gel and immunoblotted for thioredoxin 
using anti-thioredoxin antisera. 
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nuclease and protease inhibitors and used in pulldown experiments.  For the purposes 
of this experiment, full-length aNPDC-1 was cross-linked to cyanogen bromide 
activated sepharose beads.  To bead-bound aNPDC-1, 1mg of extract was added and 
following incubation at 40C with rotation, the beads were washed with APB as 
described in materials and methods.  The bead-bound proteins were resolved by SDS-
PAGE and immunoblotted.  The blots were probed with an anti-thio antibody (Santa 
Cruz).  As observed in Figure 42 (top), aNPDC-1 is able to specifically complex with the 
aTRβ from the HEK293 lysates, whereas vector alone is not.  Figure 42 (bottom), 
represents an equivalent amount of the two HEK lysates (from pTriex and pTriex-
aTRβ cells) run in separate lanes and probed for cytoplasmic thiolase.  These studies 
demonstrate that aNPDC-1 can specifically pull-down aTRβ from cellular lysates, 
suggesting that the interactions between aNPDC-1 and aTRβ are highly specific and 
most probably biologically relevant.  
 
Analysis of the impact aNPDC-1 has on aTR DNA binding 
 My previous studies with aRARγ suggested that aNPDC-1 could directly impact 
aRARγ DNA binding. This potential was also investigated with respect to aTR DNA 
binding.  The group that first identified and cloned the axolotl homologs for TRα and 
TRβ identified a Xenopus DR4 (xDR4) response element that could be bound 
specifically by axolotl TRs (108).  The axolotl TRs were shown to bind to xDR4 only as 
TR-RXR heterodimers and the specificity of the binding was demonstrated by 
competition with cold and non-specific oligonucleotides (108). Due to the lack of any 
available cloned axolotl RXR, for experiments in this study I was relegated to using 
recombinant human RXRα. Although the sequence of axolotl RXRα is not known, it 
can be reasonably deduced that both the protein sequence and structure between  
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Figure 42:  In vivo interaction between aTRβ and aNPDC-1.  HEK293 cells 
were transfected with either pTriex or pTriex-aTRβ and the lysate was used 
in pulldown experiments.  Full-length aNPDC-1, crosslinked to cyanogen 
bromide activated sepharose beads, was incubated with 1mg of cell extract.  
The bead-bound proteins were resolved by SDS-PAGE and immunoblotted 
onto nitrocellulose membrane and blotted with an anti-thioredoxin antibody.  
As observed in panel A, aNPDC-1 is able to specifically complex with aTRβ.  
Panel B, represents an equivalent amount of the 2 HEK lysates run in 
separate lanes and probed for cytoplasmic thiolase to demonstrate equal 
loading.  
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higher (such as human and rat) and lower vertebrates (such as Xenopus and axolotl) is 
highly conserved. This assumption is supported by the recent publication in which 
antisera developed to the human RXR isoforms were observed to specifically detect 
RXR protein isolated from the testis of the marbled newt T. marmoratus marmoratus 
(158).  
In Figures 43 and 44, annealed oligonucleotides for Xenopus DR4 (108) were 
radiolabeled with 32P using a Klenow fill-in reaction.  The radiolabeled xDR4 was then 
allowed to complex with aTRα (43), aTRβ (44), hRXRα (43 and 44) and/or aNPDC-1 (43 
and 44) recombinant proteins.  The DNA/protein complexes were resolved on non-
denaturing polyacrylamide gels and visualized by autoradiography. As shown in Figure 
43, aTRα, while not able to complex with DNA effectively on its own (lane 2), forms a 
strong heterodimer complex with hRXRα (lane 3), which is competed effectively by the 
addition of excess cold xDR4 oligonucleotide (lane 4).  Addition of recombinant 
aNPDC-1 (lane 5) results in the formation of a stronger upper complex than the one 
observed for TR/RXR alone.  The recombinant aNPDC-1 mutants, aNPDC-1∆PEST 
(lane 6) and aNPDC-1∆HLH (lane 7), conversely do not appear to be able to impact 
aTRα/hRXRα heterodimer DNA binding. 
 In figure 44, the ability of aTRβ to complex with DNA was examined.  Similar to 
the observations made for aTRα, aTRβ is not able to complex with DNA alone (lane 2), 
but is able to complex with DNA when heterodimerized with RXRα (lane 3).  The 
complex can be competed away with cold oligonucleotide (lane 4).  Also similar to the 
aTRα observations, addition of recombinant aNPDC-1 results in a stronger complex, 
but the mobility of this complex is not altered.  The aNPDC-1 deletion mutants, 
aNPDC-1∆PEST (lane 6) and aNPDC-1∆HLH (lane 7), do not appear to impact the 
aTRβ/hRXRα heterodimer DNA binding.  A similar effect to that observed with pure  
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Figure 43: Electromobility Shift Assay with axolotl NPDC-1 and aTRα.  
An oligonucleotide corresponding to xDR4 was radiolabelled with 32P-dCTP 
with Klenow enzyme.  The resultant DNA binding probe was incubated with 
recombinant hRXRα, aTRα, aNPDC-1, aNPDC∆PEST and aNPDC∆HLH.  
Unlebelled (cold) oligo was used to show specificity of binding.  DNA:protein 
complexes were resolved on non-denaturing PAGE gels which were 
subsequently exposed to Kodak Xar-5 film. 
 
*This is an accurate representation of an experiment performed at least three 
times. 
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Figure 44: Electromobility Shift Assay with axolotl NPDC-1 and aTRβ.  
An oligonucleotide corresponding to xDR4 was radiolabelled with 32P-dCTP 
with Klenow enzyme.  The resultant DNA binding probe was incubated with 
recombinant hRXRα, aTRβ, aNPDC-1, aNPDC∆PEST and aNPDC∆HLH or 
nuclear extract from either Cos7 cells or axolotl skin.  Unlabelled (cold) oligo 
was used to show specificity of binding.  DNA:protein complexes were 
resolved on non-denaturing PAGE gels which were subsequently exposed to 
Kodak Xar-5 film. 
 
*This is an accurate representation of an experiment performed at least three 
times. 
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recombinant protein are observed in the presence of Cos7 nuclear extracts 
supplemented with recombinant protein.  When aTRβ and hRXRα are added to Cos7 
nuclear extracts (lane 8), no difference is observed compared to recombinant protein 
alone (lane 2).  However, addition of aNPDC-1 (lane 9) results in a stronger upper 
complex than that of recombinant proteins alone.  This observation is in agreement 
with recombinant protein data and with observations made for other response 
elements, such as the RARE (95).   
I also examined axolotl skin nuclear extract for its ability to form shift 
complexes with the labeled xDR4 element in the absence of supplemented 
recombinant proteins (Figure 44, lane 10).  Addition of lysates forms what appears to 
be a single shift complex, and cold oligonucleotide is able to compete this band away 
(lane 11).  Interestingly, addition of aNPDC-1 recombinant protein results in a single 
more intense complex with altered mobility from that observed with extract alone (lane 
12).  Therefore, similar to the study with recombinant proteins, complex formation is 
enhanced by the addition of aNPDC-1, but unique to this study is the increased 
mobility of the complex and the increase size of the complex relative to that seen with 
recombinant proteins.  These data suggest that the composition of axolotl DR4 binding 
complexes found in skin nuclear extracts vary substantially from that of recombinant 
TR/RXR proteins, and that aNPDC-1 impacts these complexes in a different manner. 
The ramifications of heterogeneity in axolotl skin nuclear extracts as well as the caveat 
of alternative TR/RXRs make it difficult to predict what is happening here, although if 
one hypothesizes that this DR4 is binding axolotl TR/RXR heterodimers in these skin 
extracts, then aNPDC-1 drastically changes the recruitment of proteins to this 
complex.  Further investigation into the mechanisms of aNPDC-1 impact on nuclear 
receptor DNA binding is necessary to establish the potential for tissue-specific  
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TR/RXR/DR4 binding complexes in axolotl. 
 
Preliminary analysis of the impact aNPDC-1 has on aTR gene expression events 
In an attempt to assign a functional significance to the observed direct binding of 
aNPDC-1 to TRs and the alteration of aTR DNA binding by aNPDC-1, the impact of 
aNPDC-1 on aTR-mediated transcription was investigated.  To study the 
transcriptional impact of aNPDC-1 on aTR, calcium phosphate technologies were used 
to co-transfect Cos7 cells with mammalian expression constructs for aNPDC-1, aTRα 
or aTRβ, a β-galactosidase expression plasmid, and a TRE-tk-luc reporter plasmid. 
Following transfection, the cells were stimulated for 24h with 1µM T3.  After 24h the 
cells were lysed and assayed for luciferase and β-galactosidase activity.  In Figure 45, 
the standardized luciferase values normalized to β-galactosidase are shown.  In 
contrast to previous observations for other nuclear receptor family members, aNPDC-1 
appeared to stimulate transcription mediated by both aTRα and aTRβ.  This 
observation may be significant in further dissecting NPDC-1 signaling and determining 
a biological function/significance for this protein.  NPDC-1 and thyroid receptors 
would appear to overlap in function through their shared roles in regulation of 
proliferation and differentiation, and these data suggest that this overlap is more than 
coincidental. Cumulatively these data suggest that aNPDC-1 may play a role in 
amphibian metamorphosis through its ability modulate transcription events mediated 
by thyroid hormone signaling pathways. 
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Figure 45: Impact of aNPDC-1 on aTR-mediated transcription.  Cos7 cells 
were transiently transfected using calcium phosphate precipitation methods 
with mammalian expression plasmids for aNPDC-1, aTRα, aTRβ, TRE-tk-luc, 
β-galactosidase and treated with 1µM T3.  Cells were lysed and assayed for 
luciferase and β-galactosidase activity.  Luciferase data was normalized to β-
galactosidase and data was reported as a % of the constitutive activation of 
the reporter plasmid (TRE). 
 
* This result presents the average from experiments repeated at least four 
times. 
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Chapter 15: Discussion 
 
 The emphasis of my dissertation research was to investigate axolotl as a model 
system for studying the role of NPDC-1 in cellular and organismal differentiation 
events.  Axolotl would appear to be an ideal system for doing this in that its life cycle 
transitions through 2 major differentiation events (embryogenesis and morphogenesis), 
these transition events can be readily reproduced in laboratory environments, and 
axolotls express a conserved homolog of NPDC-1. In the results from Chapter 14 I 
present strong circumstantial evidence that axolotl NPDC-1 can modulate the 
activities of the axolotl intracellular receptors for thyroid hormone.  Amphibian 
metamorphosis is a developmental process governed by thyroid hormones.  Prior to 
metamorphosis, the circulating levels of thyroid hormones are minimal (160) and 
increase slowly (161) peaking at metamorphosis (108), largely due to increased TSH 
levels (161).  In nature, the importance and extent of metamorphosis across 
amphibian species varies (108) and alternative mechanisms such as neoteny and 
direct development can be found (108).  The axolotl Ambystoma Mexicanum is a 
facultative neotenic species and is sexually mature as a larva, but the reason for this 
phenotype is not clear and seem dependent on environmental conditions (161).  In the 
laboratory setting, most Ambystoma species undergo metamorphosis when treated 
with TH (108).  The replacement of larval with adult tissues that occurs during 
metamorphosis results in organogenesis and tissue remodeling (159).  Each of these 
processes involves a coordinated process of cell proliferation, differentiation and death 
(159).  These functions of TH, echo similar functions by the NPDC-1 protein, which 
has been identified as a neuronal protein involved in cellular proliferation and 
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differentiation (89) and is described in previous chapters of this dissertation.  Both 
proteins have also been shown to be expressed in CNS development (91, 170). 
To investigate the impact of aNPDC-1 had on axolotl thyroid hormone signaling 
it was necessary that I first clone the axolotl homologs for the intracellular receptors 
for thyroid hormone.  Conveniently the axolotl homologs for TRα and TRβ had recently 
been cloned and partially characterized, and the receptors we identified proved to be 
identical to those previously described receptors.  While the presence of thyroid 
receptors in axolotl has been suspected for a while, it was not fully established until 
recently when Safi et al cloned the axolotl thyroid receptors and shown them to be 
functional (108).  Axolotl TRs were shown to have strong homology to other known 
TRα and TRβ sequences, with the DBD and LBD being the most conserved.  The 
sequence conservation between human and axolotl TR DBDs was observed to be 98% 
for aTRα and 92.5% for aTRβ.  An overall sequence comparison between human, rat 
and axolotl TRα showed a consensus conservation of 83% and identity conservation of 
66.5%, whereas axolotl TRβ does not appear to be as well conserved with consensus 
conservation of 68.4% and identity conservation of 49%.  The sequence comparison for 
aTRβ is a little bit deceptive as most of the sequence deviation between human and 
axolotl TRβ occurs in the A/B domain due to the considerably larger size of hTRβ 
(108).  Comparison of the sequence of axolotl TRα with axolotl TRβ shows that the 
protein is conserved between the two isoforms for the most part, with consensus 
conservation at 83% and identity conservation at 76.3%, deviating mostly at the amino 
terminus due to size differences between the two isoforms.  The human isoforms are 
similarly conserved with consensus at 77.6% and identity at 76.6%, with the carboxyl 
terminus not being conserved between the two isoforms.  
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The tissue distribution of thyroid receptors is as varied in axolotl as it is in 
mammals.  In mammals, TRα is expressed in brain, kidney and heart among other 
tissues (185, 186), and TRβ is expressed in most tissues (32, 187). In studies 
presented here, using RNAse protection and PCR technologies, I demonstrate that in 
axolotl, TRα mRNA is expressed in heart, and in lower levels in brain, eye gill, spleen, 
spinal cord, lung, liver, muscle and skin, whereas TRβ mRNA is expressed in high 
levels in heart, brain, eye, skin, gill and spinal cord and at lower levels in spleen, lung, 
liver and muscle.  Due to the absence of an antibody that could recognize the axolotl 
form of TRs, it was not possible to examine TR expression at the protein level. 
The expression of TR mRNA has been extensively studied in metamorphosis in 
amphibians.  In the closely related species to axolotl, Xenopus, TRα mRNA levels 
appear to fluctuate from tissue to tissue within the tadpole during metamorphosis, but 
are always higher than TRβ mRNA levels, which appear to fluctuate mostly in the head 
portion and appear at a higher level in the tail at metamorphotic climax (181, 188-
190).  Data presented in this dissertation demonstrate that, in axolotl tissues, the level 
of expression of TRα mRNA appears to be lower than TRβ mRNA, and tissue-specific 
fluctuations were observed for both the TRα and TRβ mRNA expression.  Tissue-
specific correlations between Xenopus and axolotl TR mRNA expression during 
metamorphosis cannot be made, as the studies in Xenopus were performed with 
portions of tadpoles and not isolated tissues (181).  However, if brain in axolotl is used 
to compare with the head portion of Xenopus, and axolotl liver with the middle portion, 
a comparison can be made. Brain TRα mRNA levels in axolotl showed temporal 
expression and were at lower levels than TRβ, whereas in Xenopus, head TRα mRNA 
was present at much higher levels than TRβ mRNA and remained unchanged during 
metamorphosis.  In axolotl liver, both TRα and TRβ mRNA was virtually undetectable 
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whereas in Xenopus both TRα and TRβ mRNA displayed temporal expression.  There 
are differences between these two amphibians and their TR expression, and this could 
simply be due to differences in their life cycle.  Whereas Xenopus will undergo 
metamorphosis as part of its normal life cycle, axolotl is a neotenic amphibian and is 
sexually mature as a larva, and will not undergo metamorphosis unless exposed to 
exogenous TH.  
Most coregulatory proteins mediate their regulation of transcription through 
modulation of the protein complexes that associate with specific DNA regulatory 
sequences in the promoters of genes they regulate (18).  In the studies presented here, 
I demonstrate that the mechanism for aNPDC-1 regulation of aTR-mediated 
transcription appears complex and may involve both direct associations with aTR as 
well as facilitating complex formation on TR response elements.  As observed 
previously for retinoid receptors [(95) and other sections of this dissertation], the 
presence of aNPDC-1 increased the intensity of the TR-RXR heterodimer complex 
binding to DNA, whereas the aNPDC-1 deletion mutants are not able to alter TR-RXR 
complex binding to DNA.  The ability of aNPDC-1 to increase the intensity of TR-RXR 
complex binding to DNA was observed for both recombinant proteins and in the 
presence of Cos7 nuclear extract.  Interestingly, when axolotl skin nuclear extract was 
used, addition of aNPDC-1 results in a mobility shift of the complex on xDR4.  It 
appears that the effects of aNPDC-1 on DNA binding are variable depending on the 
origin of the protein (recombinant, cell or tissue).  The mechanism for aNPDC-1 effects 
on DNA binding is unclear. One possibility is that NPDC-1 facilitates complex 
formation on the response element, but its loose associations are lost in the 
subsequent electrophoretic procedures.  These observations with respect to aNPDC-1 
and aTR DNA binding parallel what was observed for aNPDC-1 and aRARγ DNA 
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binding, in that complex formation is stronger in the presence of aNPDC-1.  In 
contrast to what was seen with aRAR-aNPDC-1 binding, no unique TR-RXR-NPDC-1 
complex was formed with purified proteins.  Cumulatively these data demonstrate that 
aNPDC-1 alters the DNA binding capabilities of the TR-RXR heterodimer, although the 
mechanism for this is unknown.   
The potential functional consequences of aNPDC-1 binding of aTRs and its 
impact on aTR DNA binding appear to be a stimulation of aTR-mediated transcription 
events. Here, I show that aTRs are able to stimulate transcription off of a human 
thyroid receptor response element, and this observation is in agreement with what has 
been reported elsewhere for axolotl TRs (108). Unique to these dissertation studies are 
the demonstration that TR-based DR4-driven reporter gene transcription can be 
stimulated by overexpression of aNPDC-1 in an in vitro transcription analysis.  This 
observation is not only unique with respect to what has been reported for aNPDC-1 
effects on aTRs, but also unique with respect to what has been reported for NPDC-1 
effects on nuclear receptor-mediated transcription. All previous reports demonstrate 
NPDC-1 to be a repressor of retinoid receptor-mediated transcription (95), and studies 
in this dissertation demonstrate that aNPDC-1 can also repress axolotl RARγ-mediated 
transcription. Retinoid and thyroid receptors are both members of the same subfamily 
of nuclear receptors, are bound to DNA in the absence of ligand, and activate 
transcription as heterodimers.  It is therefore surprising, that NPDC-1 has opposing 
effects on these receptors.  These analyses were performed in the Cos7 mammalian 
cell line, expressing axolotl TR and NPDC-1 proteins.  It is difficult to predict if the 
axolotl proteins were correctly expressed and processed correctly in the mammalian 
cells.  Ideally, these studies would be repeated in an axolotl cell line, but due to the 
lack of established axolotl cell lines and transfection limitations, we were limited to the 
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Cos7 cell line.  A more reasonable explanation for these contrasting responses would 
be the specific recruitment of alternative coregulatory complexes by the binding of 
NPDC-1.  Thyroid and retinoid receptors have been shown to associate with a variety 
of coregulatory complexes (28-30, 84-87), and it can be hypothesized from the 
observations in this dissertation that, at least in the axolotl system, NPDC-1 functions 
as a molecular target for either co-repressor complexes in the case of retinoid 
receptors or co-activator complexes in the case of thyroid receptors.   Further studies 
will be required to establish the validity of this hypothesis. Cumulatively, these studies 
suggest aNPDC-1 can modulate gene expression events mediated by aTRs and that 
this ability could have direct implications in the regulation of metamorphosis in 
axolotls.  
In summary, this study presents the first evidence for interaction between 
NPDC-1 and TR in axolotl.  The axolotl is an interesting system that allows the study 
of development and differentiation, functions that are impacted by both TR and NPDC-
1.  It is the first report of NPDC-1 acting as an activator of transcription and may help 
shed some light into the biological function of NPDC-1 and its biochemical 
mechanism.  This study showed that axolotl TRs are able to activate transcription off a 
human DR4 element, and aNPDC-1 is able to bind to aTRs and stimulate 
transcription.  Future directions for these studies include the utilization of the axolotl 
as a model organism for the study of aTR and aNPDC-1 interactions in vivo and their 
impact on differentiation and morphogenesis.  Overall, these studies are the first step 
towards dissecting the impact of NPDC-1 on TR mediated signaling in development 
and differentiation. 
 
Copyright © Maria Theodosiou 2006 
 
- 171 - 
SECTION VI: PLACING EVERYTHING INTO CONTEXT 
 
The studies in this dissertation attempt to address the hypothesis that the 
nuclear receptor coregulatory protein NPDC-1, through its ability to modulate 
transcription events mediated by retinoid and thyroid families of nuclear receptors, 
can serve as a critical regulator of differentiation and development in the axolotl 
animal model system. Towards establishing the validity of this hypothesis I cloned 
and/or characterized axolotl homologs for; a) the nuclear receptor co-regulatory 
protein aNPDC-1, whose expression appears to be linked to the regulation of 
differentiation; b) a nuclear receptor critical for axolotl embryonic differentiation and 
development, aRARγ; and c) the nuclear receptors critical for axolotl morphogenesis, 
aTRα and aTRβ.  These homologs were shown to be structurally homologous to those 
found in higher vertebrates and to contain all of the functional domains identified in 
these higher vertebrate forms. 
 Examination of the tissue-specific expression and distribution of these axolotl 
homologs for NPDC-1, RARγ, TRα and TRβ suggested that these various regulators of 
differentiation and morphogenesis might be functionally related.  Axolotl NPDC-1 is 
expressed in brain, heart, eye, skin, gill, spinal cord, lung, liver and muscle whereas 
aRARγ is expressed in heart, eye, gill, skin and lung.  The TRs add another level of 
complexity to analyzing the associations between these three proteins.  Axolotl TRα 
was detected in heart, brain, eye, spleen, gill, spinal cord and lung whereas TRβ was 
found in all tissues aTRα was detected and in skin, liver and muscle.  Overall, all 
axolotl tissues examined with the exception of spleen were observed to express all four 
proteins, but some seem better suited for further studies by strongly expressing all 
four proteins, and these are heart, eye and skin.  Tissues expressing all four proteins 
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may be utilized in future experiments to study the impact of aNPDC-1 on RARγ and TR 
target genes during development.   
The developmental expression of these proteins also varies.  For example, 
aRARγ mRNA expression peaks early in development and then reduces at hatching 
and increases again at the larval stage while aNPDC-1 mRNA appears to peak slightly 
later in axolotl embryogenesis and maintain this level of expression through hatching 
and into larval development.  Levels of Thyroid receptors were examined after stage 27 
by which time aRARγ levels have decreased and aNPDC-1 levels are on the rise.  Levels 
of aTRβ mRNA are detectable at stage 27 and peak at stage 36 and gradually decrease 
until hatching and remain at constant levels 2 months post-hatching at the larva 
stage, whereas aTRα levels are detected at higher levels than aTRβ, are first detected 
at stage 27, are observed to decrease by stage 36 and remain at low levels until 
hatching and remain relatively constant post-hatching.  The developmental expression 
pattern of these mRNAs suggests that gene expression events regulated by RARγ occur 
early during embryogenesis and are down-regulated just prior to hatching when gene 
expression events regulated by NPDC-1 and TRs begin to peak. This, perhaps not 
coincidentally, also parallels the impact aNPDC-1 has on gene expression events 
mediated by aRARγ and the aTRs, wherein it was observed that aNPDC-1 repressed 
retinoic acid-mediated signaling events but facilitated thyroid hormone-mediated 
signaling events.  Further studies will be required to establish any direct links between 
NPDC-1, these signaling pathways and axolotl development. 
 Having established the possibility that these various regulators of differentiation 
and development overlap in both the tissues and the times of development they are 
expressed, I next examined whether there might be any direct linkage between these 
proteins.  Using pull-down and immunoprecipitation analyses I was able to 
- 173 - 
demonstrate that aNPDC-1 interacts directly with aRARγ, aTRα and aTRβ.  The 
interaction between these nuclear receptors and aNPDC-1 was localized to the amino 
terminus of aNPDC-1 between amino acids 1 and 97.  This region of the aNPDC-1 
protein houses a conserved LXXLL motif, a HLH domain and a coiled coil domain.  
Further studies are necessary to determine the exact domain where aNPDC-1 and 
nuclear receptors interact.  
Having established this potential for direct interactions between aNPDC-1 and 
these nuclear receptor mediators of differentiation and development, I then performed 
2 sets of experiments to investigate the possible functional consequences of these 
direct interactions between aNPDC-1 and the axolotl nuclear receptors.  The first of 
these was an analysis of the impact aNPDC-1 had on nuclear receptor DNA binding.  It 
was observed that aNPDC-1 modified DNA binding by both retinoid and thyroid 
receptors.  In agreement with previous studies, addition of aNPDC-1 recombinant 
protein resulted in stronger RAR-RXR DNA binding.  Contrary to previous observations 
for human NPDC-1 and RARs where no altered complex mobility was observed (95), 
addition of aNPDC-1 also resulted in a complex with altered mobility, consistent with 
the formation of a RAR-RXR-NPDC-1 complex.  With respect to aTRs aNPDC-1 
resulted in stronger TR-RXR complex without altering complex mobility.   
In a second set of experiments looking at function, I analyzed the impact 
aNPDC-1 had on transcription events mediated by the aTR and aRAR nuclear 
receptors. These studies revealed that the effects of aNPDC-1 on aRARγ and aTR 
mediated transcription was varied.  Previous studies have shown hNPDC-1 to be a 
strong repressor of RAR and RXR mediated transcription (95).  Axolotl NPDC-1 was 
also found to repress aRARγ-mediated transcription, but not as strongly as the human 
homologs.  With human proteins a 90% repression was observed for RAR and RXR, 
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whereas with axolotl proteins only 30% repression was detected.  This discrepancy 
may be due to a number of factors such as proper processing of axolotl proteins in 
mammalian cells and the different isotypes examined.  On the other hand, aNPDC-1 
was observed to stimulate axolotl thyroid receptor-mediated transcription for both TR 
homologs.  Transcription mediated by aTRβ was stimulated 200%, whereas 
transcription mediated by aTRα was stimulated 163%.  This observation is consistent 
with a proposed role for aNPDC-1 as a propagator of axolotl morphogenesis.   
 Therefore, the studies presented in this dissertation strongly implicate axolotl 
NPDC-1 in the regulation of gene expression events mediated by the axolotl retinoid 
and thyroid receptors.  As extensively discussed in the introduction and throughout 
this dissertation, these 2 families of nuclear receptors play critical roles in both higher 
and lower vertebrate embryogenesis and development.  The axolotl is an ideal animal 
model system for studying differentiation and development because its life cycle is 
conveniently segmented into embryogenesis, larval development, morphogenesis and 
adult development.  Furthermore, the axolotl species used in these studies is neotenic, 
meaning it does not spontaneously go through morphogenesis, but will go through 
normal morphogenesis upon stimulation with thyroid hormone. This provides the 
selective experimental advantage of accurately staging the morphogenesis events in a 
laboratory setting.  These reasons cumulatively were the impetus behind my research 
investigation into the potential utility of the axolotl for studying the molecular 
mechanism of NPDC-1.  Marrying my preliminary studies of characterizations of 
NPDC-1, RAR and TR expression and function, with what has previously been 
reported for both axolotl and other amphibian embryogenic and morphogenic events, I 
have developed a potential model for aNPDC-1’s role in these events (Figure 46).  This 
model hypothesizes that NPDC-1 may serve as a critical moderator of retinoid and 
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thyroid signaling pathways during embryogenesis and morphogenesis.  The 3 major 
molecular keys to this hypothesis are the data supporting NPDC-1 as a repressor of 
cellular proliferation events, data supporting NPDC-1 as a repressor of retinoid 
signaling events and data supporting NPDC-1 as a stimulator of thyroid hormone 
signaling events. Based upon the embryonic and developmental patterns of aNPDC-1 
expression, aRARγ expression and aTR expression, one can hypothesize that during 
early embryogenesis of axolotls when cellular proliferation and patterning occurs, 
aRARs would be highly expressed and aNPDC-1 expression would be suppressed.  
This is reflective of what others have shown for aRARγ mRNA expression (106) and 
what I show in this dissertation for aNPDC-1 expression.  At the molecular level, data 
presented in this dissertation coupled with our previously published (95) and 
unpublished data would suggest this expression pattern is more than coincidental, in 
that we are able to demonstrate that aNPDC-1 can directly bind and inhibit gene 
expression events mediated by aRARγ, and in unpublished studies looking at the 
human NPDC-1 gene promoter we have identified a highly specific RAR response 
element.  These data support the possibility that aRARs may be involved in some 
coordinate upregulation of aNPDC-1 expression and that upregulation of aNPDC-1 
may be involved in some coordinate down-regulation of aRAR-mediated events.  This is 
represented in the model posed in Figure 46 wherein it is seen that during 
embryogenesis (stages 1-43) of the axolotl aRARγ expression is shown to initiate early, 
peak and then decline as the embryo nears hatching (stage 43). On the other hand, 
data for aNPDC-1 expression would suggest it begins to take off slightly later in 
embryogenesis, peak around hatching and remain at a moderately high level of 
expression.   
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Figure 46: Proposed model of the role of aNPDC-1 in the signaling of 
aRARγ and aTRs.  aNPDC-1 may act as a moderator of embryogenesis and 
morphogenesis in axolotl. 
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The story for thyroid signaling is less clear primarily due to the limited data 
available, but combining what I have been able to demonstrate in this dissertation 
along with extrapolations from other published reports (181, 188-190) one might 
hypothesize that molecular signaling by thyroid hormone at onset of morphogenesis is 
strongly facilitated by the presence of NPDC-1.  This is depicted in Figure 40 where in 
axolotl lung, a tissue that undergoes extensive changes during morphogenesis, 
aNPDC-1 expression appears to increase while aTRβ levels display a temporal 
expression.  At day 8 following T4 treatment, aNPDC-1 and aTRβ levels both increase 
in axolotl lung, but while aNPDC-1 levels continue to remain high during 
metamorphosis, aTRβ levels decrease.  The levels of aTRα also appear to increase in 
axolotl lung by day 8 of metamorphosis and remain higher than at day 0 (before T4 
treatment). 
There are obviously a lot of gaps in this model of NPDC-1’s role in regulation of 
differentiation and development in axolotl, and many other components in this process 
that need to be married into the model. Fortunately, with the tools developed through 
the studies in this dissertation we may now be able to more accurately define the 
molecular role of this highly conserved nuclear receptor coregulatory protein.  With 
this in mind I have listed several future directions that expand on the studies and 
findings from this dissertation.  
 
FUTURE STUDIES 
The preliminary studies presented in this dissertation suggest the hypothesis 
that aNPDC-1 plays a critical role in aRAR- and aTR-mediated gene expression events.  
To establish this hypothesis it will be important that these preliminary data be 
expanded in a more comprehensive manner.  The axolotl is a convenient system for 
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doing this in that tissues can be cultured in vitro.  Therefore, the proposed studies 
would be to investigate the effects aNPDC-1 small interfering RNAs (siRNAs) have on 
global gene expression in various hormone-treated, in vitro cultured axolotl tissues or 
primary cell cultures.  Micro array analyses could be tailored toward a variety of RAR-
specific, TR-specific and other developmentally regulated genes. These studies would 
be expected to provide direct evidence for NPDC-1 regulation of molecular events 
associated with axolotl development, as well as potential tools for further dissecting 
the molecular mechanism by which NPDC-1 is regulating these events. 
Pending the results of these in vitro analyses, this work could be expanded to 
look at the effects of conditionally knocking out the aNPDC-1 gene in axolotl.  A variety 
of published data strongly support a role for NPDC-1 in brain development.  Similarly, 
both retinoids and thyroid hormone have been implicated in the embryonic and 
premetamorphic patterning of axolotl brain.  Therefore, the experiment would be to 
either conditionally knock out or overexpress the aNPDC-1 gene in a tissue-specific 
manner. A cre-loxP system could be used to conditionally knockout the gene, and if 
the cre recombinase was placed under an inducible and neuronal-specific promoter, 
the activity could be targeted to the brain.  Alternatively, overexpression of NPDC-1 
could be accomplished by creating transgenic axolotls that have a ligand-inducible 
(e.g. doxycycline) aNPDC-1 gene inserted into their genome.  The developmental 
impact of knocking out and over-expressing NPDC-1 could be monitored, both 
organismally and molecularly (e.g. using similar gene array analyses mentioned 
above), in the presence and absence of hormone-stimulated events.  
At the molecular level, perhaps the most surprising observation made in my 
dissertation studies is the intriguing possibility that axolotl NPDC-1 can function as 
both a nuclear receptor co-repressor or co-activator protein, dependent upon which 
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receptors transcriptional apparatus it is associating with.  What makes this finding 
even more interesting is the observation that these antagonistic activities can occur in 
the same host cell, suggesting that it is either something innate to aNPDC-1’s 
interaction with the specific nuclear receptor, aNPDC-1’s interaction and recruiting of 
other coregulatory proteins, or something unique in the response elements used in 
these studies.  To investigate these possibilities I would propose a set of experiments 
that specifically elucidate the protein complexes that associate with the 2-specific 
response elements (βRE and TRE) used in my dissertation studies. These experiments 
could be accomplished using matrix-associated (e.g. biotin labeled response elements 
and streptavidin agarose) pull-down purification technologies to isolate proteins 
associated with these response elements, and proteomic technologies to specifically 
identify these proteins. 
In summary, these studies are the first step towards assigning a measurable, 
biological function to NPDC-1.  The evolutionary conservation of NPDC-1 suggests an 
important role for this protein in development and differentiation of organisms, but so 
far the biochemical mechanism for this protein is yet to be fully determined.  
Hopefully, these studies shed some light on the biochemical function of NPDC-1 and 
provide a model system and template for establishing NPDC-1’s molecular mechanism 
for regulation of differentiation. 
 
Copyright © Maria Theodosiou 2006 
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